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Abstract 
 
Meningococcal meningitis is endemic in sub-Saharan Africa while sporadic outbreaks 
burden the developed world by preying on the young and immunocompromised. The 
causal pathogen Neisseria meningitidis exclusively colonises the human nasopharynx. 
With a relatively concise genome, it can invade across multiple bodily compartments, 
which can be highly debilitating and life-threatening.  
Nine genomic “islands” have been identified in N. meningitidis and N. gonorrhoeae, 
absent from their commensal cousin N. lactamica. Many are predicted to have roles in 
bacterial transport, metabolism and regulation. 
Genomic Island 5 contains three genes and was correctly annotated to encode enzymes 
involved in the synthesis of the polyamine putrescine, protecting bacteria from oxidative 
stress. Mutant N. meningitidis lacking these genes grew poorly in rich media. The lesion 
can be restored by putrescine supplementation or gene complementation. 
Genomic Island 3 contains two genes poorly annotated to be spermidine-synthesising – a 
higher polyamine. Mutant N. meningitidis lacking these genes, however, grew poorly in 
chemically-defined media. Shuffling amino acid profiles and culturing with a labelled 
arginine isotope suggest a role in the acquisition and metabolism of arginine and 
glutamine, which are key to meningococcal maintenance. 
Enhanced systems circumventing host resource-denial, scavenging amino acids and 
resisting challenges from free radicals are examples of virulence. These islands are 
believed to support the general fitness of N. meningitidis as a highly competitive 
commensal but paradoxically “accidental” pathogen, where disease is a likely a result of 
risk-taking lifestyles in response to complex microenvironment changes. 
This behaviour is contrasted by N. gonorrhoeae which prefers recurrent infection episodes 
and long-term establishment. The closely-related but phenotypically diverse members of 
the Neisseria genus hence serve as research foci of much interest. In a broader sense, 
investigating why meningococci conserve such pathogen-specific sequences may help 
inspire new clinical strategies and provide alternative perspectives towards the biology of 
similar organisms. 
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Chapter 1 – General Introduction 
1.1 Overview of the genus Neisseria  
Prussian dermato-bacteriologist Albert Neisser first identified Neisseria gonorrhoeae as 
the cause of the sexually-transmitted infection (STI) gonorrhoea in 1879 (Jayakumar and 
Lipoff, 2017). Named after the Breslau academic, this bacterial genus Neisseria belongs to 
the family Neisseriaceae, under the order Neisseriales and class ß-proteobacteria. Today, 
the only other species within the genus pathogenic to humans is Neisseria meningitidis, 
which is paradoxically capable of both commensal carriage and life-threatening disease.  
With few exceptions, members of the genus are usually 0.6 – 1.9 µm in diameter and 
normally occur as singlets, in pairs or in tetrads of cocci where adjacent sides appear 
flattened, while other general features include being haemolytic, oxidase and catalase 
positive, do not produce exotoxins and are found in mammalian mucosal surfaces 
(Tønjum, 2015). The sequenced genomes of N. meningitidis, N. gonorrhoeae and N. 
lactamica strains are very closely related and relatively small in size (around 2.2 Mbp), yet 
highly diverse as over 10,000 unique sequence types of the three species were deposited at 
the PubMLST database (Maiden, 2008). 
1.1.1 Neisseria gonorrhoeae 
The diplococcal, non-encapsulated Neisseria gonorrhoeae is an obligate human pathogen 
that causes gonorrhoea, which is characterised by frequent recurrence following treatment 
(Unemo et al., 2017). Bacterial vaginosis in women is also a predisposition of high risk 
with strong causal and predictive links to gonorrhoea and other STIs (Wiesenfeld et al., 
2003; Gallo et al., 2012). More severe complications include pelvic inflammatory disease, 
infertility and even ectopic pregnancy, but the disease is further complexed into a major 
public health concern due to its advanced antibiotic resistance profile (Unemo et al., 2016). 
Unlike other Neisseria species, gonococcal infections are showing increasingly severe 
cases of antibiotic resistance at alarming rates which are recognised worldwide (Costa-
Lourenço et al., 2017). This hallmark trait is facilitated by horizontal gene transfer 
occurring between other bacterial species and the naturally competent N. gonorrhoeae – 
even from humans (Cehovin and Lewis, 2017; Anderson and Seifert, 2011a; Anderson and 
Seifert, 2011b). As last resort antibiotics such as extended-spectrum cephalosporins were 
widely reported to have been compromised, the grave prospect warrants immediate 
collaborative action by international communities to combat the disease with new drugs 
and ideally gonococcal vaccines (Wi et al., 2017). 
  2 
1.1.2 Neisseria meningitidis 
On the other hand, first identified by Anton Weichselbaum in 1887 from patient 
cerebrospinal fluid (CSF), N. meningitidis is closely related to N. gonorrhoeae but without 
the aforementioned notoriety. While the gonococci infect human genito-urinary tracts 
resulting in inflammation, pain and discharges, the meningococci infect through the human 
throat. N. meningitidis first colonises the infant nasopharynx along with harmless 
commensal strains such as N. lactamica, and as age increases, meningococcal colonisation 
becomes increasingly predominant until adolescence (Christensen et al., 2010). Along with 
Streptococcus pneumoniae, Group B Streptococcus, Haemophilus influenzae and Listeria 
monocytogenes, N. meningitidis is one of the major causal pathogens capable of the deadly 
condition known as bacterial meningitis which has serious clinical consequences (CDC, 
2017). 
1.1.3 Neisseria lactamica 
Neisseria lactamica is the most closely-related non-pathogenic species to N. meningitidis 
and is believed to be how infants naturally prime their immunity towards the latter (Gold et 
al., 1978). In infants, sustained carriage of lactose-fermenting (useful for lactose-rich 
infant diets) N. lactamica – hence the namesake – is accompanied by the presence of anti-
meningococcal serum bactericidal antibodies (SBAs) despite relatively low proportions of 
N. meningitidis colonies (Bennett et al., 2005). In adults, this can also be achieved by 
raising mucosal and systemic humoral immunity against N. lactamica where 
opsonophagocytic antibodies (but not SBAs) cross-react to cover N. meningitidis (Evans et 
al., 2011). This strait had been exploited in the development of some non-universal 
meningococcal vaccines (Gorringe et al., 2009).  
Although they both colonise the nasopharynx, a gradual transition occurs as we progress 
from childhood to adulthood, during which predominance shifts from the commensal to the 
pathogen (Bakir et al., 2001). Carriage of N. lactamica is usually stable and homogenous 
in human populations regardless of seasonal variations or the presence of vaccination 
efforts against its pathogenic cousin (Kristiansen et al., 2012). Although both N. lactamica 
and N. meningitidis occupy the same ecological niche and share similar mechanisms in 
energy acquisition, interactions with host cells differ where the commensal tends to induce 
expression of pro-inflammatory genes, while the pathogen can down-regulate and evade 
host defences (Wong et al., 2011). Inoculation with N. lactamica was even shown to 
displace and prevent N. meningitidis carriage in young adults through competition (Deasy 
et al., 2015).  
  3 
Other non-pathogenic species of Neisseria include but are not limited to: N. sicca, N. 
mucosa, N. elongata, N. flavescens, N. flava, N. subflava, N perflava, N. cinerea, N. canis, 
N. weaveri, N. polysaccharea, N. dentiae etc., which are often found in the human flora as 
well as other mammalian hosts. Although often underappreciated in comparison to the 
three human colonisers of outstanding clinical significance (N. meningitidis, N. 
gonorrhoeae and N. lactamica), this genetically, morphologically and phenotypically 
diverse genus may have great implications as a model for comparative molecular research 
(Liu et al., 2015). 
1.2 Microbiology of Neisseria meningitidis  
Neisseria meningitidis is a Gram-negative, fastidious, aerobic bacterium which commonly 
resides as commensals in the human upper respiratory tract (URT) mucosa, but can also 
become pathogens. It can grow on a wide range of nutrient-rich media – such as blood agar 
and Müller-Hinton broth (MHB) used extensively in this study – but requires strict primary 
carbon sources like pyruvate or glucose. Colonies are round, grey, convex and moist in 
appearance with clearly-defined edges, growing optimally at around 37°C in the presence 
of carbon dioxide (Tønjum, 2015). At the heart of the meningococcal central carbon 
metabolism is the citric acid cycle (Leighton et al., 2001). N. meningitidis also possesses 
high-affinity uptake systems for iron and iron complexes such as lactoferrin, transferrin, 
haemoglobin, which are both essential to normal metabolism as well as major determinants 
of pathogenicity (Perkins-Balding et al., 2004). Along with systems that respond to 
changes in carbon source, metal and oxygen availability, these processes fall under a 
handful of transcriptional regulators in N. meningitidis (Golfieri, 2015). Examples include 
nitric oxide sensitive repressor (NsrR), fumarate and nitrate reductase regulator protein 
(FNR), Neisserial adhesin Regulator (NadR) and ferric uptake regulator (Fur) (Grifantini et 
al., 2004) etc. Regulatory pathways also believed to contribute to pathogenicity include 
CrgA (Ieva et al., 2005; Deghmane et al., 2000) for attachment and MarR (Nichols et al., 
2009) for resistance etc. The Lrp/AsnC family of global regulatory proteins also play a role 
when N. meningitidis grows under nutrient-limiting conditions, an aspect of meningococcal 
lifestyle explored and discussed in Chapter 5. 
N. meningitidis does not possess flagella and hence lacks swimming motility found in other 
bacteria. In rare cases of invasive pathogenesis, however, N. meningitidis may move across 
the mucosal epithelia and enter the blood stream to cause septicaemia. This “twitching 
motility” is achieved through the actions of type IV pili, filamentous organelles which 
allow the bacteria to traverse and adhere to moist surfaces by tethering cells through 
extension and retraction of thin polymers of pilin (Mattick, 2002). In N. meningitidis the 
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pilins are a source of antigenic variation which contribute to host immune evasion, and 
characterisation of the meningococcal pili structure demonstrates the organism’s 
heterogeneity and elasticity (Gault et al., 2015; Kolappan et al., 2016). 
Another crucial virulence determinant – the endotoxin lipo-oligosaccharide (LOS) – is also 
a source of antigenic variation in N. meningitidis. Unlike the lipopolysaccharides (LPS) of 
typical enteric Gram-negative bacteria such as E. coli, the corresponding meningococcal 
molecules LOS lack O-antigen repeating units and are localised as small operons in the 
chromosome, where polymorphisms occur through random rearrangements and contribute 
to survival in light of selective pressure from host response (Kahler and Stephens, 1998). 
As encapsulated bacteria, the 13 meningococcal serogroups – A, B, C, D, H, I, K, L, W-
135, X, Y, Z and 29E – were duly classified based on structural variations in capsular 
polysaccharides (Spinosa et al., 2007). Variations in class II/III (e.g. PorB porin) and class 
I (e.g. PorA porin) outer membrane proteins determine serotype and serosubtype 
respectively, while differences in LOS further determines immunotype (Stephens et al., 
2007). Together these typical Gram-negative bacteria features contribute towards 
meningococcal virulence and immunogenicity (Rouphael and Stephens, 2012). Helping N. 
meningitidis adapt and attach to its host are also expression of surface adhesive proteins, 
mimicry of host antigens as well as high frequency of recombination events, which confers 
evolutionary advantages through genome plasticity and phenotype diversity (Stephens, 
2009). Independent of serogroups, multilocus sequence typing (MLST) has helped identify 
hypervirulent strains that are highly associated with disease relative to carriage with the 
use of polymorphisms in 7 “housekeeping” genes (Maiden et al., 1998). This proved to be 
a vital tool in molecular epidemiology, disease surveillance and prompt investigation of 
meningococcal outbreaks (Vogel, 2010). 
1.3 Carriage, pathogenicity and disease burden of Neisseria meningitidis 
1.3.1 Aetiology and Epidemiology  
About 10% of any non-outbreak population would harbour N. meningitidis 
asymptomatically (Caugant et al., 1994). Disease caused by N. meningitidis, on the other 
hand, primarily affects infants around 1 year of age, adolescents and young adults. Of the 
13 N. meningitidis serogroups only 6 (A, B, C, W-135, X and Y) are pathogenic in 
humans, where 5 (A, B, C, W-135 and Y) of them are responsible for most disease 
outbreaks worldwide. Each of these serogroups distributes differently across the globe 
(Figure 1.1), where epidemics are usually caused by strains belonging to hypervirulent 
lineages (Harrison et al., 2009). In Europe, serogroup B strains account for the majority of 
cases followed by serogroup C (ECDC, 2016). In the US, serogroups B, C and Y are 
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predominant amid a historic low rate of disease (<1 per 100,000 population) with around 
10% case fatality (Cohn et al., 2010). These figures are understandably higher in less-
developed endemic regions such as Africa, reaching up to 1000 cases per 100,000 
population with an over-representation of serogroup A in terms of prevalence (Gabutti et 
al., 2015). 
 
 
Fig. 1.1 – Worldwide distribution of N. meningitidis pathogenic serogroups: A, B, C, X, Y and 
W-135, with the sub-Saharan “African Meningitis Belt” circled in dashed lines and other endemic 
regions coloured in grey (from Pelton, 2016). 
Circulating strains of N. meningitidis can be transiently contracted between humans 
through aerosolised respiratory droplets or salivary secretions, which results in either 10 – 
20% asymptomatic carriage among populations, or invasive disease following an 
incubation period of 2 – 10 days (WHO, 2015). Apart from residing at or travelling to 
endemic countries, risk of contact with the bacteria is especially high in enclosed 
communities such as tertiary educational or military accommodations where adolescents or 
young adults are in frequent exposure (CDC, 2000). Smoking is also a risk factor as it is 
believed that damage to the respiratory tract mucosa increases the chances of successful 
invasion by the meningococci, where there is a positive correlation between disease 
incidence and smoker prevalence (Norheim et al., 2014). It was also reported that 
immunocompromised individuals, such as patients with HIV/AIDS, oncological or 
haematological lesions, those with immature immune systems and those who are on 
chemotherapy, post-operational or post-transplant prophylaxis, may also be at risk of being 
infected by N. meningitidis (Vogel et al., 2004). 
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1.3.2 Pathogenesis 
Despite the knowledge of a reservoir within the human population, the precise mechanism 
and stimulus for meningococcal pathogenesis remain unclear. Some suggested that 
invasive strains are perhaps not a result of within-host evolution where virulence equates 
bacterial fitness in face of selective pressure, but are simply neutral accumulation of 
genomic mutations during asymptomatic carriage (Klughammer et al., 2017). More refined 
upper respiratory tract models for Neisseria are required in order to better understand the 
interactions and dynamics between human hosts and their resident Nesseria species 
(Weyand, 2017). Nonetheless, the multistep invasion process is a demonstration of the 
remarkable versatility of N. meningitidis, where variability in meningococcal capsule 
expression, in concert with type IV pili-mediated interactions with host cell, are summarily 
responsible for bacterial survival in at least three diverse bodily compartments (i.e. URT 
mucosa, blood, CSF) and its ability to breach the barriers in-between (Coureuil et al., 
2012). As differences between host compartments amount to distinct ecological niches, a 
multitude of host-pathogen interactions such as complement-binding via CD46 and 
CD147, as well as the activation of pro-inflammatory cytokines and chemokines such as 
tumour necrosis factor a (TNF-a) in the brain, all contribute towards meningococcal 
survival and translocation (Doran et al., 2016). In particular, the recruitment of factor H 
(fH), a key regulator of the Alternative Pathway of the complement system, is a hallmark 
interaction and a major source of host immune evasion in N. meningitidis (Schneider et al., 
2009). Other factors such as recruitment of negative complement regulators such as 
complement 4-binding protein (C4BP), the meningococcal polysaccharide capsule and 
LPS are also necessary to prevent complement-mediated lysis (Schneider et al., 2007). 
Apart from binding to surface-exposed adhesins (Schubert-Unkmeir, 2017) or eliciting cell 
signalling to promote internalisation into host cells (Slanina et al., 2014), many genes 
involved in normal aspects of meningococcal lifestyle (Nassif et al., 1999) are also found 
to be upregulated for the colonisation of various host sites (Capel et al., 2016). 
A major virulence factor, capsule expression influences immunogenicity to the benefit of 
the meningococci. Clinical strains were found encapsulated while isolates from carriers 
often lacked capsular antigens, which were believed to confer selective advantages by 
evading bactericidal phagocytosis or complement-mediated killing (Yazdankhah and 
Caugant, 2004). The other major virulence factor – type IV pili – enable the normally URT 
mucosa-bound meningococci to penetrate epithelial cells and enter the bloodstream (See 
Section 1.2).  
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1.3.3 Meningococcaemia 
Once inside the bloodstream, the pathogen can induce meningococcaemia (meningococcal 
sepsis) which have severe medical consequences such as acute fever, rashes, disseminated 
intravascular coagulation (DIC) and eventually death by multiple organ failure as the host 
complement responses are activated for a systemic inflammation (Takada et al., 2016). 
Meningococcal septic shock is therefore far more fatal than the exacerbation 
(meningococcal meningitis) that potentially follows (de Greeff et al., 2008; Brandtzaeg 
and van Deuren, 2012). Other complications include haemorrhages, tissue necrosis and 
limb loss, all of which affect recovery (van Deuren et al., 2000). Typical of Neisseria spp., 
however, important components such as porins (PorA and PorB), adhesins, opacity-
associated proteins (Opa and Opc), iron metabolism surface proteins, pili (fimbriae) 
expression and LOS all contribute towards N. meningitidis colonisation, nutrient 
acquisition, establishment in host, evasion of host immune response, cellular invasion and 
pathogenesis as well as virulence (Coureuil et al., 2012). This paints a complex picture for 
the meningococci throughout its transition from symbiotic colonisation to parasitic 
multiplication in the human host. 
1.3.4 Meningitis 
The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) – located at 
cerebral microvessels and choroid plexus respectively – protect the human central nervous 
system (CNS) by closely regulating the exchange of solutes and macromolecules by 
restricting physical permeability of the adherens and tight junctions (Dando et al., 2014). If 
high level of bacteraemia occurs and is left unchecked, the meningococci can disrupt and 
cross the BBB within hours of disease onset, triggering a massive inflammatory response 
towards bacterial proliferation in the CNS (Coureuil et al., 2013). This is achieved by the 
meningococci type IV pili signalling the recruitment of cortical plaque-forming molecules 
following initial attachment, which accumulate at cell-cell junctions where microcolonies 
eventually detach and breach through to the CNS (Miller et al., 2013). As aforementioned, 
encapsulation enables the meningococci to translocate into CNS by also adhering to the 
BCSFB-forming human brain microvascular endothelial cells, as well as surviving and 
replicating in intracellular compartments (Nikulin et al., 2006). The end result is a 
potentially fatal medical emergency known as meningococcal meningitis, an inflammation 
of the meninges and CSF-filled subarachnoid space, with clinical manifestations of 
meningitis ranging from headache, fever and neck stiffness all the way to compromised 
mental status, impaired consciousness, aphasia, palsies and seizures (van de Beek et al., 
2016).  
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Meningococcal meningitis is a serious condition where fatalities are mostly due to 
intracranial pressure build-up and herniation, while 8-20% of recovered victims are often 
scarred with various degrees of highly debilitating audial or neurological sequelae (van 
Deuren et al., 2000). The morbidity and mortality cause considerable disease burden even 
in high-income countries, characterised by the financial strain to public health resources 
associated with follow-up care, outbreak management, lifelong disabilities, the need for 
rehabilitation as well as societal consequences (Martinón-Torres, 2016).  
1.3.5 Treatment and Resistance 
Fortunately, prompt treatment by broad-spectrum antibiotics such as ß-lactams is able to 
drastically reduce mortality in most cases of N. meningitidis infection (Dwilow and 
Fanella, 2015). The challenge lies in the timely identification of any suspected 
meningococcal infection and applying treatment before waiting for laboratory-confirmed 
diagnosis, as the disease is fulminant in nature and early clinical presentations were often 
mistook for their similarities with less severe but more common febrile illnesses (CDC, 
2014). Reduced susceptibility to penicillins and third-generation cephalosporins had 
emerged and was made possible by innate gene exchange mechanisms in the meningococci 
(Arreaza et al., 2002; Deghmane et al., 2017). Examples are efflux pumps or LOS 
modification which defend the meningococci against innate killing as well as cationic 
peptides such as polymixin B (Tzeng et al., 2005; Tzeng and Stephens, 2015). With 
regards to disease management, resistance is not the major clinical concern as N. 
meningitidis remains susceptible to a wide range of antibiotics (Jorgensen et al., 2005). 
1.4 Vaccines for Neisseria meningitidis 
1.4.1 Vaccines against serogroups A, C, W-135 and Y 
As aforementioned, the 6 major disease-causing N. meningitidis serogroups (A, B, C, W-
135, X and Y) were classified based on their phase and antigenic variations of capsular 
polysaccharides (Talà et al., 2014). Quadrivalent conjugate polysaccharide vaccines 
protecting against A, C, Y and W-135 (Menveo® by Novartis; Menomune® and 
Menactra®, both by Sanofi Pasteur) have long been incorporated as part of routine 
vaccination programmes in many developed countries (Figure 1.2 (a)). Conjugate vaccines 
targeting meningococcal serogroup C were also introduced in developed countries which 
successfully saw decline in incidence through herd immunity effected by reduction in 
carriage (Figure 1.2 (b)) (Trotter and Maiden, 2009). In addition, MenAfriVacTM, the result 
of an international charitable effort to deliver affordable vaccines targeting N. meningitidis 
serogroup A to the “African Meningitis Belt” in sub-Saharan Africa, has led to sharp 
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decreases in incidence, herd immunity as well as eradication of carriage from populations 
following vaccination (Kristiansen et al., 2013).  
   
Fig. 1.2 (a) – Meningococcal polysaccharide vaccines, covering 4 major epidemic 
serogroups. 
   
Fig. 1.2 (b) – Depending on regional epidemiological patterns and needs, immunisation 
programmes for children with serogroup C conjugate vaccines may also be found in certain 
countries Note that Menitorix® is a combined vaccine for Haemophilus influenzae type C and N. 
meningitidis serogroup C. 
1.4.2 Vaccines against serogroup B: recent advancements and reverse vaccinology 
Effective universal vaccines against serogroup B strains, however, had only been approved 
and licensed for use by regulating authorities in recent years. The peculiar lack of vaccine 
coverage for serogroup B led it to being responsible for 90% of meningococcal diseases in 
the UK (Shea, 2013). The major challenge in developing a sufficiently immunogenic 
vaccine for serogroup B was due to high similarities between its capsular polysaccharides 
and human sialic acid moieties. The incorporation of polysialic acids in bacterial surface 
glycans such as the capsule or lipopolysaccharide (LPS, which is LOS in N. meningitidis) 
is a recognised mechanism of host response evasion, but the serogroup B capsule consists 
of polymers of α(2-8)-linked N-acetylneuraminic acid which share structural identities 
with human neural cell-adhesion molecule (NCAM) (Hill et al., 2010). Albeit displaying 
opsonic activity, the result is a reluctance by the host to develop anti-meningococcal SBA 
in order to prevent autoimmune responses against delicate brain tissue (Christodoulides 
and Heckels, 2017). This prompted a need for investigating vaccine candidates using sub-
capsular antigens and minor proteins which were preferably invariably expressed, 
accessible, effectively immunogenic and cover all disease-associated strains of 
meningococci (including hyperinvasive lineages) (Caugant and Maiden, 2009). 
The availability of the serogroup B strain MC58 complete genome sequence contributed 
greatly to this cause by allowing for the comprehensive blind screening of genome-derived 
surface antigens for potential vaccine candidates (Delany et al., 2013). Termed “reverse 
vaccinology”, this process was first applied in the development of N. meningitidis 
serogroup B universal vaccines, where the genome was first screened in silico for novel 
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antigens prior to confirming potentially immunogenic candidates with in vitro means 
(Kelly and Rappuoli, 2005; Pizza et al., 2000). In fact, the discovery and subsequent 
thorough characterisation of factor H-binding protein (fHBP) was a direct beneficiary of 
this methodology, while also revealing fresh aspects of meningococcal pathogenicity 
(McNeil et al., 2013). It must be noted that although outer membrane vesicle (OMV)-based 
vaccines specific against particular epidemic N. meningitidis serogroup B strains had been 
devised during the past decades, the immunogenicity was not broad enough to cover 
circulating strains where high antigenic variations were often expressed (Acevedo et al., 
2014). The lessons learned from OMV vaccine trials and reverse vaccinology resulted in 
the successful introduction of two serogroup B meningococcal vaccines, rLP2086 
(Trumenba® by Pfizer) and 4CMenB (Bexsero® by Novartis but acquired by GSK) within 
two decades of sequencing the whole genome (Figure 1.2 (c)) (Gandhi et al., 2016; Seib et 
al., 2015). 
  
Fig. 1.2 (c) – The two commercially-available universal N. meningitidis serogroup B vaccines: the 
fHBP-based Trumenba® marketed by Pfizer and quadrivalent (containing the antigens fHBP, 
NadA, Neisserial Heparin Binding Antigen plus OMV) Bexsero® developed by Novartis but 
acquired by GSK. 
The first to receive US FDA approval was Trumenba® (Pfizer), a suspension carrying two 
recombinant lipidated fHBP variants (Brendish and Read, 2015). The second, more 
expensive one was Bexsero® (originally Novartis, now GSK), a suspension of OMV 
carrying 4 antigens (Gorringe and Pajón, 2012). The latter had long been approved for use 
in the EU, Australia and Canada, but only received approval in the UK in late 2013 and in 
the US in early 2015. In March 2015, the UK commenced its national infant vaccination 
programme against N. meningitidis serogroup B with Bexsero®, which had since “halved” 
the number of reported cases after the first 10 months (Public Health England, 2016). 
Following settlement of patent disputes between the two pharmaceutical giants, 
Trumenba® also received approval for use in the EU in 2017. Aside from infants, both 
serogroup B vaccines are also recommended by the US FDA for use on adolescents and 
young adults (high risk populations aged 10 – 25) (Sunasara et al., 2017). 
Reverse vaccinology is an invaluable technological advancement and a huge 
accomplishment for translational research in the combat against vaccine-preventable 
diseases with such remarkable clinical implications (Rappuoli et al., 2011). With the 
advent of serogroup B vaccines completing coverage for 5 major pathogenic serogroups, 
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there is now a rise in previously sporadic cases of invasive meningococcal meningitis 
caused by serogroup X in endemic African regions where vaccines are needed (Xie et al., 
2013). Lessons learned from the development of serogroup B vaccines, however, were 
revealed to have promising contributions towards the development of potential serogroup 
X vaccines (Acevedo et al., 2017). Challenges remain to ensure continued success of 
disease prevention, such as emerging virulent strains not covered by vaccines and the need 
for multiple doses of delivery (Watson and Turner, 2016; Wang and Pollard, 2017). 
1.5 Genomic profile of Neisseria meningitidis compared to other bacteria 
1.5.1 The value of genomic data 
The successful development of serogroup B (NmB) vaccines was largely facilitated by the 
availability of complete genome of strain MC58 around the start of the millennium 
(Tettelin et al., 2000). Since then there has been an exponential rise in assembled whole 
genome sequence data deposited at online databases, which serve as powerful analytic 
tools for devising improved surveillance, diagnostics and vaccine strategies (Harrison et 
al., 2017). The protein-coding genomic data allowed for a computational approach which 
underlies reverse vaccinology in the effort to identify putative vaccine-suitable antigen 
candidates (Heinson et al., 2015). Regardless of the now-improved coverage of vaccines, 
the MC58 genome remains an invaluable asset upon which the continuous research effort 
and further understanding of N. meningitidis may be based. As strictly human pathogens 
both Neisseria species pose challenges for the adoption of suitable animal and even 
primate models (Weyand et al., 2013). Questions as to how the meningococci maintain this 
unique niche or becomes invasive, for example, as well as foundation work for the 
understanding of other competing organisms, remain topics of great interest. 
1.5.2 Genomic features of N. meningitidis  
Like N. gonorrhoeae, N. meningitidis is also naturally competent and, obeying certain 
constraints, maintains a highly flexible chromosome that is capable of acquiring foreign 
genetic materials, incorporating such elements into its genome or even conduct intragenic 
recombination (Schoen et al., 2009). Therefore, the mosaic genomic structure was often 
speculated to be virulence-associated in its own right, through which pathogenic Neisseriae 
as well as clinical isolates from other bacteria survive the human immune response 
(Hughes, 2000). The polygenic nature of meningococcal virulence can be reflected by the 
multi-faceted recombination strategies that occur in its core genome, where a substantial 
portion of recombinant genes are often first associated with disease but also turn out to be 
supportive of bacterial fitness upon closer examination (Joseph et al., 2011).  
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Small clusters of sequences, believed to evolutionary foreign DNA acquired with integrase 
and transposase, were first identified exclusively in pathogenic gonococci and 
meningococci genomes but not in the commensal N. lactamica (Perrin et al., 1999). Traits 
such as G+C content different to the genome and tendencies towards chromosomal 
integration are all reminiscent of pathogenicity-associated genetic islands first described in 
E. coli, (Hacker et al., 1997). However, those classical islands are often much larger in size 
(up to 200 kbp) and encode more purposeful, disease-empowering virulence genes such as 
invasins and toxins (Hacker and Kaper, 2000).  
1.5.3 Meningococcal Genomic Islands conserved in pathogenic Neisseriae 
A pan-Neisseria microarray containing the complete sequences of N. meningitidis strains 
Z2491 (serogroup A), MC58 (serogroup B), FAM18 (serogroup C) and N. gonorrhoeae 
strain FA1090 was constructed and used to analyse both pathogenic and commensal 
Neisseriae genomes, which revealed genes specific to the disease-causing meningococci 
and gonococci (Stabler et al., 2005). In an effort to reveal more consistent differences 
between members of the genus, further sequence analyses eventually led to the 
identification of 9 small islands in the pathogenic meningococcal genome (Figure 1.3) 
(Catenazzi, 2013).  
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Fig. 1.3 – Complete genome of N. meningitidis serogroup B (NmB) strain MC58 and its 9 
pathogen-conserved genomic islands. The designations for coding sequences were adapted from 
their respective microarray reporter elements, and are to be regarded as gene numberings when 
referred to henceforth. Brackets denote genomic island numbers. Colours denote the respective 
annotated functions based on the broad gene ontology of each product. Positions are approximate 
and not drawn to scale. (Adapted from Catenazzi, 2013) 
These clusters of sequences often hold roles in metabolism and transport, but are thought 
to be disease or pathogenicity-associated as they are found highly conserved in pathogenic 
N. meningitidis strains, mostly conserved in N. gonorrhoeae, but absent in commensal N. 
lactamica strains (Perrin et al., 2002). In the 2.27 Mbp circular NmB genome, the largest 
of these islands is no longer than 10 kbp in size. Several larger regions of genomic 
sequences with foreign nucleotide signatures – known as “islands of horizontal transfer” 
(IHT) – were previously identified, but are neither well-conserved amongst pathogenic 
species nor across the genus and hence should not be confused with those discussed here 
(Snyder et al., 2005). 
Many of these Neisseria island genes are still uncharacterised and encode unknown 
proteins. Preliminary bioinformatics background was obtained using tools such as BLAST 
and StringDB queries to compare the potential products annotated to be expressed by these 
N. meningitidis sequences (using strain MC58, NCBI GenBankTM accession no.: 
AE002098.2; genes denoted with prefix “NMB”), their flanking genes (where present) and 
putative functional homologues in N. gonorrhoeae (using strain FA1090, NCBI 
GenBankTM accession no.: AE004969.1; genes denoted with prefix “NGO”) and N. 
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lactamica (using strain 020-06, NCBI GenBankTM accession no.: FN995097.1; genes 
denoted with prefix “NLA_”). Many homologous flanking genes were often found closely 
adjacent to each other in commensal Neisseriae (Figures 1.4-1 to -9). Acquisition of these 
genomic islands was thought to be via horizontal gene transfer, a popular mode of 
diversification employed among Neisseria species (Hotopp et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  15 
Genomic Island 1 comprises of three genes and is possibly involved in the oxidation of D-
amino acids due to the annotated D-amino acid dehydrogenase (DadA) functionality. It has 
been shown that the DadA operon, of which a putative subunit is located on Genomic 
Island 1 in N. meningitidis as NMB0176 (Figure 1.4-1), is required in some pathogens such 
as cystic fibrosis-adapted Pseudomonas aeruginosa isolates for the expression of virulence 
factors (Oliver and Silo-Suh, 2013). Mutants with genetic lesions leading to inability to 
catabolise D-amino acids show decreased competitiveness in in vivo infection models 
(Boulette et al., 2009). This is believed to confer advantages to bacteria when colonising a 
wide range of environments, including their respective hosts, by being able to utilise as 
many forms of nutrient as possible for growth. 
 
 
Fig. 1.4-1 – Meningococcal Genomic Island 1. (a) Bioinformatics queries annotate: NMB0175 as a 
zinc transporter (ZupT) homologue; NMB0176 as containing a small D-amino acid dehydrogenase 
(DadA) subunit, and; NMB0177 as a sodium/alanine symporter homologue, also indicated to be 
encoded by NMB0194 and NMB1647. (b) N. gonorrhoeae lacks the NMB0175 homologue but 
conserves the rest, while (c) all three island genes were replaced with three hypothetical proteins in 
N. lactamica not found in the two pathogenic Neisseriae genomes. (Adapted from Catenazzi, 2013) 
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Genomic Island 2 comprises of 7 genes and, due to the predicted presence of an 
allophanate hydrolase domain, may possibly be involved in urea and amino acid 
metabolism. Many bacteria can utilise urea as a nitrogen source. One such mechanism is 
through the enzyme urea amidolyase (UA), which contains two domains: urea carboxylase 
(UC) and allophanate hydrolase (AH), of which a putative sub-unit Ahs1 (allophanate 
hydrolase subunit 1) is located on Genomic Island 2 as NMB0230 (Figure 1.4-2) (Zhao et 
al., 2018). The domains themselves are enzymatic, and AH works with UC to convert urea 
into ammonium and carbon dioxide (Fan et al., 2013). The activities of the two are said to 
be functionally independent, and overall UA contributes to bacterial pathogenicity as it 
facilitates survival in host immune cells  (Lin et al., 2016). 
 
 
Fig. 1.4-2 – Meningococcal Genomic Island 2. (a) Bioinformatics queries annotate: NMB0225 as a 
member of the IS30 transpose family, also indicated to be encoded by 13 other sequences in NmB; 
NMB0226 as a hypothetical protein, also indicated to be encoded by NMB2035; NMB0227 as a 
putative transmembrane protein; NMB0228 as a rni3 homologue, a member of the LamB/YcsF 
family; NMB0229 as a hypothetical protein; NMB0230 as a putative Ahs1 (allophanate hydrolase 
subunit 1) homologue, and; NMB0231 as a hypothetical protein. This island is completely absent in 
both (b) gonococci and (c) N. lactamica. (Adapted from Catenazzi, 2013) 
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Genomic Island 3 comprises of two genes and is possibly involved in the production of 
the polyamines spermine and spermidine (Figure 1.4-3). This island will be investigated 
within the thesis and is discussed in detail in Chapter 4. 
 
 
Fig. 1.4-3 – Meningococcal Genomic Island 3. (a) Bioinformatics queries annotate: NMB0239 as a 
putative transmembrane protein with structural motifs reminiscent of major facilitator superfamily 
1 (MFS-1), and; NMB0240 as a putative transmembrane protein with a possible 
spermine/spermidine synthase domain. This island is also (b) conserved in gonococci, but (c) 
completely absent in N. lactamica. The flanking gene homologous to NMB0237 was rearranged 
elsewhere in the gonococcal genome, while the NMB0238 homologue is not found in N. lactamica. 
(Adapted from Catenazzi, 2013) 
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Genomic Island 4 comprises of 6 genes and, with a size of 9329 bp, is the largest of the 9 
genomic islands (Figure 1.4-4). This island has been has been the subject of study by 
Catenazzi et al. (2014), where characterisation work shows that this prp gene cluster 
enables the meningococci to utilise propionic acid – an end-product of fermentation by 
neighbouring anaerobes in its niche – as a carbon source, which enhances colonisation 
capacity but is not central to virulence.  
 
 
Fig. 1.4-4 – Meningococcal Genomic Island 4. (a) Previous work describes or annotates: 
NMB0430 as a 2-methyl-isocitrate lyase (PrpB) homologue; NMB0431 as a 2-methylcitrate 
synthase (PrpC) homologue; NMB0432 as a hypothetical transmembrane protein; NMB0433 as a 
aconitate hydrolase (AcnD) homologue; NMB0434 as a 2-methylcitrate dehydratase (PrpF) 
homologue, and; NMB0435 as a putative propionate (acetate) kinase (AckA1) homologue. This 
island is also (b) conserved in gonococci but (c) completely absent in N. lactamica. (Adapted from 
Catenazzi, 2013) 
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Genomic Island 5 is possibly involved in the synthesis of the polyamine putrescine due to 
the predicted presence of a direct pathway comprised of arginine decarboxylase and 
agmatinase (Figure 1.4-5). This island will be investigated within this thesis and is 
discussed in detail in Chapter 3. 
 
 
Fig. 1.4-5 – Meningococcal Genomic Island 5. (a) Bioinformatics queries annotate: NMB0468 as 
an arginine decarboxylase (SpeA) homologue; NMB0469 as an agmatinase (SpeB) homologue, 
and; NMB0470 as a putative transmembrane protein with structural motifs reminiscent of C4-
dicarboxylate transporters. This island is also (b) conserved in gonococci but (c) completely absent 
in N. lactamica. (Adapted from Catenazzi, 2013) 
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Genomic Island 6 comprises of three genes and is possibly involved in the production of 
biotin. Biotin, also known as vitamin H or coenzyme R, is central to the metabolism of 
many organisms. In bacteria, many species either synthesise biotin de novo or encode 
transporters to acquire them from exogenous sources. In E. coli and a number of other 
bacteria, the bacterial biotin synthesis pathway have been extensively characterised, such 
as the bioABCDF operon (where bioA transcribes divergently from the others) and the 
bioH gene (Streit and Entcheva, 2003). Here in N. meningitidis, the products of some of 
these genes, BioF and BioC, are annotated to be located on Genomic Island 6 as NMB0472 
and NMB0474 respectively (Figure 1.4-6). In E. coli and S. aureus the transporter BirA is 
both responsible for biotin uptake and transcriptional repressor of biotin synthesis genes, 
where switching between the two roles is thought to be important for bacterial maintenance 
and virulence (Satiaputra et al., 2016). In the human pathogen Mycobacterium 
tuberculosis, de novo biotin synthesis is thought to be vital to both lifestyle and virulence 
as the pathway is its sole mode of biotin acquisition and close link with the production of 
key lipid components of the cell membrane (Salaemae et al., 2016). 
 
 
Fig. 1.4-6 – Meningococcal Genomic Island 6. (a) Bioinformatics queries annotate: NMB0472 as a 
8-amino-7-oxononanoate synthase (BioF); NMB0473 as a hypothetical protein, and; NMB0474 as 
a putative biotin synthesis protein (BioC) homologue. This island is also (b) conserved in 
gonococci but (c) completely absent in N. lactamica. In its place is a 1359 bp gene NLA_5070 
which was predicted to encode a tRNA methyltransferase (RlmD), but has no genetic homology to 
pathogenic Neisseriae apart from a small 95 bp fragment also present in the gap region between 
NMB0471 and NMB0472. (Adapted from Catenazzi, 2013) 
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Genomic Island 7 comprises of 6 genes coding for hypothetical proteins, all of which are 
currently completely uncharacterised and lacking any investigation in literature (Figure 
1.4-7). 
 
 
Fig. 1.4-7 – Meningococcal Genomic Island 7. (a) Bioinformatics queries return no specific hits for 
NMB0856 through to NMB0861. The island is also (b) conserved in gonococci but (c) completely 
absent in N. lactamica. The flanking genes homologous to NMB0855 were rearranged elsewhere in 
the gonococcal (NGO0427) and commensal (NLA_13820) genomes. (Adapted from Catenazzi, 
2013) 
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Genomic Island 8 comprises of two divergently-transcribed uncharacterised genes. Here, 
the Island gene product NMB1048 is annotated to be involved in sodium pyruvate uptake, 
under the regulation of an adjacent Island gene product NMB1049, a putative LysR-type 
regulator (as mentioned in Section 1.2) (Figure 1.4-8). As is the case for many other 
bacteria, N. meningitidis can utilise pyruvate as a carbon source along with glucose under 
the scrutiny of transcriptional regulators. 
 
 
Fig. 1.4-8 – Meningococcal Genomic Island 8. (a) Previous work describes and annotates: 
NMB1048 as a transmembrane protein with unconfirmed involvement in sodium pyruvate 
transport, and; NMB1049 as containing a domain for LysR-type transcriptional regulator (LTTR) 
proteins, which regulates expression of NMB0148. This island is also (b) conserved in gonococci 
with the exception of the flanking NMB1050 homologue, but (c) completely absent in N. 
lactamica. (Adapted from Catenazzi, 2013) 
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Genomic Island 9 largely comprises of hypothetical and uncharacterised proteins which 
are incompletely conserved in the pathogenic N. gonorrhoeae genome, while both flanks 
and genes are completely absent from the commensal N. lactamica. Some of these genes 
are loosely annotated to share some motif similarities with the domains of OMP and HlyD 
secretion proteins, located on Genomic Island 9 as NMB1737 and NMB1738 respectively 
(Figure 1.4-9). These are common features in Gram negative bacteria and are often linked 
with drug efflux, hence thought to contribute to virulence through antibiotic resistance. 
 
 
Fig. 1.4-9 – Meningococcal Genomic Island 9. (a) Bioinformatics queries annotate: NMB1737 as a 
putative secretion protein with domain motifs reminiscent of the outer membrane efflux protein 
(OMP) family; NMB01738 as a putative secretion protein with domain motifs reminiscent of the 
HlyD family, and; NMB1739 through to NMB1743 as hypothetical proteins. (b) Only the last three 
genes are conserved in gonococci. (Adapted from Catenazzi, 2013) 
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1.6 Metabolism and stress response in pathogenic Neisseria 
The overall predicted nature of the above genomic islands re-iterates the importance of 
metabolism and stress response in able human pathogens such as N. meningitidis and its 
cousin N. gonorrhoeae. The fates of metals, carbon sources, stress response regulons and 
enzymes are often intertwined with one another, contributing to fitness, survival and 
ultimately enhanced general performance during disease. 
1.6.1 Nutrient acquisition 
As previously mentioned (Section 1.2), N. meningitidis possesses uptake systems for the 
acquisition of metals such as iron from metalloproteins such as lactoferrin, transferrin and 
haemoglobin, as well as zinc from calprotectin. Understandably host defences against 
pathogenic bacteria include restricting them from direct access to metals. This 
sequestration of nutrients is sometimes referred to as “nutritional immunity”, and 
corresponding bacterial counteraction is therefore vital to survival and pathogenicity (Stork 
et al., 2013). To this end, both N. gonorrhoeae and N. meningitidis have devised ingenious 
mechanisms that hijack bound metal ions from host metalloproteins, thus overcoming host 
denial of these essential transition metals (McKenna et al., 1988; Neumann et al., 2017). 
Equally important to bacterial success is the maintenance of equilibrium through metal 
metabolism, tolerance and even exporters due to the toxic nature of transition metals 
including manganese (Veyrier et al., 2011; Guilhen et al., 2013). 
N. meningitidis is able to utilise glucose, maltose, pyruvate, lactate or certain amino acids 
as sole carbon sources in growth, which all have varying levels of availability as the 
bacteria physically traverse from the nasopharynx (e.g. saliva, mucosa and other co-
occupying flora), blood to CSF microenvironments (Schoen et al., 2014). Although the 
meningococci possess pathways necessary for the complete catabolism of glucose and 
biosynthesis of pyruvate (Baart et al., 2007), preferential acquisition of carbon sources can 
depend on circumstances such as competition, stress, metabolic or disease progress. For 
example, lactate can be catabolised at a faster rate than simultaneously available glucose, 
while its use also contributes to LPS sialylation and hence resistance to complement-
mediated killing by host immune responses (Exley et al., 2005a; Smith et al., 2007). 
Transport of glucose and maltose in N. meningitidis are carried out by ion-driven 
symporters GlcP and MalY (Derkaoui et al., 2016), while transport of lactate is carried out 
by a lactate permease (LctP) homologue NMB0543 (Exley et al., 2005b). Amino acids 
such as glutamate can also serve as carbon sources, acquired by two transporter systems in 
N. meningitidis: the ABC-family transporter GltT-GltM and sodium-dependent transporter 
GltS (Takahashi et al., 2015), but can also utilise its NADP-specific glutamate 
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dehydrogenase GdhA to synthesise glutamate (Pagliarulo et al., 2004). Interestingly, influx 
of glutamate via these transporters triggers internalisation of meningococci into host cells 
which also appears to be a crucial pathogenicity trait when surviving in human blood or 
CSF (Takahashi et al., 2011). In turn, amino acids and – most importantly – ammonia 
serve as primary nitrogen sources for N. meningitidis (Jyssum, 1959). Other systems 
implicated in meningococcal nitrogen assimilation include the regulatory protein IIANtr 
(Ren et al., 2005).  
Thus, the meningococcal citric acid cycle indeed serves as a highly versatile workhorse 
which contributes to adaptation towards a plethora of nutrients, fitness and ultimately 
virulence.  
1.6.2 Stress response mechanisms 
Both endogenous and exogenous sourced oxidative stress are encountered by N. 
meningitidis, mainly in the form of reactive oxygen species (ROS). Firstly, leakage of 
electrons from bacterial respiratory chain results in the natural accumulation of peroxides 
(H2O2) and superoxide (O2.-), which can be managed by basal defences. Secondly, the 
major adversary to meningococcal establishment are patrolling host macrophages capable 
of generating peroxides as “oxidative bursts” (Duane et al., 1993). This is achieved 
through the phagosomal NADPH oxidase (NOX) system (DeCoursey and Ligeti, 2005; 
Panday et al., 2015). The third type consists of competing organisms such as Streptococcus 
pneumoniae which can also generate similar levels of bactericidal peroxides via pyruvate 
oxidase (SpxB), killing niche co-occupants (i.e. Haemophilus influenzae) and contributing 
to host cytotoxicity (Pericone et al., 2000). Appreciably these challenges are further 
heightened during pathogenesis, and must therefore be dealt with through dedicated 
oxidative stress response mechanisms.  
N. meningitidis employs a catalase (KatA) expression mechanism tightly regulated by 
OxyR (Ieva et al., 2008). OxyR also regulates other enzymes such as the two-domain 
peroxiredoxin-glutaredoxin (Prx) and glutathione oxidoreductase (Gor) which belong to 
the same operon in N. gonorrhoeae (Seib et al., 2007). Other antioxidant enzymes used by 
N. meningitidis include Bcp (of the alkylhydroperoxidase C family AhpC) (Poole, 2005) 
and GpxA (glutathione peroxidase) (Moore and Sparling, 1995; Moore and Sparling, 
1996). Different catalases and peroxidases have varying affinity depending on substrate 
levels, which arguably confer flexibility enabling N. meningitidis to deal with both low and 
high concentrations of ROS effectively. Another popular method in pathogenic Neisseriae 
involves metalloenzyme superoxide dismutase (SOD), where N. gonorrhoeae sees a 
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predominantly manganese-cofactered SOD ([Mn]-SOD) system in action while N. 
meningitidis makes use of copper and zinc-cofactored SOD ([Cu,Zn]-SOD) (Dunn et al., 
2003; Seib et al., 2004). These periplasmic SODs, together with their cytosolic 
counterparts, protect bacteria against exogenous and endogenous sources of superoxide 
damage respectively, which act as major virulence determinants and potentially worthy 
therapeutic targets (Pratt et al., 2015). 
Lastly, the most illustrious case linking metabolism and stress response rests with the 
partial denitrification pathway in Neisseria. In the absence of oxygen, both pathogenic 
Neisseriae can respire by converting nitrite (NO2-) to nitrous oxide (N2O) via an 
intermediate nitric oxide (NO). NO is known as a reactive nitrogen species (RNS) and 
induces nitrosative stress to bacterial cells. Both Neisseriae possesses the copper-
containing nitrite reductase (AniA) converting nitrite to NO, while the nitric oxide 
reductase (NorB) catalyses the detoxification of NO to nitrous oxide (Jen et al., 2015). The 
anoxic urogenital tract occupied by N. gonorrhoeae and the aerobic nasopharynx occupied 
by N. meningitidis may have contributed to differences in regulation and expression of this 
system (Edwards et al., 2012). In brief, this example describes a scenario where nutrient 
(metal) acquisition and utilisation, metabolism (respiratory adaptation) and stress response 
all come together to contribute to the lifestyle of N. meningitidis.    
1.7 Aims of this work 
Prior to invasive disease, exclusive human pathogens such as N. meningitidis capable of 
prolonged periods of asymptomatic carriage first need to demonstrate general fitness in the 
form of successful colony establishment, where a key combination of host immune 
evasion, defence against competition and acquisition of nutrients from an ever-changing 
environment indisputably account for much of that prowess. The 9 genomic islands highly 
conserved in pathogenic Neisseria represent an intriguing aspect of meningococcal 
research due to their general association with cellular functions that are seldom considered 
iconic virulence determinants. 
The functional characterisation of Genomic Islands 3 and 5 is the focus of this study. The 
two are of particular interest as bioinformatics suggest a commonality between the two in 
the form of possible polyamine biosynthesis pathways originating from a mutual amino 
acid (i.e. arginine) and precursors. Positively-charged polyamines were often associated 
with protecting bacterial cells against oxidative stress experienced during exponential 
growth by aiding in the maintenance of normal homeostasis. Although meningococcal 
pathogenicity is multi-factorial, the fact that genes predicted to encode for such systems are 
highly conserved in pathogenic strains of Neisseria warrants further investigation in an 
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ongoing effort to determine if they contribute to fitness and to what extent promote 
disease.  
This work aims to characterise the genomic islands by assessing the strength and 
legitimacy of the preliminary data, confirming their purported functions experimentally 
and to extrapolate their general significance to the human pathogen with current and 
potential new findings. It is hoped that new knowledge derived from this work will 
contribute to combating infectious meningococcal disease, as well as improving 
understanding of a highly-capable bacteria responsible for only human deaths. 
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Chapter 2 – Materials and Methods 
2.1 Bacterial strains and plasmids used in this work 
2.1.1 Bacterial strains used in this work 
Strain Genotype and Description 
Source / 
Reference 
Escherichia coli  
DH5α 
For general clong, carrying F-φ80dlacZ∆M15 
∆(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ- 
InvitrogenTM 
N. meningitidis  
MC58 
Wild-type, serogroup B, clonal group ET-5 
McGuinness 
et al., 1991 
N. meningitidis 
NMB0240::SpecR 
MC58 with spectinomycin resistance cassette 
insertion disrupting genomic copy of 
NMB0240 
Catenazzi, 
2013 
N. meningitidis 
NMB0468::SpecR 
MC58 with spectinomycin resistance cassette 
insertion disruption genomic copy of 
NMB0468 
Catenazzi, 
2013 
N. meningitidis 
NMB0468::SpecR 
NMB0468+NMB0469+ 
NMB0468- mutant complemented with intact 
copies of NMB0468 and NMB0469 
This work 
N. meningitidis  
NMB0573::KanR 
MC58 transformed with disrupted genomic 
copy of NMB0573 from NMV_1850- 
kanamycin resistant 
mutant serogroup C strain 8013 
Dr. V. Pelicic 
and this work 
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2.1.2 Plasmids used in this work 
Plasmid Description 
Source / 
Reference 
pCR®-Blunt II-TOPO® 
For cloning blunt-end PCR product, 
linearised plasmid cloning vector with  
kanamycin resistance cassette 
InvitrogenTM 
pKHE2 
Vector with erythromycin resistance 
cassette from pYHS25 plasmid,  
Opa promoter replaced by  
pBluescript multiple cloning site 
Dr. K. 
Heurlier 
 
2.2 Culturing bacterial strains 
2.2.1 General growth and stocking of Escherichia coli DH5α 
Once transformed, E. coli DH5α works as an intermediate host commonly employed in 
molecular cloning for the amplification of desired plasmid constructs. The chemical 
composition of LB media (Table 2.1 (a)) and agar plates (Table 2.1 (b)) are listed 
accordingly, differing only in the addition of agar powder. Both were mixed and sterilised 
by autoclaving, but LB agar enters a molten state and should be cooled down to about 40 
˚C in a warm water bath before pouring to Petri dishes 85 mm in diameter (Sterilin®) at 20 
ml portions. The appropriate antibiotics can be added to select for mutant strains just 
before pouring molten agar plates or at the start of freshly inoculated liquid cultures. 
To prepare new stocks for storage or obtain fresh culture for experimental work, fresh 
colonies were spread onto LB agar plates from previous glycerol stocks and incubated at 
37 ˚C overnight. For liquid cultures, E. coli colonies were then inoculated into 8 ml LB 
media in 30 ml McCartney bottles and grown overnight under aerobic conditions at 37 ˚C 
on an Innova® 2000 open air platform shaker (New Brunswick Scientific) at 220 rpm. 
Glycerol stocks can be created by storing equal volumes of liquid E. coli cultured in LB 
with 50 % (v/v) glycerol/water in appropriately-sized Eppendorf tubes (Sarstedt) at -80 ˚C.  
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 (a) LB media [g/L] (b) LB agar plates [g/L] 
Tryptone (Melford) 10 g 10 g 
Yeast Extract 
(FormediumTM) 
5 g 5 g 
NaCl (Fisher Chemical) 5 g 5 g 
Agar (FormediumTM) N/A 15 g 
Deionised H2O Topped to a final volume of 1 L 
Table 2.1 – Composition of Lysogeny Broth (LB) (a) media and (b) agar plates.  
2.2.2 Preparation of chemically-competent Escherichia coli DH5α cells 
Chemically-competent E. coli DH5α cells were used in this work to enable the uptake of 
pCR®-Blunt II-TOPO® (InvitrogenTM) constructs containing desired genetic sequences, 
which were first amplified by PCR, purified, treated and blunt-end-cloned onto the plasmid 
according to the manufacturer’s instructions. The original non-competent E. coli DH5α 
cells were prepared according to the methodology as described by Hanahan (Hanahan, 
1983) before being stored as single-use aliquots at -80 ˚C. 
Fresh colonies were spread onto LB agar plates from glycerol stocks and incubated at 37 
˚C overnight. Colonies were picked and inoculated into 50 ml LB media, which were then 
incubated at 37 ˚C at 200 rpm on an Innova® 2300 open air platform shaker (New 
Brunswick Scientific) until an OD600 (optical density reading at 600 nm) of around 1 
(approximately 109 cfu/ml) was reached. Cells were harvested by transferring the liquid 
culture into 50 ml CELLSTAR® Falcon tubes (greiner bio-one) before placing into an 
AllegraTM X-22R benchtop centrifuge (Beckman CoulterTM) to be spun down at 4000 rpm 
at 4 ˚C for 20 minutes.  The supernatant was discarded and the pellet resuspended in 15 ml 
of ice-cold RF1 Buffer (Table 2.2(a)) before being further centrifuged at 4 ˚C for another 
10 minutes. Lastly, the supernatant was again discard and the pellet resuspended in 5 ml of 
ice-cold RF2 Buffer (Table 2.2(b)) and kept on ice for 15 minutes. At this step, the cells 
must not be allowed to warm up if they are to remain competent. If the cells were not 
immediately used for transformation, they may be stored as single-use 400 µl aliquots (100 
µl per transformation reaction). 
 
 
 
  31 
(a) RF1 Buffer Amount Final concentration 
KCl (Fisher Scientific) 2.4 g 160.94 mM 
MgCl2•6H2O (Fisher Scientific) 2.4 g 59.02 mM 
K acetate (Melford) 0.6 g 30.57 mM 
CaCl2•2H2O (Fisher Chemical) 0.3 g 10.20 mM 
Glycerol (Sigma-Aldrich®) 30 ml 15 % (w/v) 
Deionised H2O Topped to a final volume of 200 ml, pH 5.8 
 
(b) RF2 Buffer Amount Final concentration 
0.5 M MOPS, pH 6.8 (Acros Organics) 4 ml 2 % (w/v) 
KCl (Fisher Scientific) 0.3 g 20.12 mM 
CaCl2•2H2O (Fisher Chemical) 2.2 g 74.82 mM 
Glycerol (Sigma-Aldrich®) 30 ml 15 % (w/v) 
Deionised H2O Topped to a final volume of 200 ml, pH 5.8 
Table 2.2 – Composition of (a) RF1 and (b) RF2 Buffers used to chemically render bacterial cells 
competent and ready for transformation. 
2.2.3 General growth, stocking of Neisseria meningitidis and bacterial growth curves 
The laboratory Neisseria meningitidis MC58 used in this work was first donated by 
Professor Robert Read from the University of Sheffield, and its genome is identical to the 
completely sequenced serogroup B strain (Tettelin et al., 2000). It was used as a wild-type 
control in experiments as well as a genomic template for molecular work. To comply with 
health and safety, all cultures or plates of N. meningitidis MC58 wild-type and genetically 
knocked-out mutant strains were handled inside a Category 2* flow hood to prevent 
contamination, exposure to air and potential release of meningococcal aerosols.  
Fresh colonies of N. meningitidis were spread onto horse blood agar (HBA) plates from 
glycerol stocks and incubated at 37 ˚C in a 5 % CO2 atmosphere for two overnights. HBA 
plates were prepared by mixing and autoclaving Columbia Blood Agar (CBA) base 
(Oxoid), cooling the molten agar to 40 ˚C in a warm water bath, adding defibrinated horse 
blood (Thermo Scientific) to a final concentration of 5 % (v/v) before pouring to Petri 
dishes 85 mm in diameter (Sterilin®) at 20 ml portions. The appropriate antibiotics can 
also be added to select for mutant strains just before pouring molten agar plates or at the 
start of freshly inoculated liquid cultures. 
For liquid cultures, colonies were inoculated into either Müller-Hinton Broth (MHB) 
(Oxoid) or a minimal, chemically-defined media (CDM) (See Chapter 4 and 5) adapted 
from the original recipe first described by Catlin (Catlin and Schloer, 1962) (Table 2.3).  
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CDM Chemicals used Stock concentration Final concentration 
Solution 1 
(Metals) 
40X 
MgCl2 (Sigma-Aldrich®) 78 mM 1.95 mM 
CaCl2 (Sigma-Aldrich®) 8.15 mM 0.20 mM 
Ferric citrate  
(Sigma-Aldrich®) 
6.5 mM 0.15 mM 
Dissolved in deionised H2O, stirred at 50˚C for 3hrs, pH adjusted to 7 and filter 
sterilised 
Solution 2 
(Salts) 
20X 
NaCl (Fisher Chemical) 2 M 100 mM 
K2SO4 (Sigma-Aldrich®) 114.8 mM 5.75 mM 
K2HPO4 (Sigma-Aldrich®) 460 mM 23 mM 
NH4Cl (Fisher Chemical) 360 mM 18 mM 
Dissolved in deionised H2O, stirred in room temperature for 10 minutes prior to 
autoclaving 
Solution 3 
(Amino Acids) 
20X 
Glycine (Fisher Chemical) 75.6 mM 3.8 mM 
L-cysteine  
(Sigma-Aldrich®) 
8.3 mM 0.4 mM 
L-arginine  
(Sigma-Aldrich®) 
14 mM 0.7 mM 
L-glutamine  
(Sigma-Aldrich®) 
80 mM 4 mM 
L-serine (Sigma-Aldrich®) 95 mM 4.75 mM 
Dissolved in deionised H2O, stirred at 40˚C for 1h and filter sterilised 
Solution 4 
(Carbon Source) 
224X 
D-glucose  
(Fisher Chemical) 
560 mM 2.5 mM 
Dissolved in deionised H2O, vortexed until complete dissolution of sodium 
bicarbonate and filter sterilised 
Solution 5 
(CO2 Source) 
100X 
NaHCO3 (Fluka) 1 M 10 mM 
Dissolved in deionised H2O, pH adjusted to 7 and filter sterilised 
Table 2.3 – Chemical composition and preparation method of stock components of the 
chemically-defined media (CDM) standard to this work. The final CDM solution was prepared 
prior to liquid culturing by freshly mixing appropriate volumes of Solutions 1, 2, 3, 4 and 5 and 
topped up with autoclaved deionised H2O. Final pH should be between 7 to 7.5. 
Both media contain a supplement of 10 mM final concentration NaHCO3 (Sigma-Aldrich) 
which was freshly administered prior to incubation. Inoculated liquid cultures were 
calibrated to start from an OD600 of 0.1 and grown in volumes of 10 ml in 25 ml 
polypropylene universal tubes (Sarstedt) under aerobic conditions at 37 ˚C in a C25KC 
incubator shaker (New Brunswick Scientific) at 200 rpm. Glycerol stocks can be created 
  33 
by storing equal volumes of liquid N. meningitidis cultured in MHB with 50 % (v/v) 
glycerol/MHB in appropriately-sized Eppendorf tubes (Sarstedt) at -80 ˚C. 
For growth curve experiments, N. meningitidis liquid cultures were grown in biological 
and technical triplicates over 24-hour periods, collecting data at the first 12 as well as the 
last hourly time points by measuring OD600 using 1.5 ml cuvettes (Kartell Labware) with a 
Jenway 6300 spectrophotometer (Jenway). Samples were usually diluted at a 1:1 ratio with 
the appropriate blank (i.e stock MHB or CDM with or without supplemented chemicals) in 
order to match the optimal sensitivity range of the spectrophotometer while avoiding over-
depletion of ongoing culture volumes. 
For CDM-based investigations, any chemical component can be introduced on top of 
existing composition, replace default components or left out from the recipe using the 
spare water volumes to accommodate for the differences. Individual amino acid stock 
solutions were prepared by dissolving in deionised H2O to 100 mM stocks in 50 ml 
CELLSTAR® Falcon tubes (greiner bio-one) prior to filter-sterilisation with 0.22 µm 
Millipore filters (Millipore). Alternatively, some amino acids were clustered together into 
combined stocks (See Chapter 4). Depending on desired final concentrations, amino acids 
can be freshly mixed into CDM along with other stock components, or spiked with a 
pipette on a tube-by-tube basis. All amino acid solutions can be unstable and should be 
kept at 4 ˚C at all times for periods no longer than 1 month, after which fresh new stocks 
must be prepared in order to prevent abnormal growth. All amino acids apart from L-
glycine (Fisher Chemical) were obtained from Sigma-Aldrich. 
Results were presented as growth curves (from representative biological replicates), which 
are joined scatter plots with error bars extrapolated from standard error of the mean (SEM) 
between technical replicates at each time point. Where necessary, the scales of the y-axes 
of individual sets of data were adjusted on a case-by-case basis to increase resolution of the 
figures for better comparison of details, and were therefore not consolidated across the 
Chapters. 
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2.2.4 Use of antibiotics 
 Where applicable, antibiotics were added to directly to liquid media or cooled molten agar 
if selective plates were desired. The final concentrations of the antibiotics used in E. coli 
and N. meningitidis were shown in Table 2.4. 
Antibiotic E. coli N. meningitidis 
Erythromycin (Ery) 200 µg/ml 5 µg/ml 
Kanamycin (Kan) 50 µg/ml 80 µg/ml 
Spectinomycin (Spec) 50 µg/ml 50 µg/ml 
Table 2.4 – Suitable final concentrations of antibiotics in selective media or plates for E. coli and 
N. meningitidis respectively. 
2.3 Molecular Techniques 
2.3.1 Polymerase chain reaction (PCR) 
Polymerase chain reactions (PCR) were used to amplify desired genetic fragments for 
screening or cloning purposes. Primer pairs specific to their complementary templates were 
first designed, where ideally melting temperatures (Tm) could be synchronised with as little 
discrepancy as possible. If products were to be digested following amplification, restriction 
enzyme sites could be created by mismatches towards the 5’ end of the primers. Three 
more bases should extend after the end of the restriction sites. To promote specific binding, 
G/C clamps should be included towards the 3’ end of the primers. 
All primers used in this work were custom synthesised as oligonucleotides by Sigma 
Oligos (Sigma-Aldrich) and listed in their corresponding results chapters (See Tables 3.2, 
3.3, 4.2 and 5). Wild-type or mutant N. meningitidis MC58 genome served as the central 
template for obtaining bacterial DNA sequences, while plasmid DNA were used in specific 
protocols instead. Genomic DNA stock can be extracted from harvested N. meningitidis 
cells using tools such as the Wizard® Genomic DNA Purification Kit (Promega) and 
stored at -20 ˚C. Template DNA mays also be obtained by picking single colonies with a 
10 µl micropipette tip and directly suspending into the PCR reaction mix. 
Typical PCR reaction mixes were prepared using GoTaq® G2 DNA Polymerase kit 
(Promega) and 2.5 mM dNTPs (Lucigen®) (Table 2.5). PCR reactions were run by a 
programmable Techne TC-3000 PCR Thermo Cycler (Table 2.6). To optimise for specific 
primers or anticipated PCR product length, annealing temperatures and extension times 
were adjusted accordingly. If subsequently used for cloning work, the amplified fragments 
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were purified using the QIAquick PCR Purification Kit (Qiagen) and a Sigma 1-13 
microcentrifuge (Sigma) according to the manufacturer’s instructions. 
Reagent Final concentration Amount 
100 µM forward primer 2 µM 1 µl 
100 µM reverse primer 2 µM 1 µl 
5X Green GoTaq® Reaction 
Buffer 
0.5X 10 µl 
2.5 mM dNTP Mix 200 µM 4 µl 
Sterile deionised H2O N/A 33 µl 
Template N/A 0.5 µl or tip-picked colony 
GoTaq® G2 DNA Polymerase 5 U/µl 0.5 µl 
Final volume 50 µl 
Table 2.5 – Typical 50 µl PCR reaction mixtures for both stock or colony-derived 
genomic DNA templates, which may be further divided into smaller aliquots. Template 
concentrations may vary depending on stock concentration or aggregated size of picked 
colonies.  
Programmed step Stage Temperature and time 
1 Initial denaturation 95 ˚C for 5 mins 
2 
35 
cycles 
Denaturation 94 ˚C for 30 sec 
Annealing* 65 ˚C for 30 sec 
Extension** 72 ˚C for 5 mins 
3 Final extension 72 ˚C for 8 mins 
Hold Storage 16 ˚C – ∞ 
Table 2.6 – PCR thermal cycler protocols typically found in this work. PCR reactions were run 
based on settings input, where annealing (*) and extension (**) times and temperatures could be 
altered for primer or product length optimisation. During complementation cloning, annealing 
temperatures varied between 60 – 69 ˚C, while extension times varied between 2 – 10 minutes. 2-
step PCR were also attempted using the Q5 High Fidelity DNA Polymerase (New England 
BioLabs®) i.e. by splitting the 35 cycle counts into 10 and 25 times for different annealing 
temperature or extension time settings. Individual primer annealing temperatures were projected 
from the calculated melting temperatures (Tm) of each synthesised oligonucleotide, while extension 
time was based approximately on an amplification rate of 1 minute per kb of DNA. 
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2.3.2 Cloning with pCR®-Blunt II-TOPO® 
This study made use of Zero Blunt® TOPO® PCR Cloning Kit (InvitrogenTM) to clone the 
complementation genes into the 3.52 kbp pCR®-Blunt II-TOPO® vector containing a 
kanamycin resistance cassette. Sequencing was done to check the resulting constructs for 
correctly oriented inserts due to the nature of blunt-end cloning, where there are 50/50 
chances of genes ligated in the opposite direction (Figure 2.1). 
 
Fig. 2.1 – Map of pCR®-Blunt II-TOPO® plasmid construct ligated with gene of interest in (a) 
normal or (b) opposite directions. KanR: kanamycin resistance cassette. 
Optimising from the manufacturer’s protocol, typical blunt-end cloning reactions were set 
up in a 1.5 ml Eppendorf tube (Sarstedt), following by mixing 3.5 µl sterile deionised H2O, 
1 µl Salt Solution, 1 µl Control PCR product or purified PCR product and 0.5 µl pCR®-
Blunt II-TOPO® vector. The 6 µl mixture was incubated for 5 minutes at room 
temperature, allowing for the ligation step, after which the reaction was kept on ice.  
2.3.3 Restriction digestion of DNA with endonucleases 
Restriction digests were performed according to the manufacturer’s instructions of each 
restriction enzyme, which were normally selected for their presence on the genes 
concerned but not their cloning vectors (i.e. pCR®-Blunt II-TOPO®).  
Typical 20 µl DNA digest reactions were conducted in 0.5 ml Eppendorf tubes (Sarstedt) 
by mixing 12 µl sterile deionised H2O, 5 µl purified plasmid DNA, 2 µl 10X Restriction 
Buffer (New England BioLabs®) specific for the enzyme of choice (container caps were 
colour-coded to match), and 1 µl restriction enzyme (Promega). 0.2 µl 100X BSA (bovine 
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serum albumin) (New England BioLabs®) may be added optionally to stabilise enzymes in 
overnight reactions. Reactions were then incubated at 37 ˚C for 1.5 hours, followed by 
treatment with 0.5 µl calf intestinal alkaline phosphatase (CIP) (New England BioLabs®) 
for 30 minutes. In the event of sticky-ended products as a result of digestion, 0.5 µl DNA 
Polymerase I Klenow Fragments (New England BioLabs®) and 0.5 µl 2.5 mM dNTP 
(Lucigen) may be added 30 minutes before the end of the incubation period. The end 
products were purified by QIAquick PCR Purification Kit (Qiagen) according to the 
manufacturer’s instructions. 
2.3.4 Ligation of DNA fragments 
Gene fragments purified from PCR or agarose gels as well as cut plasmids may be ligated 
together to create intermediate constructs, where sequences of interest may be investigated 
following transformation or introduced to cells for amplification. Typical ligation reactions 
consist of 5 µl sterile dH2O, 3 µl linearised, purified gene of interest, 1 µl 10X T4 DNA 
Ligase Buffer (Promega) and 1 µl T4 DNA Ligase (Promega), which were mixed and 
incubated overnight at room temperature. The resulting constructs may be subsequently 
transformed into competent cells and selected for using the corresponding antibiotics. To 
check for correctly ligated constructs, transformed plasmids may be restriction digested 
using the corresponding enzymes as aforementioned (Section 2.3.3), ran on an agarose gel 
and see if expected DNA fragment sizes were observed before sending purified samples 
for sequencing for final confirmation. 
2.3.5 Agarose gel electrophoresis and DNA gel extraction 
Products obtained from PCR (Section 2.3.1) or restriction digests (Section 2.3.3) can be 
resolved in agarose gel electrophoresis to assess fragment sizes and expression. 1 % 
agarose gels were typically prepared by fully dissolving 1 g agarose powder (Melford) in 
100 ml of 0.5X Tris-Borate-EDTA (TBE) buffer (Table 2.7) under heat in a microwave for 
about 2-3 minutes. Following cooldown to 40 ˚C by running tap water against the glass 
container with constant shaking, the molten solution was stained with 10 µl 10,000X 
SYBR® Safe DNA Gel Stain concentrate (InvitrogenTM) for nucleotide visualisation and 
poured into the desired casting trays with corresponding combs matching required number 
of lanes. 
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Reagent Final concentration Amount 
UltraPureTM Tris (InvitrogenTM) 45 mM 54.5 g 
Boric acid  
(Fisher Chemical) 
45 mM 27 g 
EDTA (Fisher Chemical) 1 mM 3.72 g 
Deionised H2O Up to 10 L 
Table 2.7 – TBE buffer is a mixture of Tris, boric acid and EDTA in dH2O, which can be stored at 
room temperature for several months. 
Air bubbles may be prevented by mixing the solution gently or eliminated by dipping an 
inverted pipette tip on top. The gel was left to set in the tray by cooling down to room 
temperature for 30 minutes, after which the set-up was placed into an electrophoresis tank 
and immersed in 0.5X TBE running buffer. Normally, about 8 µl of PCR samples stained 
with 5X Green GoTaq® Reaction Buffer was directly loaded to each well by careful 
pipetting, as they already contain blue and yellow loading dyes. Other unstained reaction 
mixtures such as restriction-digested products or DNA ladders were mixed with 6X Purple 
Gel Loading Dye (no SDS) (New England BioLabs®) before loading into the wells, e.g. 1 
µl of 6X loading dye for 5 µl of sample mixture or ladder. Ideally two flanking lanes of of 
7 µl of Low Molecular Weight DNA Ladder (New England BioLabs®), 2-Log DNA 
Ladder (New England BioLabs®) or 1 kb DNA Ladder (Thermo Scientific) were added as 
reference according to the expected size ranges of the sample DNA fragments for 
comparison. Gels were run at 100 V for at least 45 minutes with a PowerPacTM 300 
apparatus (Bio-Rad), and may be extended to better resolve bands of similar sizes or to 
facilitate possible gel excision. DNA was visualised under UV illumination using a 
GeneGenius BioImaging System apparatus (Syngene) and the GeneSnap software, where 
digital photos were taken and saved as TIFF files or printed. 
DNA fragments of interest may be excised from the gel with a sharp, clean scalpel and 
placed into 1.5 ml Eppendorf tubes (Sarstedt), which were subsequently purified using the 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. 
2.3.6 Transformation of chemically-competent Escherichia coli DH5α  
Plasmid DNA constructs may be introduced into E. coli DH5α cells made competent 
following chemical treatment (Section 2.2.2). 100 µl aliquots of chemically-competent E. 
coli DH5α cells were quickly thawed on ice and mixed with 6 µl blunt-end cloned reaction 
mixture (Section 2.3.2). The combined mixture was incubated on ice for 30 minutes, heat 
shocked at 42 ˚C for 90 seconds and finally cooled on ice for a further 2 minutes. As a 
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recovery stage, the reaction was incubated at 37 ˚C on a SSL1 shaker (Stuart®) at 200 rpm 
for 1 hour following addition of 800 µl of liquid LB medium. Cells were harvested by 
centrifugation at 13000 rpm for 60 seconds and the pellet resuspended with 100 µl fresh 
liquid LB medium, which can then be plated onto corresponding antibiotic LB agar plates 
i.e. kanamycin in the case of pCR®-Blunt II-TOPO®. Plates were incubated overnight at 
37 ˚C for selection and resistant colonies were picked for screening or re-streaked where 
necessary. 
2.3.7 Isolating plasmid DNA 
Correct resistant colonies acquired from above (Section 2.3.6) were picked and inoculated 
into 8 ml of liquid LB medium in 30 ml McCartney bottles. Antibiotics corresponding to 
the ones used on selective plates were added to the growth medium to maintain selection 
for cells containing the resistant plasmid constructs. For Minipreps, cells were aerobically 
cultured on an Innova® 2000 open air platform shaker (New Brunswick Scientific) at 220 
rpm at 37 ˚C overnight, and subsequently harvested by spinning at 4500 rpm at 4 ˚C for 10 
minutes using a AllegraTM X-22R centrifuge (Beckman CoulterTM). For low yield plasmids 
such as pKHE2, Midipreps were prepared by growing 50 ml of cells overnight in a sterile 
250 ml conical flask on an Innova® 2300 open air platform shaker (New Brunswick 
Scientific) and harvested using the QIAGEN Plasmid Midi Kit (Qiagen) together with a 
highspeed Sorval Evolution RC Centrifuge (Sorval). Extraction and purification of 
plasmidal DNA were carried out with QIAprep Spin Miniprep Kit (Qiagen) with a Sigma 
1-13 microcentrifuge (Sigma) according to the manufacturer’s instructions. The resulting 
plasmids were stored at -20 ˚C until further use. 
2.3.8 Transformation of Neisseria meningitidis strain MC58 
Naturally competent N. meningitidis cells actively conducts DNA uptake of foreign genetic 
materials followed by homologous chromosomal recombination. This facilitates 
transformation of meningococcal strains in molecular biology. Cultures of N. meningitidis 
strain MC58 grown in MHB were prepared as described in Section 2.2.3 until they reach 
an OD600 of approximately 1.0, after which they were placed in 2 ml Eppendorf tubes 
(Sarstedt) and harvested with a Sigma 1-13 microcentrifuge (Sigma) at 8000 rpm for 5 
minutes.  
Dr. Melanie Thomson and Dr. Willa Huston devised a protocol for a Transformation and 
Storage Buffer (TSB), which is a filter-sterilised solution of MHB with 10% PEG 4000, 10 
mM MgCl2, 10 mM MgSO4 and 5% DMSO at a final pH of 6.5. 1 ml single-use aliquots 
were stored at -80 ˚C. Harvested pellets of N. meningitidis were resuspended in 200 µl ice-
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cold TSB and incubated on ice for 10 minutes. 10 µl of purified plasmid constructs was 
mixed into the TSB-suspended cells and incubated on ice for a further 50 minutes to allow 
for transformation. No plasmid was added as a control.  
For each transformation reaction, 1.5 ml aliquots of MHB with 10 mM NaHCO3 was pre-
warmed to 37 ˚C in 25 ml polypropylene universal tubes (Sarstedt). The reaction mixture 
was subsequently transferred into the pre-warmed MHB for recovery and cultured 
aerobically in a C25KC incubator shaker (New Brunswick Scientific) for 1.5 hours at 37 
˚C and 200 rpm. Pellets were harvested by centrifugation at 8000 rpm for 5 minutes and 
resuspended in 100 µl of fresh MHB prior to plating onto corresponding antibiotic HBA 
plates. The control was also split and plated on HBA with and without antibiotics to check 
for spontaneous resistance. Following overnight incubation at 37 ˚C and 5% atmospheric 
CO2, antibiotic-resistant mutants were selected and colonies were picked for PCR 
screening and overnight re-streaking using the same antibiotic plates and conditions. This 
was to reduce the possibility of seeing wild-type bands from dead wild-type cells in the 
background during PCR. Multiple colonies were picked again for PCR screening following 
re-incubation, and glycerol stocks of the colonies yielding the expected DNA fragments 
were prepared and stored at -80 ˚C. 
2.3.9 DNA sequencing  
Plasmid DNA was diluted to approximately 100 ng/µl with deionised H2O and sent for 
sequencing by the Technology Facility at the University of York using a 16-capillary 
electrophoresis instrument – ABI 3130xl Genetic Analyzer (Applied Biosystems) – and the 
3130xl Data Collection Software (Applied Biosystems). The data acquired was exported in 
.ab1 file format which was analysed with the Sequence Scanner Software v2.0 software 
(Applied Biosystems), or converted to a Word document for analysis with other 
bioinformatics tools. For constructs derived from the pCR®-Blunt II-TOPO® plasmid, 
both forward and reverse T7 sequencing primers were used. 
2.3.10 Determining DNA or RNA concentrations 
Nucleotide concentration and purity were measured and determined using a NanoDrop® 
ND-1000 Spectrophotometer (Thermo Scientific). Concentration is based on absorbance at 
wavelength (λ) 260 nm and the respective wavelength-dependent extinction coefficient for 
DNA (“DNA-50” mode for double-stranded DNA, 50 ng-cm/µl) or RNA (“RNA-40” 
mode for RNA, 40 ng-cm/µl), on a baseline “zero” absorbance at λ 340 nm.  
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The ratio 260/280 is commonly used to assess nucleic acid purity in samples and is 
particularly important in determining DNA contamination in RNA samples. Acceptably 
pure DNA samples should generally have a ratio value of around 1.8, while for pure RNA 
samples it should be around 2.0. The ratio 260/230 is commonly used to assess ethanol 
contamination during respective nucleic acid purification processes, where pure samples 
should have expected values in the range of 2.0-2.2 
Upon each reading, the instrument was blanked with 1.2 µl of Nuclease-Free dH2O 
(Ambion®). 1.2 ul of DNA or RNA sample was then pipetted onto the spectrophotometer 
and the automatic measurements presented in the aforementioned values by the ND-1000 
v3.7.1 software.  
2.3.11 Extraction of total RNA from N. meningitidis 
Total RNA from both wild-type and mutant N. meningitidis strains were extracted for 
quantitative PCR (qPCR) experiments. Cells were plated overnight and cultured 
aerobically in MHB up to a desired OD600 as described in previous sections, or up to mid-
log phase for about 12 hours. At appropriate time points or the end, 1 ml of each sample 
was transferred into 1.7 ml RNase-free MaxyClearTM Snaplock microcentrifuge tubes 
(Axygen®) and harvested with a Sigma 1-13 microcentrifuge (Sigma) at 12000 rpm for 5 
minutes. The supernatant was discarded and the pellet quickly stored in -80 ˚C due to 
instability of bacterial RNA. 
A stock solution of Tris-EDTA Buffer 100X (Sigma-Aldrich®) diluted to 1X with 
Nuclease-Free dH2O (Ambion®) was prepared and stored indefinitely at room 
temperature. Nuclease-free Lysozyme Ultrapure (usb®) was dissolved in Nuclease-Free 
dH2O (Ambion®) and filter sterilised to give a 10 mg/ml lysozyme solution to be stored at 
-20 ˚C. 10 µl ß-mercaptoethanol (Sigma-Aldrich®) per 1 ml of Buffer RLT (Qiagen) were 
mixed to give a Buffer RLT / ß-mercaptoethanol stock solution to be stored at room 
temperature up to one month. All of the above stock solutions were contained in 1.7 ml 
RNase-free MaxyClearTM Snaplock microcentrifuge tubes (Axygen®). 
Without interruption, all the following steps should be performed in a clean hood or bench 
sprayed, wiped and dried with ethanol, with minimal clutter and clearly organised work 
zones to minimise risk of sample contamination. Sterile protective disposable sleeves are 
also recommended, as well as surgical face masks, hair nets, goggles which are useful if a 
hood is not available. RNase-free tips (Axygen®), microcentrifuge tubes (Axygen® or 
Sarstedt) and dedicated pipetting equipment should also be used for RNA work. Adapting 
from “Protocol 1: Enzymatic Lysis of Bacteria” from RNAprotect® Bacteria Reagent 
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Handbook version 1/2015 (Qiagen), frozen pellets were resuspended with 1 ml 
RNAprotect® Bacteria Reagent (Qiagen) and incubated for 10 minutes at room 
temperature, whilst vortexed for 10 seconds every 2 minutes. Samples were then 
centrifuged at 13000 rpm for 5 minutes, the supernatant discarded and the pellets 
resuspended in 180 µl 1X stock Tris-EDTA Buffer. 1 mg/ml lysozyme stock solution was 
added to each sample and incubated for a further 10 minutes at room temperature, whilst 
vortexed for 10 seconds every 2 minutes. Afterwards, 700 µl Buffer RLT / ß-
mercaptoethanol stock solution was added to each sample and vortexed briefly. If 
particulates were visible, the samples were centrifuged at 13000 rpm for 2 minutes to 
retrieve only the supernatant. 500 µl 100% ethanol was mixed into the lysate by gentle 
pipetting and transferred onto the spin-column provided by the RNeasy® Mini Kit 
(Qiagen). Following the manufacturer’s instructions, “Protocol 7: Purification of Total 
RNA from Bacterial Lysate Using the RNeasy Mini Kit” version 1/2015 (Qiagen), total 
RNA was finally extracted. An optional but recommended on-column DNase digestion 
step can also be carried out according to Appendix B (Qiagen) of the manufacturer’s 
handbook prior to washing and eluting the RNA extract. 
Purified RNA samples may be assessed with a NanoDrop spectrophotometer as described 
in Section 2.3.10 or stored at -80 ˚C until use for the subsequent cDNA synthesis stage. 
2.3.12 Synthesis of cDNA 
SuperScriptTM II Reverse Transcriptase kit (InvitrogenTM) was used to synthesise cDNA 
copies of total RNA extracts according to the manufacturer’s instructions. Typical reverse 
transcription reactions were set up in 1.7 ml RNase-free MaxyClearTM Snaplock 
microcentrifuge tubes (Axygen®) by mixing 1 µl 500 µg/ml Random Primers (Promega) 
and 1 µl 10 mM dNTP Mix PCR Grade (InvitrogenTM) to 10 µl purified total RNA. If the 
stock samples were more concentrated than the recommended range of 1 ng/ml – 5 µg/ml, 
Nuclease-Free dH2O (Ambion®) may be used to dilute the total RNA. 
The reactions were incubated at 65 ˚C for 5 minutes and quickly cooled on ice for 1 minute 
before adding 4 µl 5X First-Strand Buffer, 2 µl 0.1 M DTT and 1 µl RNaseOUTTM 
Recombinant Ribonuclease Inhibitor (40 units/µl) (InvitrogenTM). Following an incubation 
period of 2 minutes at 37 ˚C, 1 µl SuperScriptTM II Reverse Transcriptase (200 units) was 
added to each reaction and incubated for a further 10 minutes at 37 ˚C. The temperature 
was then increased to 42 ˚C for another 1 hour and 50 minutes, and the reaction finally 
stopped by inactivating the enzyme at 70 ˚C for 15 minutes.  
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The final step involves adding 0.5 µl RNase H (5000 units/ml) (New England BioLabs®) 
to remove remaining RNA complementary to the 20 µl cDNA reaction mixtures, 
incubating at 37 ˚C for 20 minutes and the enzyme inactivated by heating at 65 ˚C for 20 
minutes. The resultant cDNA solution was stored at -80 ˚C until further use. 
2.3.13 Quantitative PCR (qPCR) for gene expression analysis 
Quantitative PCR (qPCR) was used for the measurement of transcript levels of any target 
genes of interest. The circumstances for which qPCR was used as well as the qPCR 
primers designed by the online Primer-BLAST (NCBI) tool in this study were described in 
Chapter 3 (Section 3.2.1).  
Typical qPCR reactions were set-up by mixing 10 µl 2X Fast SYBR® Green Master Mix 
(Applied Biosystems), 5 µl diluted (at least 20 ng per 20 µl reaction) 0.1X cDNA sample, 
1 µl of each forward and reverse primer mixes (at least 200 nM each, working 
concentration of 10 µM from 100 µM stock), with the difference topped to a final volume 
of 20 µl using 3 µl Nuclease-Free dH2O (Ambion®). The reactions were then transferred 
onto 96-well Optical Reaction Plates (Applied Biosystems) and sealed before inserting into 
an ABI StepOnePlusTM Real Time PCR System instrument (Applied Biosystems) to be 
run. No-template control (NTC) wells were also included. Samples were run in triplicates 
and transcript levels were determined using the threshold cycle (CT) values (relative 
expression method) logged by the ABI StepOnePlusTM Software v2.3.  
2.4 Analytic chemistry techniques 
2.4.1 Nanocontainer-coupled mass spectrometry 
This technique was used to measure polyamine levels in culture or solution, where detailed 
procedures and background knowledge were described in Chapter 3 (Section 3.6). 
2.4.2 Labelled isotope MALDI mass spectrometry 
This technique was used to detect and assess incorporation of heavier, labelled arginine 
isotopes in bacterial peptides compared to the naturally occurring form of arginine, where 
detailed procedures and background knowledge were described in Chapter 4 (Section 4.5). 
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2.5 Protein techniques 
2.5.1 SDS-PAGE 
An important step in labelled isotope mass spectrometry (Section 2.4.2, Section 4.5), 
protein bands from N. meningitidis whole cell lysates were visualised, identified and 
selected by gel staining following resolving with SDS-PAGE. 15% SDS gels were 
prepared as described in Table 2.8.  
Chemical Resolving gel Stacking gel 
Deionised H2O 2 ml 700 µl 
Resolving gel buffer 1.5 ml N/A 
Stacking gel buffer N/A 300 µl 
10% SDS solution (Melford) 60 µl 12 µl 
Ultra Pure ProtoGel® 30% (w/v) acrylamide / 0.8% 
(w/v) bis-acrylyamide stock solution (37.5:1) 
(National Diagnostics) 
2.4 ml 200 µl 
10% (w/v) APS  
(Sigma-Aldrich®) 
50 µl 10 µl 
TEMED (Flowgen Bioscience) 10 µl 5 µl 
Table 2.8 – Composition of a 15% SDS-PAGE gel, which were typically freshly prepared but 
can be stored overnight at 4 ˚C once cast. The resolving and stacking layer were added gently to 
avoid air bubbles during acrylamide polymerisation, both of which required 30 minutes intervals to 
allow the gel to fully set. Air bubbles on top of the resolving layer can be flattened by gently 
pipetting a few drops of isopropanol. Once set, the isopropanol can be washed out with deionised 
H2O and the last drip dried by inserting a folded strip of filter paper. Air bubbles on top of the 
stacking layer can be eliminated by overflowing the stacking gel solution and gently inserting the 
comb. 
1X SDS running buffer was prepared by dissolving 25 mM UltraPureTM Tris 
(InvitrogenTM), 125 mM Glycine (Fisher Chemical) and 1.75 mM SDS (Melford). 
Resolving gel buffer was prepared by dissolving 1.5 M UltraPureTM Tris (InvitrogenTM) 
with 0.4% (w/v) SDS (Melford) calibrated to a final pH of 8.8. Stacking gel buffer was 
prepared by dissolving 0.5 M UltraPureTM Tris (InvitrogenTM) with 0.4% (w/v) SDS 
(Melford) to a pH of 6.8. 4X Native PAGE Loading Buffer supplemented with 2% SDS 
(Melford) served as a lysis and dying solution in this work, which is prepared by mixing 
0.375 ml 1% Bromophenol Blue dissolved in 100% absolute ethanol (VWR), 6.25 ml 1 M 
Tris-HCl at pH 6.8 and 8.38 ml deionised H2O in 100 ml 100% (w/v) glycerol (Sigma-
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Aldrich®). 800 µl 4X Native PAGE Loading Buffer were freshly mixed with 200 µl 10% 
SDS solution (Melford) on the day of SDS-PAGE experiment. 
SDS-PAGE gels were cast between glass plates using the Mini-Protean® System (Bio-
Rad) to a size of 6 x 8 cm wide and 1 mm thick. Typical 10-well gels can safely hold 15 µl 
of dyed samples. Protein samples were prepared by mixing harvested pellets from whole 
cell lysates with 100 µl 2% SDS-supplemented 4X Native PAGE Loading Buffer. 
Following incubation at room temperature for 1 hour for lysis and 5 minutes of heating at 
95 ˚C for protein denaturation, samples were loaded into cast wells, ideally flanked by two 
lanes of 7 µl PageRulerTM Plus Prestained Protein Ladder (Thermo Scientific). It is 
recommended that blank wells in between lanes without ladders or samples should be 
filled with loading-dyed deionised H2O at volumes equal to that of the samples. This is to 
prevent lane warping due to unequal pressure caused by large volume differences between 
lanes. The 15% gel was fastened onto a casket and immersed under 1X SDS running buffer 
in the aforementioned Bio-Rad gel tank system, and ran with a Power PAC 300 (Bio-Rad) 
power supply at a constant current of 30 mA for 30 – 60 minutes under room temperature. 
2.5.2 Staining of SDS gels 
Protein bands SDS gels were stained with either Coomassie Brilliant Blue or InstantBlueTM 
Ultrafast Protein Stain (Expedeon Protein Solutions). Coomassie Brilliant Blue stain was 
prepared by mixing 20% methanol (Sigma-Aldrich®) and 10% glacial acetic acid (Sigma-
Aldrich®) in deionised H2O, followed by addition of 0.1% (w/v) Coomassie Blue R350. 
An ethanol or methanol destain solution was also prepared by mixing 10% absolute 
ethanol (VWR) or 10% methanol (Sigma-Aldrich®) with 10% glacial acetic acid (Sigma-
Aldrich®) in deionised H2O. Both solutions were stored at room temperature indefinitely. 
Coomassie staining takes about 1 hour while detaining takes at least 1 – 2 hours or 
overnight until resolved protein bands were clearly visible. The InstantBlueTM solution, on 
the other hand, stains gels in 15 – 30 minutes and destains indefinitely in deionised H2O, 
but the solution needs to be kept at 4 ˚C after opening. During both staining and destaining 
steps, gels retrieved from SDS-PAGE were rinsed with deionised H2O, kept moist, 
immersed under the respective solutions and placed on a Gyro-Rocker® STR 9 (BIBBY 
Stuart) at 20 rpm.  
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Chapter 3 – Defence against oxidative stress  
in Neisseria meningitidis 
3.1 Introduction and Bioinformatics 
Oxidative stress management is an important factor in pathogen persistence and virulence. 
As Neisseria meningitidis resides naturally in the human nasopharyngeal region, the 
mucosal epithelium plays a significant role in maintaining a largely commensal presence 
for the bacteria. This microenvironment, characteristic of the upper respiratory tract, is rich 
in nutrients, as well as competing organisms and host immune cells which generate varying 
levels of oxidative and nitrosative stress upon the meningococci (Eason and Fan, 2014). 
The highly similar organisms N. gonorrhoeae and N. meningitidis both possess a complex 
set of detoxification mechanisms yet with varying priorities, where their overlapping but 
distinctive roles provide responses to a different profile of endogenous and exogenous 
stress encountered in the two bacteria’s respective ecological niches (Seib et al., 2004).  
Reactive oxygen species (ROS) such as hydrogen peroxides (H2O2) and superoxide anions 
(O2.-) are natural products of aerobic respiration where oxygen reacts with leaked electrons 
to form radicals (Fang, 2011). From the host, activated leukocytes such as 
polymorphonuclear (PMN) neutrophils or phagocytic monocytes are capable of rapid 
discharges of ROS known as “oxidative bursts”, but are often ineffective against able and 
well-established human pathogens such as N. gonorrhoeae (Seib et al., 2005). Direct 
detoxification systems such as catalase and superoxide dismutase (SOD) (See Section 
1.6.2), together with DNA repair systems, are therefore of great importance in ensuring 
pathogen survival and in facilitating successful establishment in the host. Alternative 
mechanisms are also thought to contribute to bacterial defence against oxidative stress, 
such as the production of polyamines which protect cellular materials through counterion 
interactions (Tkachenko et al., 2012). 
3.1.1 Role of polyamines in bacterial stress response 
Polyamines are small, polycationic organic molecules carrying two or more primary amino 
groups (Figure 3.1-1). Examples are putrescine, spermidine, spermine and cadaverine. 
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Fig. 3.1-1 – Simplified chemical structures of the primary di-amines (a) putrescine (1,4-
diaminobutane) and (d) cadaverine (1,5-diaminopentane), with the (b) tri-amine spermidine and (c) 
tetra-amine spermine. The hallmark regularly-spaced positive charges were shown. 
 
The most important characteristic of polyamines is that their highly positive charges are 
distributed evenly along the linear, unsaturated hydrocarbon backbone. This enables 
polyamines to have key roles in metabolism, particularly in rapidly proliferating cells 
where, for example, polyamines can stabilise the conformation of negatively-charged 
nucleic acids. Thus they offer protection when challenged by reactive oxygen species 
(ROS) (Chattopadhyay et al., 2003). As polycations the anti-oxidant properties of 
polyamines have long been investigated in both mammalian and bacterial cells, but have 
only received increased recognition in recent years as an important virulence factor. 
Indeed, in many cases cells deficient in polyamine synthesis often display premature death 
and impaired invasiveness during pathogenesis (Shah et al., 2011). 
In bacteria, polyamines may be synthesised from amino acids such as arginine and 
glutamate (glutamic acid). Extensive work has been carried out on E. coli, the model 
organism upon which most existing findings on bacterial polyamine metabolism is based 
(Shah and Swiatlo, 2008). However, analyses with bioinformatics tools show that not all 
bacteria possess the same enzyme homologues or pathways (Figure 3.1-2).  
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Fig. 3.1-2 – The classical E. coli polyamine synthesis pathway, superimposed with that of N. 
meningitidis. All genes, enzymes and pathways shown here are present in E. coli. Colour-coding is 
used to denote predicted presence (blue) or absence (orange) of functional homologues or 
simplified pathways in the meningococcal genome. Both spermidine synthase (E. coli SpeE 
homologue; EC 2.5.1.16) and spermine synthase (EC 2.5.1.22) are closely-related 
aminopropyltransferases that require decarboxylated S-Adenosyl-L-Methionine (SAM), but require 
different substrates resulting in different products. 
 
In N. meningitidis, due to the predicted absence of a S-Adenosyl-L-Methionine (SAM) 
decarboxylase (E. coli SpeD) homologue, SAM cannot be converted into decarboxylated 
SAM, which is an essential substrate in the synthesis of the higher polyamines spermidine 
and spermine from putrescine. Of the two arginine-dependent pathways for putrescine 
biosynthesis, N. meningitidis is not predicted to possess the classic arginase and ornithine 
decarboxylase (E. coli SpeC) homologues more commonly and often simultaneously 
featured in animals (Morris, 2009). Instead, typical of bacteria and plants, the major route 
for putrescine production appears to be the one through arginine decarboxylase (E. coli 
SpeA) and agmatinase (E. coli SpeB), where arginine is converted to agmatine and finally 
putrescine and urea (Morris, 2004). 
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In the Neisseria meningitidis genome there are elements that have been annotated for 
polyamine synthesis (Tettelin et al., 2000). A genomic island conserved among pathogenic 
Neisseria has been predicted to encode a biosynthesis pathway for the di-amine putrescine, 
indicating a possible role for polyamines in the behaviour of N. meningitidis in human 
colonisation and pathogenicity. 
3.1.2 Distribution of Genomic Island 5 in N. meningitidis 
As previously discussed in Chapter 1, 9 genomic islands were found conserved in all 
Neisseria meningitidis strains, but absent from its closely related commensal cousin 
Neisseria lactamica. One such pathogen-specific island is comprised of three genes of 
unknown functions, NMB0468, NMB0469 and NMB0470 in N. meningitidis serogroup B 
strain MC58. The island is present in both pathogenically significant Neisseriae (i.e. N. 
meningitidis and N. gonorrhoeae) but is absent from all other Neisseria species with 
complete genomes. It is believed to have been acquired via horizontal gene transfer 
followed by gene rearrangements (Figure 3.1-3).  
 
Fig. 3.1-3 – Genomic Island 5 is present in both pathogenic Neisseria species but absent in the 
commensal N. lactamica. (a) The meningococcal genes NMB0468 and NMB0469 are homologous 
to (b) gonococcal genes NGO1487 and NGO1486. (c) The N. lactamica gene NLA5050 
corresponds to meningococcal NMB0467 and gonococcal NGO1488, while NLA5060 corresponds 
to meningococcal NMB0471 and gonococcal NGO1484. The meningococcal gene NMB0470 is 
homologous to gonococcal gene NGO1485, and is absent from non-pathogenic Neisseria species. 
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Neisseria meningitidis Genomic Island 5 is a 4579 bp three-gene cluster consisting of the 
1893 bp NMB0468, 924 bp NMB0469 and 1467 bp NMB0470. The island has a total of 674 
bp worth of intergenic regions spanning from just after the end of the flanking gene 
NMB0467 to just before the start of the flanking gene NMB0471. In comparison there is 
only an 80 bp distance between the N. lactamica flanking homologues NLA_5050 and 
NLA_5060, which contains the same 12-mer DNA uptake sequence (DUS) 5’-
ATGCCGTCTGAA-3’ (Duffin and Seifert, 2010) also found in the 166 bp intergenic 
region between the flanking gene NMB0467 and island gene NMB0468. Protein BLAST 
analysis revealed specific hits for arginine decarboxylase (E. coli SpeA, E.C. 4.1.1.19) 
active sites, binding sites and catalytic residues in NMB0468 (Table 3.1-1)., while a search 
with NMB0469 returned specific hits for agmatinase (E. coli SpeB, E.C. 3.5.3.11) (Table 
3.1-2). 
Alignment hit Query cover E value Identity Accession no. 
Arginine decarboxylase 
(Kingella kingae) 
100% 0 88% WP_038316412.1 
Arginine decarboxylase 
(Alysiella crassa) 
100% 0 84% WP_034293401.1 
Arginine decarboxylase 
(Pasteurella multocida) 
99% 0 82% WP_005757582.1 
Arginine decarboxylase 
(Pasteurella dagmatis) 
99% 0 82% WP_032855566.1 
Arginine decarboxylase 
(Gallibacterium salpingitidis) 
99% 0 80% WP_066109380.1 
Arginine decarboxylase 
(Gallibacteria genomosp. 3) 
99% 0 80% WP_065234030.1 
Arginine decarboxylase 
(Gallibacterium anatis) 
99% 0 79% WP_039144822.1 
Arginine decarboxylase 
(Halfnia alvei) 
98% 0 70% WP_040046206.1 
Arginine decarboxylase 
(Yersinia aldovae) 
98% 0 70% WP_042546832.1 
Arginine decarboxylase 
(Pectobacterium carotovorum) 
98% 0 70% WP_039361763.1 
Table 3.1-1 – Top 10 hits from protein BLAST results of Genomic Island 5 member 
NMB0468 against species outwith Neisseria. Redundant hits belonging to the same species are 
omitted. Accessed 4th May 2017. 
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Alignment hit Query cover E value Identity Accession no. 
Agmatinase 
(Kingella kingae) 
99% 0 92% WP_032133140.1 
Agmatinase 
(Alysiella crassa) 
99% 0 77% WP_034295711.1 
Agmatinase 
(Pasteurella multocida) 
99% 1e-180 77% WP_046339245.1 
Agmatinase 
(Pasteurella dagmatis) 
99% 5e-180 77% WP_005764265.1 
Agmatinase 
(Gallibacterium salpingitidis) 
98% 7e-179 78% WP_066109319.1 
Agmatinase 
(Gallibacteria genomosp. 3) 
99% 2e-178 77% WP_065237308.1 
Agmatinase 
(Gallibacterium anatis) 
99% 3e-178 77% WP_018347311.1 
Agmatinase 
(Morganella psychrotolerans) 
99% 3e-173 74% WP_067360410.1 
Agmatinase 
(Morganella morganii) 
99% 6e-173 74% WP_032098326.1 
Agmatinase 
(Escherichia albertii) 
98% 3e-172 74% WP_000105568.1 
Table 3.1-2 – Top 10 hits from protein BLAST results of Genomic Island 5 member 
NMB0469 against species outwith Neisseria. Redundant hits belonging to the same species are 
omitted. Accessed 4th May 2017. 
 
NMB0468 encodes a protein of 630 amino acids (with a predicted molecular mass of 
70902), while NMB0469 encodes a protein of 307 amino acids (with a predicted molecular 
mass of 33905). Both NMB0468 and NMB0469 are soluble proteins (using online 
TMHMM software packages by CBS, SOSUI and by SACS). In concordance with initial 
annotations, multiple alignments and crystal structure comparison revealed that key amino 
acid residues of NMB0468 are highly conserved and similar to that of the E. coli SpeA 
enzyme arginine decarboxylase (Figure 3.1-4), while NMB0469 is homologous to the E. 
coli SpeB enzyme agmatinase (Ahn et al., 2004; Andréll et al., 2009) (Figure 3.1-5) (see 
Appendices: Figures A, B). 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
Fig. 3.1-4 – The E. coli arginine decarboxylase SpeA: (a) crystal structure of the SpeA 
homodimer from E. coli strain BL21 (PDB accession number: 2VYC) and (b) key amino acid 
residues in its active site (from Andréll et al., 2009), compared to (c) the predicted structural 
representation of NMB0468 homodimer generated by the SWISS-MODEL software package 
(Biasini et al., 2014). SWISS-MODEL used the biosynthetic E. coli SpeA homodimer (PDB 
accession number: 3NZQ) as a template, sharing 68.82% of its sequence identity with NMB0468 
and has a decent estimated quality score of 0.83 out of 1. Options for visualising the model online 
in multicolour, however, is limited, therefore (d) when visualised with the offline program UCSF 
Chimera (Pettersen et al., 2004), the predicted homodimer structure is more visibly comparable to 
that of the solved SpeA. 
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(a) 
 
(b) 
 
(c) 
 
  
Fig. 3.1-5 – The E. coli agmatinase SpeB: (a) crystal structure of manganese-activated (Carvajal 
et al., 1999) SpeB homologue monomer from Deinococcus radiodurans (PDB accession number: 
1WOI) (from Ahn et al., 2004) and (b) key amino acid residues in its active site, compared to (c) 
the predicted structural representation of NMB0469 monomer generated by the RaptorX software 
package (Källberg et al., 2012) and visualised by UCSF Chimera (Pettersen et al., 2004). RaptorX 
used the Burkholderia thailandensis agmatinase (expressed in E. coli) (PDB accession number: 
4DZ4) as a template, with 100% of its residues modelled and low estimated modelling error. 
Options for directing visualising the model online is very limited, hence the file was exported and 
presented using the offline program UCSF Chimera instead. 
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NMB0470 encodes a protein of 480 amino acids (with a predicted molecular mass of 
51692) which contains around 11 or 12 predicted transmembrane spans (Figure 3.1-6; 
Figure 3.1-7). Such a structural profile is typical of proteins involved in transport of 
metabolites (Henderson, 1993). Initial analysis shows it has been annotated as a C4-
dicarboxylate transporter. C4-dicarboxylates are 4-carbon compounds containing two 
carboxyl functional groups, such as succinate, fumarate, malate, aspartate, tartate and 
orotate. However, NMB0470 lacks substantial clusters of charged amino acid residues 
(Table 3.1-3) typical of known members of the transporter family (Janausch et al., 2002) 
due to the anionic nature of C4-dicarboxylates (Kneuper et al., 2005). Moreover, the crystal 
structures of the known C4-dicarboxylate transporter family Dcu (DcuA and DcuB) have 
not yet been resolved for detailed comparison. On the other hand, the crystal structure of a 
dicarboxylate transporter from the DASS (divalent anion/sodium symporter) family 
VcINDY (Vibrio cholerae I’m not dead yet), a sodium-dependent succinate transporter, 
had been purified and resolved (Mancusso et al., 2012; Mulligan et al., 2016), but 
sequence alignments with NMB0470 do not suggest that they are highly conserved in N. 
meningitidis (see Appendices: Figure C).  
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(a) 
 
(b) 
 
(c) 
 
  
Fig. 3.1-6 – The Vibrio cholerae sodium-dependent dicarboxyate transporter VcINDY: 
(a) crystal structure of sodium-activated bacterial INDY homologue monomer (PDB 
accession number: 4F35) (from Mancusso et al., 2012) and (b) key amino acid residues in 
its active site, compared to (c) the predicted structural representation of NMB0470 
monomer generated by the SWISS-MODEL software package (Biasini et al., 2014), which 
used DASS belonging to the NadC family as templates amid relatively low sequence 
similarities. 
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No. N Terminal Transmembrane Region C Terminal Type Length 
1 58 LYAMMKLGFKPIPLAIAAVLCAL 80 Primary 23 
2 102 VGVIAAIIGKAMPLGALSIIAVG 124 Primary 23 
3 140 MSDALSAFANPLIWLIAIAVMIS 162 Primary 23 
4 250 NPISSAMFITATAPNPLIVNLIA 272 Secondary 23 
5 288 WAMAVPGVIAFFVMPLILYFLYP 310 Primary 23 
6 335 ADEIIMAVIFGILLLLWADVPAL 357 Primary 23 
7 368 ATATAFIGLSLLLLSGVLTWDD 389 Primary 23 
8 399 TIIWFGALIMMAAFLNKLGLIKW 421 Primary 23 
9 429 SVGGLGVSGTAAGVILVLAYMYA 451 Primary 23 
10 458 TTAHITAMFGAFFAAAVSLNAPA 480 Secondary 23 
11 521 KAGFIMSVVNFLIFFVIGSIWWK 543 Primary 23 
Table 3.1-3 – The transmembrane domains and charged amino acid residues (in bold: 
positives in red; negatives in blue) of NMB0470 from SOSUI. Positives: arginine (R), lysine (K); 
negatives: glutamate (E), aspartate (D). 
 
(a) 
 
(b) 
 
Fig. 3.1-7 – The 11 or 12 predicted transmembrane helices of NMB0470 from (a) 
SOSUI and (b) TMHMM by CBS.  
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Further BLAST searches revealed low sequence identity or coverage for NMB0470 hits 
outwith the Neisseria genus. Non-pathogenic species such as N. lactamica returned hits 
poorly aligned with NMB0470. In contrast, the presence of highly-identical, single-copy 
specific hits for NMB0470 among sequenced Neisseria meningitidis and N. gonorrhoeae 
strains suggest strong conservation in the two pathogenic species.  
In this chapter, a knockout mutant unable to express intact NMB0468 was constructed by 
Catenazzi (2013) for the experimental characterisation of its metabolic properties with an 
aim of identifying the function(s) of Genomic Island 5. 
3.2 Construction of a Genomic Island 5 knockout mutant 
A mutant strain of N. meningitidis serogroup B strain MC58 unable to synthesise intact 
copies of the gene NMB0468 was previously constructed by Catenazzi (2013). All N. 
meningitidis strains used were cultured according to methodologies as previously described 
(See Chapter 2), while protocols for the molecular work involved are reiterated as follows. 
No. Primer Name Primer Sequence (5’ to 3’) Nucleotide Position 
(a) NMB0468-for 5’-CTTTTCAACACGACAGACGG-3’ 488122 – 488141 
(b) NMB0468-rev 5’-GCTTCAGACGGCATATCCGATG-3’ 490079 – 490058 
(c) NMB0468bis-for 5'-GTATGGGGCATCAGTCAGGC-3' 489086 – 489105 
(d) NMB0468bis-rev 5'-CGGTAATGGGACAAACAGGG-3' 489602 – 489583 
Table 3.2-1 – List of primers used for the construction of a NMB0468-deficient mutant strain of 
N. meningitidis MC58: (a) forward and (b) reverse cloning primers; (c) forward and (d) reverse 
transformation-confirming primers which flank the three AclI recognition sites in NMB0468. 
Underlined bases are intended mismatches of the genomic sequence in order to increase 
frequencies of transformation through the introduction of DNA uptake sequences. 
The NMB0468 gene was amplified from wild-type N. meningitidis strain MC58 using the 
primers shown in Table 3.2-1 (a, b). The resulting 1958-base product was then cloned onto 
an intermediate vector pCR-Blunt II-TOPO (Invitrogen). The product was digested out 
with the single-cut restriction enzyme AclI, which has three recognition sites in the 
NMB0468 gene (Promega). The sticky ends were rendered blunt by treating with the DNA 
Polymerase I Klenow Fragment (New England BioLabs®) in the presence of dNTPs. The 
Ω cassette containing a spectinomycin resistance gene was digested from its 4.3 kbp native 
vector pHP45Ω (Prentki and Krisch, 1984) with the restriction enzyme SmaI (Promega), 
which was subsequently ligated with the linearised NMB0468 clone using T4 DNA ligase 
(Promega). This yielded a construct containing a cloned copy of NMB0468 disrupted by 
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the insertion of a spectinomycin resistance cassette (Figure 3.2-1), which was confirmed by 
Sanger sequencing.  
The above NMB0468-knockout construct was then transformed by Catenazzi (2013) into 
N. meningitidis following protocols as previously described by Heurlier et al., (2008), 
selecting for the mutant strain with 50 µg/ml spectinomycin. The formation of a disrupted 
NMB0468 gene through correct chromosomal rearrangement was confirmed by PCR 
(Figure 3.2-2) using primers (Table 3.2-1(c,d)) that flank the spectinomycin cassette 
insertion site within NMB0468 (Figure 3.2-1).  
 
Fig. 3.2-1 – Layout of a Neisseria meninigitidis serogroup B strain MC58 Genomic Island 5 
mutant. A spectinomycin resistance cassette containing transcription-terminators is inserted into 
NMB0468, resulting in a mutant deficient in intact copies of the gene as well as the rest of the 
genomic island following chromosomal rearrangement. The primers 0468bis-for and 0468bis-rev 
confirm the presence of the resistance cassette. 
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Fig. 3.2-2 – PCR confirmation of spectinomycin resistance cassette insertion by primers 
NMB0468bis-for and NMB0468bis-rev which flank the site of disruption. The “bis” primers read 
the wild-type NMB0468 gene as a 517 bp product and the mutant (0.517 + 1.98 kbp cassette insert) 
as an approximately 2.497 kbp product. When referring to band weights, 1 kb DNA ladder (New 
England BioLabs®) was used. 
3.2.1 Quantitative PCR confirms the knockout affects expression of NMB0468 and 
NMB0469 but not NMB0470 
From Section 3.1.2, it was suggested that the third gene in Genomic Island 5 had been 
inaccurately annotated as a C4-dicarboxylate transporter, which appears unrelated to the 
purported functions of the two upstream island members. To assess this implication, 
quantitative PCR (qPCR) was carried out to compare the expression of NMB0470 in the 
NMB0468- knockout mutant, in comparison to NMB0468 regions both anterior and 
posterior to the spectinomycin resistance cassette insert as well as NMB0469, all 
normalised against 16S ribosomal RNA (rRNA) and wild-type N. meningitidis MC58 
expression. The list of primers used are listed in Table 3.2 and were synthesised by Sigma 
Oligos (Sigma-Aldrich). 
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No. Primer Name Primer Sequence (5’ to 3’) 
(a) NMB_MC58_16S_A_for 5'-GCCTTCGGGTTGTAAAGGAC-3' 
(b) NMB_MC58_16S_A_rev 5'-GCCGGTGCTTATTCTTCAGG-3' 
(c) NMB0468q_ant_for 5'-TTGATGGGCGAAAAACTGGG-3' 
(d) NMB0468q_ant_rev 5'-TGCCATTTTCCCGAACCTTG-3' 
(e) NMB0468q_post_for 5'-TGTTGTAGGGGAAGACGGAC-3' 
(f) NMB0468q_post_rev 5'-GGCAACGGTGTTTCCTTCAT-3' 
(g) NMB0469q_for 5'-CGTTCCGTACAAATCGGCAT-3' 
(h) NMB0469q_rev 5'-ATTGACTTTAGGGGCGGACA-3' 
(i) NMB0470q_for 5'-CTTCGCCTGTGATTTTCGGT-3' 
(j) NMB0470q_rev 5'-GATAAAACCCGCCTTCCACC-3' 
Table 3.2-2 – List of qPCR primers used for determining expression levels of genes NMB0468, 
NMB0469 and NMB0470 in both wild-type MC58 and NMB0468- mutant strain of N. meningitidis, 
normalised against meningococcal 16S rRNA: (a) forward and (b) reverse qPCR primers for 
meningococcal 16S rRNA; (c) forward and (d) reverse qPCR primers for the region anterior to the 
spectinomycin resistance cassette insertion site in NMB0468; (e) forward and (f) reverse qPCR 
primers for the region posterior to the insert in NMB0468; (g) forward and (h) reverse qPCR 
primers for NMB0469, and; (i) forward and (j) reverse qPCR primers for NMB0470. 
Liquid cultures of both N. meningitidis wild-type and mutant strains were harvested mid-
log phase, where their total RNA was extracted, purified and their corresponding cDNA 
synthesised according to the methodology described in Chapter 2. Upon analysing the 
qPCR data, it was revealed that the insert had an impact on relative expression level of all 
probed regions, where the region downstream of the insert in NMB0468 as well as 
NMB0469 were further downregulated by approximately 10-fold (Figure 3.2-2). This was 
in accordance with the spectinomycin resistance cassette containing strong transcriptional 
terminators, which indicated at the very least that NMB0468 and NMB0469 likely belong 
to the same operon. 
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Fig. 3.2-3 – Fold decrease (i.e. downregulation) of various regions of Genomic Island 3, 
normalised against wild-type N. meningitidis MC58 and 16S rRNA. The NMB0468q_ant primer 
pair synthesises the region anterior to the spectinomycin resistance cassette inserted in NMB0468 in 
the mutant, while the NMB0468q_post pair reads the posterior region; the NMB0469q and 
NMB0470q primer pairs monitor expression of NMB0469 and NMB0470 respectively. Positive 
∆∆CT values indicate downregulation, and therefore decimals were converted into and expressed as 
fold change values. 
The results did not rule out the possibility of NMB0470 sharing functional association with 
NMB0468 and NMB0469, as all Genomic Island 5 genes were collectively downregulated 
in the mutant strain. The rationale behind the strong incorporation of a putative transporter 
in pathogenic Neisseria genomes and in close proximity to a functionally disparate 
pathway is unclear, which remains to be explored in the future. 
3.3 Complementation of the Genomic Island 5 knockout lesion 
To complement the NMB0468- knockout mutant in this study, genes from Genomic Island 
5 were reintroduced into the cell following protocols as described by Catenazzi (2013). 
The two adjacent genes NMB0468 and NMB0469, representing the meningococcal 
putrescine synthesis pathway, were first amplified by polymerase chain reaction (PCR). 
There was no need to include NMB0470 in the complementation construct. 
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No. Primer Name Primer Sequence (5’ to 3’) Nucleotide Position 
(a) NMB0468c_for 5'-GCTGGATCCTTTGATGGAAAGATGAACC-3' 487982 – 488009 
(b) NMB0469c_rev 5'-CGTGGATCCGATATGCGGCTCCGGGC-3' 491177 – 491152 
Table 3.3 – List of primers used for the construction of a plasmid-complemented NMB0468-
deficient mutant strain of N. meningitidis MC58, in addition to the primers used in Table 3.2-1: (a) 
forward and (b) reverse transformation-confirming primers. Underlined bases are intended 
mismatches of the genomic sequence in order to increase frequencies of transformation through the 
introduction of DNA uptake sequences. 
This combined 2.9 kbp sequence was then cloned onto a pCR®-Blunt II-TOPO® vector 
(Invitrogen) according to the manufacturer’s instructions and transformed into competent 
E. coli DH5α. Colony PCRs were carried out to screen for correct construct, pCR®-Blunt 
II-TOPO®-NMB0468-NMB0469, which was then harvested and purified by QIAprep Spin 
Miniprep Kit (QIAGEN). 
Since the pCR®-Blunt II-TOPO® plasmid cannot be maintained in N. meningitidis, the 
insert was subcloned in N. meningitidis via the complementation vector pKHE2 (Heurlier 
et al., 2009). pKHE2 is an approximately 5 kbp plasmid with an erythromycin resistance 
cassette derived from pYHS25. To provide some background, pYHS25 itself was in turn a 
complementation vector containing the tail-to-tail-oriented genes NMB0102 and NMB0103 
including their intergenic region (Winzer et al., 2002). To construct pKHE2, the multiple 
cloning site (MCS) and opa promoter between two DNA uptake sequences (DUS) were 
removed from pYHS25 by reverse PCR. In their place, a MCS from the commercially 
available vector pBlueScript-II KS (Stratagene) was cloned via the (also commercially 
available) vector pUC6S (Stratagene) and introduced into the BglII restriction site in the 
aforementioned pYHS25∆Popa, allowing future cloned inserts to make use of their natural 
promoters. Promoters from the opa multigene family are involved in phase variation of 
Opa proteins in Nesseria spp. and found in their genomes (Belland et al., 1997; 
Sadarangani et al., 2016). Both pKHE2 and the sequence NMB0468-0469 were first 
excised by the single-cut restriction enzyme BamHI, ligated to each other and the resultant 
construct shown in Figure 3.3-1. This was subsequently transformed into the N. 
meningitidis mutant chromosome as a single-copy insert between chromosomal NMB0102 
and NMB0103 genes, resulting in a MC58∆NMB0468::NMB0468-0469ect (ectopic 
expression) complemented strain NMB0468-0469c. 
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Fig. 3.3-1 – Simplified schematic of the pKHE2 plasmid carrying the genes NMB0468 and 
NMB0469, resulting in the erythromycin-resistant pKHE-NMB0468-0469 construct. 
 
Fig. 3.3-2 (a) – Schematics of the pKHE2-NMB0468-0469 construct acting as an in-genome 
insertion under its own promoter within the NMB0468- mutant chromosome, as the genes and 
erythromycin resistance cassette (EryR) crossed over and were incorporated into the intergenic 
region between NMB0102 and NMB0103. 
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Fig. 3.3-2 (b) – PCR products of the wild type NMB0468 gene (WT), the disrupted mutant gene 
(0468-) and the complemented gene (0468-0469c) using (left) the “c” primers that synthesise the 
entire gene and (right) the “bis” primers that synthesise only the spectinomycin resistance cassette 
insertion region. When referring to band weights, 2-log DNA ladder (New England BioLabs®) was 
used. 
The NMB0468-0469-complemented mutant (NMB0468-0469c) was successfully created 
by reintroducing genes NMB0468 and NMB0469 into the NMB0468- mutant chromosome 
via the erythromycin-resistant vector pKHE2 (Figure 3.3-2 (a)). Sequencing and PCR 
checks confirm the presence of the pKHE2-NMB0468-0469 construct (Figure 3.3-2 (b)). 
The “bis” primers read the short 517 bp region where the 1.98 kbp spectinomycin 
resistance cassette was inserted, and are able to synthesise both the wild type (or vector-
based complement) and the longer, disrupted 2.497 kbp (0.517 + 1.98 kbp) genomic 
sequences. The “c” primers were used to make the entire sequence inclusive of parts of the 
intergenic and flanking regions, and preferentially synthesises the shorter, 1.893 kbp wild 
type (or vector-based complement) product over the longer, approximately 3.893 kbp 
(1.893 + 1.98 kbp) disrupted genomic NMB0468 gene. It is therefore possible to recover 
both intact and disrupted copies of Genomic Island 5 due to the nature of the construct 
crossing over. 
 
 
 
 
  65 
3.4 Effects of putrescine on growth of N. meningitidis 
3.4.1 Genomic Island 5 mutant grows poorly in MHB compared to wild-type N. 
meningitidis 
Müller-Hinton Broth (MHB) (Oxoid) is a rich, undefined liquid media commonly used in 
microbiology. For more refined analysis of meningococcal growth phenotypes a 
chemically-defined minimal media (CDM) was used in this study of which the recipe was 
derived from a modified version of the original Catlin formula (Catlin and Schloer, 1962; 
Catenazzi, 2013). Details on how to obtain liquid cultures of N. meningitidis as well as the 
complete CDM formula used were described in Chapter 2.  
When culturing N. meningitidis, aerobic growth of the NMB0468- mutant in MHB showed 
significant impairment in yield and rate compared to the wild-type (Figure 3.4-1 (a)). In 
light of bioinformatics predictions discussed in Section 3.1, mutant growth was therefore 
assessed under the more tightly controlled conditions provided by the CDM. While both 
the wild-type and NMB0468- mutant grew noticeably poorer in CDM, significant 
differences in both yield and rate were observed (Figure 3.4-1 (b)).  
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(a) 
 
(b) 
 
 
Fig. 3.4-1 – Differences in growth phenotypes of NMB00468- mutant compared to wild-type 
MC58 in (a) rich (MHB) and (b) minimal media (CDM). The growth curves shown here are 
representative figures of experiments carried out in technical and biological replicates. The dent in 
the mutant curve in MHB indicates diauxic growth, where the short lag phase suggests a switch 
between carbon sources (or other prominent nutrients) during exponential growth (see Section 6.2). 
The results were generally in line with the hypothesis that a genetic lesion in the NMB0468 
gene, predicted to be involved in the synthesis of putrescine – which was thought to elicit 
anti-oxidative effects, was responsible for poorer growth of the meningococci. 
3.4.2 Culturing N. meningitidis under microaerobic conditions eliminates growth 
deficit between NMB0468- mutant and wild-type 
Follow-up to the aforementioned hypothesis (See Section 3.4.1), both the wild-type and 
NMB0468- mutant strains of N. meningitidis were cultured in microaerobic conditions. 
This was achieved by culturing the meningococci in 20 ml of liquid MHB (instead of the 
usual 10 ml), reducing the volume of air made immediately in contact within the Sterilin® 
tubes, and reducing the shaker speed to 90 rpm (down from 200 rpm). These settings 
lowered the oxidative stress incurred upon the bacteria through carefully limiting the rate 
at which oxygen was made available to proliferating cells.  
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(a) 
 
(b) 
 
Fig. 3.4-2 – Growth of N. meningitidis wild-type MC58 and NMB0468- mutant under (a) 
microaerobic and (b) aerobic conditions. The growth curves shown here are representative figures 
of experiments carried out in technical and biological replicates. 
The results again provided support for the hypothesis thus far, showing that despite a 
drastic reduction in both growth rate and yield in both strains (Figure 3.4-2(a)), their 
growth trends were highly similar to one another when compared to the fully aerobic 
control (Figure 3.4-2(b)). If Genomic Island 5 was indeed involved in putrescine 
production, the low oxidative stress present under microaerobic culturing conditions 
should allow for a growth trend without a marked deficit compared to that of the wild-type 
through compensating for the inability of the NMB0468- mutant to synthesise the 
polyamine for anti-oxidative purposes. The general slow growth would also be attributable 
to the limited rate at which oxygen was mixed into the liquid meningococcal culture under 
microaerobic conditions. This showed that the mutant strain can be similarly sensitive 
towards such changes when its genetic lesion was accounted for. 
3.4.3 Removal of arginine results in poorer NMB0468- mutant growth in CDM 
To further test for a putrescine biosynthesis pathway in N. meningitidis, the starting 
material L-arginine was removed from the CDM. Both strains were cultured in arginine-
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free CDM and the resulting growth trends (Figure 3.4-3(a)) were compared with a control 
grown in complete CDM (Figure 3.4-3(b)).  
(a) 
 
(b) 
 
Fig. 3.4-3 – Effects of (a) removal of L-arginine from CDM on N. meningitidis wild-type MC58 
and NMB0468- mutant growth, compared to (b) growth of both strains in complete CDM. The 
growth curves shown here are representative figures of experiments carried out in technical and 
biological replicates. 
The observations fitted with the ongoing hypothesis and bioinformatics predictions (See 
Chapter 4 for discussion on alternative arginine synthesis pathways). The NMB0468- 
mutant strain appeared to grow significantly poorer in arginine-free CDM than its control 
in terms of both rate and yield. The wild-type meningococci also displayed a longer lag 
phase and slower growth rate in arginine-free conditions, suggesting a need to 
endogenously provide arginine for essential metabolism through alternative means which 
are energetically less favourable. This was believed to have coupled with the effects of the 
genetic lesion in the mutant in arginine-free CDM, resulting in both an inability to 
synthesise putrescine for oxidative protection under aerobic conditions, and a need to 
utilise other metabolites to synthesise arginine for cellular processes essential to 
meningococcal maintenance. In summary, arginine removal did not prevent the lesion in 
the mutant, indicating that the wild-type can still make putrescine (e.g. through 
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endogenous arginine) in the absence of exogenous arginine albeit experiencing much 
poorer growth compared to complete CDM. 
3.4.4 Exogenous putrescine supplementation restores growth of NMB0468- mutant in 
MHB 
Previous findings (See Section 3.4.3) showed that removing L-arginine, the starting 
material of putrescine biosynthesis pathway, impacted meningococcal growth. To 
investigate the effects of the end-product, exogenous putrescine was supplemented into 
MHB at a final concentration of 5 mM (Kurihara et al., 2009) and the growth of both N. 
meningitidis wild-type MC58 and NMB0468- mutant were monitored. The results largely 
conformed to the hypothesis that the mutant was unable to synthesise intact Genomic 
Island 5, and that adding putrescine appeared to improve both growth rate and yield of the 
mutant to levels more comparable to that of the wild-type (Figure 3.4-4 (a)) when 
compared against a putrescine-free plain MHB control (Figure 3.4-4 (b)). 
(a) 
 
(b) 
 
Fig. 3.4-4 – Effects of (a) supplementation by 5 mM putrescine in MHB on N. meningitidis 
wild-type MC58 and NMB0468- mutant growth compared to that in (b) plain MHB. The growth 
curves shown here are representative figures of experiments carried out in technical and biological 
replicates. The lag phase is particularly prominent in the first figure with putrescine (see Section 
6.2 for diauxic growth). 
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For further analysis, these growth conditions were also repeated by supplementing 
putrescine into CDM. However, the results suggested that it was not possible to rescue 
growth by adding exogenous putrescine in CDM. Putrescine appeared to incur a certain 
degree of toxicity towards meningococci at 5 mM, resulting in a prolonged entry into 
exponential growth phase of the wild-type, as well as lower growth rate and yield of both 
the wild-type and the mutant strains (Figure 3.4-5(a)).  
(a) 
 
(b) 
 
(c) 
  
Fig. 3.4-5 – Effects of supplementation by (a) 5 mM and (b) 0.01 mM putrescine in CDM on N. 
meningitidis wild-type MC58 and NMB0468- mutant growth compared to (c) plain CDM. The 
growth curves shown here are representative figures of experiments carried out in technical and 
biological replicates. 
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When compared to putrescine-free CDM-cultured control (Figure 3.4-5 (c)), poorer growth 
in the form of a longer wild-type lag phase, together with poor growth rate and yield for 
both strains, were still observed even at low concentrations as 0.01 mM (Figure 3.4-5 (b)). 
It was possible that competition had arisen between exogenous putrescine and certain 
CDM-derived metabolites for crucial transporters that resulted in general poor growth, 
which manifested only in the relatively sensitive nutrient-limited environment of the CDM.  
3.4.5 Complementation restores mutant growth to wild-type levels in MHB  
Following from Section 3.3, results from culturing the complement construct-transformed 
MC58∆NMB046::NMB0468-0469ect strain showed that exponential growth rate was 
restored in the NMB0468- mutant to wild-type levels (Figure 3.4-6 (a)). The addition of 
exogenous putrescine also appeared to have no discernible effect on the complemented 
strain, including the retention of its inability to reach wild-type levels of optimal yield, 
suggesting possible redundancy of supplementation with construct function and energetic 
load (Figure 3.4-6 (b)). 
(a) 
 
(b) 
 
Fig. 3.4-6 – Growth of N. meningitidis NMB0468- mutant transformed with erythromycin-resistant 
pKHE2-NMB0468-0469 (a) construct restores exponential growth of now-complemented mutant to 
levels comparable to that of wild-type MC58, but (b) not yield even in the presence of exogenous 
putrescine. The growth curves shown here are representative figures of experiments carried out in 
technical and biological replicates. A noticeable lag phase is present here (see Section 6.2 for 
diauxic growth). 
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As part of genetic changes occurring frequently in N. meningitidis, the complementation 
construct crossed over into the intergenic region between NMB0102 and NMB0103 on the 
chromosome. It must therefore be noted that it was possible for intact copies of both wild-
type Genomic Island 5 and spectinomycin-disrupted mutant NMB0468 be recovered.   
3.5 Genomic Island 5 is independent of enzymatic defences against oxidative stress 
Continuing on the theme of bacterial oxidative stress response mechanisms, catalase and 
superoxide dismutase (SOD) are enzymes commonly employed by bacteria to deal with 
reactive oxygen species (ROS).  Superoxide dismutase catalyses the breakdown of 
superoxide radicals into hydrogen peroxide and oxygen, while catalase further breaks 
down hydrogen peroxide into oxygen and water. In both pathogenic Neisseria species, 
catalase expression is tightly regulated by OxyR (Ieva et al., 2008; Sainsbury et al., 2010; 
Seib et al., 2006), while both cytosolic and periplasmic metal-cofactored superoxide 
dismutases protect N. meningitidis from host killing (Dunn et al., 2003). Therefore, to 
explore the possible relationship between Genomic Island 5 and the enzymatic oxidative 
stress response system, bovine catalase (210U/ml) (from previous work by Fergusson et 
al., unpublished) (Sigma-Aldrich®) and bovine superoxide dismutase (0.01U/ml) (Wilks et 
al., 1998) (Sigma-Aldrich®) were freshly prepared and supplemented to cultures of N. 
meningitidis wild-type and NMB0468- mutant in MHB (Figure 3.5-1). 
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(a) 
 
(b) 
 
(c) 
 
Fig. 3.5-1 – Effects of supplementation of (a) catalase and (b) superoxide dismutase in MHB on 
N. meningitidis wild-type MC58 and NMB0468- mutant growth, compared with growth in (c) plain 
MHB. The growth curves shown here are representative figures of experiments carried out in 
technical and biological replicates. Some short lag phases can be observed in the figures (see 
Section 6.2 for diauxic growth). 
The results showed that the presence of exogenous catalase and superoxide dismutase had 
little to no discernible effect on the aerobic growth of both N. meningitidis strains in MHB. 
Both enzymes did not appear to confer any noticeable growth benefits to the mutant, which 
lacked an intrinsic putrescine synthesis pathway. It is possible that the enzymes acting on 
oxidative stress response pathways differed from those that normally interact with 
putrescine, or that putrescine was simply too crucial to omit for N. meningitidis. It also 
remains unclear whether the knockout of the putrescine biosynthesis pathways 
downregulated the expression of other genes that were vital to meningococcal well-being 
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which cannot be remedied by catalase and SOD. In summary, the results suggested that 
enzymatic defences against oxidative stress in N. meningitidis was independent of the 
availability of and ability to synthesise putrescine. 
3.6 Measurement of putrescine in N. meningitidis  
Given its importance as demonstrated by the deficient mutant, it is desirable to be able to 
quantify or monitor the concentrations of putrescine in culture and within N. meningitidis 
undergoing exponential growth so as to assess how the polyamine may work under 
physiological conditions. As polyamines do not significantly absorb above 250 nm, it is 
difficult to achieve direct optical detection using UV. Protocols that involve chemical 
derivatisation such as benzoylation (i.e. adding benzoyl group to molecule for UV 
absorbance) prior to analyses by mass spectrometry or HPLC (high-performance liquid 
chromatography) are commonplace for polyamines but lengthy, while the presence of other 
molecules impacts assay sensitivity and specificity. Getting separation on typical C18 
columns also requires strong ion-pairing reagents which have a tendency of contaminating 
equipment in the long-term. Advancements in analytical chemistry allow for the use of 
synthetic, “supramolecular” structures (Anslyn, 2007). By altering the chemical or physical 
properties of the target molecule, these techniques are believed to be comparatively more 
selective and robust in its application. Given that polyamines have highly charged yet 
relatively low molecular weights, detection could be achieved by diluting the samples into 
an appropriate matrix to obtain a cationic pseudo chromatographic peak through direct 
infusion into a mass spectrometry system. The polyamine components could subsequently 
be identified by their m/z values, as they are intensely protonated at low pHs, by comparing 
the now-enhanced peaks with that of a suitable internal standard molecule. 
Samples were prepared by harvesting fresh cultures of N. meningitidis wild-type MC58 
and NMB0468- mutant strains grown to mid-log phase in MHB. Each 1 ml aliquot was then 
centrifuged at 12000 rpm, after which the supernatant was carefully separated from the 
pellet. For safety reasons, both the supernatant and pellet samples were treated with 100 µl 
1 M hydrochloric acid (HCl) (Fisher Chemical) for 5 minutes followed by neutralisation 
with 100 µl 1 M sodium hydroxide (NaOH) (Fisher Chemical) for 5 minutes to allow for 
thorough killing of the pathogen prior to transport to non-Category 2* laboratory 
environments. Both the killed pellet and supernatant samples were centrifuged at 
maximum speed and resuspended in fresh, plain MHB. The samples were then analysed by 
flow-injection mass spectrometry or frozen until further use. 
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By coupling free putrescine in solution with a curcubit[7]uril nanocontainer, and using 
amantadine as an internal standard, the samples were analysed by adapting the protocol 
described by Galego et al., (2016). As a clean-up step, samples were loaded onto an 
UltiMate 3000 HPLC system (Thermo Scientific) equipped with a Security GuardTM 
cartridge C18 trap column (2 mm x 4 mm) (Phenomenx) in aqueous 1% (v/v) formic acid.  
After 2 minutes the eluent was switched to methanol 1% (v/v) formic acid and held for 1.5 
minutes.  The column was re-equilibrated to aqueous 1% (v/v) formic acid for 0.5 minutes 
before subsequent injections. A flow rate of 200 µl/min and a column temperature of 40 °C 
were used throughout.  
The HPLC system was interfaced with a maXis HD mass spectrometer (Bruker Daltonics) 
with an ESI source (Bruker Daltonics). Instrument control, data acquisition and processing 
were performed using Compass 1.7 software (microTOF control, Hystar and DataAnalysis) 
(Bruker Daltonics). Positive ESI-MS spectra were acquired using the following instrument 
settings: ion spray voltage: 4000 V, dry gas: 4 L/min, dry gas temperature 200°C, ion 
acquisition range: m/z 400-1,300, MS spectra rate: 1 Hz, quadrupole low mass: 400 m/z, 
collision RF: 1200 Vpp, transfer time 110.0 µs. 
Bruker DataAnalysis 4.4 software was used for peak picking and integration. Extracted ion 
chromatograms at m/z 626.73 and 657.74 were extracted with ± 0.02 m/z tolerance. Sum 
Peak algorithm was used for peak picking with S/N threshold of 1, relative intensity 
threshold (base peak) 0.1% and absolute threshold 100. Chromatograms were integrated 
using algorithm version 3.0 MS with sensitivity 99 %, intensity threshold 100 and min 
peak valley 10%. 
To establish a putrescine standard, 1 ml MHB was spiked with putrescine and serially 
diluted to give final concentrations of 5 mM, 2.5 mM, 1 mM, 0.5 mM, 0.25 mM and 0.05 
mM respectively. Analysis of the raw data (Table 3.6-1) showed that putrescine can be 
confidently identified as low as 0.025 mM (Figure 3.6-1). 
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Fig. 3.6-1 – Putrescine standard curve generated through diluting stock putrescine solution with 
MHB in series and the internal standard amantadine. The ratio of the area under the peaks of 
putrescine to that of amantadine is plotted, and a line of best fit extrapolated with the slope 
equation and R2 value shown. 
Putrescine 
Concentration (mM) 
Putrescine 
Area 
Internal 
Standard Area 
Putrescine / 
Internal Standard 
0.05 10952.9 591081.8 0.0185 
0.25 35012.7 1254127.1 0.0279 
0.5 85044.1 816295.4 0.1042 
1.0 122699.4 994418.0 0.1234 
2.5 379616.8 648549.9 0.5853 
5.0 779677.4 1168902.6 0.6670 
Table 3.6-1 – Raw data used for the generation of the putrescine standard curve from serially-
diluted putrescine and the internal standard amantadine in MHB. The ratio of the area under the 
peaks of putrescine and amantadine is proportional to their corresponding putrescine 
concentrations.  
 
However, when analysing the data for the N. meningitidis wild-type and NMB0468- mutant 
supernatant samples, no clearly-defined signal could be observed for putrescine (data not 
shown). To ensure that putrescine was detectable in the supernatant sample mixtures, they 
were spiked with a final concentration of 0.05 mM putrescine, from which clear signals 
could be seen. This implied that the level of putrescine in both supernatant samples, if 
present, were below the protocol’s limit of detection. 
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The pellet samples of the wild-type and NMB0468- mutant strains were analysed similarly 
but also failed to show detectable signals. Similarly, spiking the pellet mixtures with a final 
concentration of 5 mM putrescine yielded clear signals for putrescine. This also implied 
that the level of putrescine in both pellet samples, if present, were below the protocol’s 
limit of detection. 
3.7 Discussion 
The above findings summarily supported the hypothesis that the two Genomic Island 5 
members NMB0468 and NMB0469 form a functional putrescine biosynthesis pathway. 
This mechanism clearly confered significant advantages to N. meningitidis by restoring the 
exponential phase when aerobically grown in rich media (i.e. MHB), a condition where 
meningococci were vulnerable to the effects of substantial levels of oxidative stress. 
Despite inconclusive results, there remained the possibility that differences in putrescine 
levels existed between wild-type N. meningitidis and the NMB0468- mutant strains but 
were below the detection threshold of the instruments employed. It is also possible that 
biogenic putrescine in culture had been complexed or reacted with other molecules prior to 
being presented for assay. Intracellular concentration of putrescine is approximately 0.1 – 
0.2 mM “in almost all bacteria” (Shah and Swiatlo, 2008). There are exceptions to this 
generalisation however, as E. coli putrescine levels are much higher (around 10 – 30 mM), 
hence in the case of N. meningitidis it is possible for that range to be both considerably 
higher or lower. Experimentally, E. coli had been shown to export up to 50 µM o-
phthalaldehyde-derivatised putrescine in (per 500 µl, approximately, of) harvested 
minimal-media-grown culture supernatants (Sugiyama et al., 2016). When taking into 
consideration of physiological and growth differences between the two bacteria, perhaps 
the actual intracellular putrescine concentrations in N. meningitidis may indeed be much 
lower as the scale reaches the lower end of the sensitivity of the techniques employed in 
this study. 
An enzyme-coupled assay was previously attempted prior to the use of more sensitive 
mass spectrometry techniques, known as the spectrophotometric diamine oxidase (DAO) 
assay (Adapted from Schwelberger, 2012). This relatively simple technique made use of 
coupling NH4+ production in the DAO-catalysed break-down of diamines (such as 
putrescine) to NH4+ consumption in a reaction catalysed by glutamate dehydrogenase 
(GLDH): 
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Reaction A: Substrate (diamine) + O2 + H3O+ —DAO⟶ Product (aminoaldehyde) + NH4+ 
+ H2O2 
Reaction B: NH4+ + α-ketoglutarate + NADH —GLDH⟶ Glutamate + NAD+ + H2O 
As one molecule of NADH oxidised by GLDH corresponded to one molecule of substrate 
converted by DAO, putrescine levels may be quantified in a one-to-one ratio by monitoring 
the decrease in NADH spectrophotometric absorbance levels through the use of the Beer-
Lambert Law ∆A = ε c ℓ (where ∆A was the change in absorbance; ε was the extinction 
coefficient; c was the concentration in mM; ℓ was the length of the solution light had to 
pass through in cm). For the width of a standard 1 ml quartz curvette, ℓ was 1 cm and ε 
was 6.22 at A340 for NADH. Both pellets and supernatants were harvested in a similar 
manner as in Section 3.6 with the addition of washing with phosphate buffer solution, and 
the reaction mixture kept in a potassium buffer of pH 7.4. The results (data not shown) 
failed to distinguish between both N. meningitidis wild-type MC58 and NMB0468- 
knockout mutant, whether the sample was pellet or supernatant. The calculated c values 
were highly similar, which suggest that the assay was either too non-specific and 
insensitive for the purpose of putrescine detection in MHB cultures, or that there were 
other substrates (such as diamines other than putrescine) in play in the meningococcal 
extracts that complexed the enzyme reactions. It therefore remains a challenge to devise a 
method to conveniently and economically quantify polyamines in N. meningitidis with 
relative precision. 
On the other hand, albeit not having a convincing conclusion to the cause of putrescine 
toxicity in CDM, one valuable aspect of work carried out in a defined media was that it 
allowed for the selective inclusion or exclusion of substrates such as L-arginine from the 
media. This enabled a fine inspection of both ends of cellular pathways in tandem with the 
construction of mutants with the corresponding lesion, as demonstrated above. Although 
unable to elicit optimal growth rate and yield for N. meningitidis, this is a powerful 
investigative tool which played a significant role in the characterisation of other 
meningococcal genomic islands (See Chapter 4) (Catenazzi, 2013). 
3.7.1 NMB0470 is unlikely to be central to Genomic Island 5 
The NMB0468-0469c complemented mutant was constructed to reinforce the essentiality 
of the meningococcal arginine decarboxylase and agmatinase homologues in aerobic 
growth, as well as determining the role of NMB0470. The uncertainty was whether the 
original NMB0468- knockout mutant is truly unable to express the downstream genes 
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NMB0469 and NMB0470, since it had not been shown whether Genomic Island 5 is an 
independent operon.  
Phenotypes generated from aerobic growth of the NMB0468-0469c strain provided no 
strong implication as to the precise function of the putative transporter NMB0470, as the 
exclusion of NMB0470 did not appear to impair the growth of the complemented mutant. 
In other pathogens such as Streptococcus pneumoniae, the genomes contain well-
characterised transporters (e.g. potABCD family of operons) for polyamines of which 
deficiency resulted in impaired pneumococcal virulence (Shah et al., 2011). In addition to 
weak bioinformatics support for its initial annotation as a C4-dicarboxylate transporter in 
N. meningitidis, there also did not appear to be any similarities between NMB0470 and this 
ABC (ATP-binding cassette) family of transporters. Although in bacteria such systems 
may be shared among or dependent on other biogenic molecules (symporters and 
antiporters) (Driessen et al., 1988), it was entirely possible that NMB0470 was unrelated to 
exclusive transport or metabolism of polyamines in N. meningitidis.  
In summary, complementation with NMB0468 and NMB0469 restored the growth of a 
Genomic Island 5 mutant independent of NMB0470. Nonetheless, this inconclusive finding 
of interest  warrants future investigation for more thorough characterisation of Genomic 
Island 5. 
3.7.2 Mechanisms for protection against biochemical stress  
One of the standing aims of the study was the proposal of a primary mechanism by which 
putrescine or other polyamines contribute to the protection of N. meningitidis against 
oxidative or nitrosative stress. Literature suggested that it may well be a mix of polyamine-
mediated defence mechanisms, interaction with the host microenvironment, as well as 
transcriptional and translational control of stress response genes. 
While there had not been solid evidence, polyamines have been regarded to act as a 
possible protective charge sink at times due to their highly cationic nature. It was first 
proposed that the higher polyamines spermidine and spermine prevent DNA 
conformational changes (Khan et al., 1992). Since then some argued more extensively for 
polyamines as free radical scavengers aside from DNA association and metal chelation (Ha 
et al., 1998). Aside from free radical damages, mutant E. coli deficient in polyamine 
biosynthetic pathways were also found to be more susceptible to damage by gastric acid 
and show impaired host colonisation, and addition of exogenous polyamines restored these 
traits – essential for food-borne pathogens – by inducing increased expression of acid-
resistance genes (Chattopadhyay and Tabor, 2013). Apart from direct biochemical 
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protection, it is also possible that polyamines play a role in the mediation of transcriptional 
changes through signalling that confer survival advantages to a pathogen. In drug-resistant 
Burkholderia cenocepacia, exposure to sublethal doses of polymyxin B induced the 
upregulation of the oxidative stress response regulator oxyR and ornithine decarboxylase 
(i.e. speC in E. coli but no predicted meningococcal homologue) (El-Halfawy and 
Valvano, 2014). It is therefore entirely possible that putrescine may also act in a similar 
fashion to provide antioxidant coverage to N. meningitidis. However, as this study was not 
able to successfully quantify or monitor putrescine levels during meningococcal growth, it 
remains an area open to follow-up investigations for exploration. 
3.7.3 N. meningitidis in face of host immunogenic challenges 
Human macrophage represents one of the primary adversaries of N. meningitidis in its 
natural niche, the nasopharyngeal mucosa. Upon induction, activated macrophages are able 
to mediate the release of reactive oxygen (ROS) and nitrogen species (RNS) to facilitate 
the killing of pathogens. Mechanisms to resist or evade these antimicrobial radicals are 
therefore important virulence factors, promoting host colonisation. Constant exposure to 
nitrosative stress generated by patrolling macrophages as well as its own metabolism has 
prompted N. meningitidis to act as denitrifiers under microaerobic conditions (Anjum et 
al., 2002). This also contributes towards the ability of N. meningitidis in adapting to 
oxygen-limiting growth conditions in the nasopharynx, as it is able to use nitrite (NO2-) as 
an alternative to oxygen (O2) (Heurlier et al., 2008).  
Apart from RNS, N. meningitidis also developed the ability to withstand the onslaught of 
ROS, such as the aforementioned OxyR-regulated catalase activity and direct dismutation 
of superoxides. The meningococci had been shown to employ iron-dependent, Fur (ferric 
uptake regulator)-regulated pathways to defend against oxidative stress generated by 
peroxides or PMN leukocytes (Grifantini et al., 2004). Fierce competition from other niche 
occupants like Streptococcus pneumoniae and Haemophilus influenzae also gave rise to 
innovative means of sabotage (Shakhnovich et al., 2002), where bacterial oxidative stress 
can be regarded as weapons against both host and competitor cells (Yesilkaya et al., 2013; 
Zahlten et al., 2015). These provide solid groundwork and sound reasoning for the ongoing 
investigation of the extent of the influence of polyamines on the maintenance of the 
meningococci, where a plausible approach would be the creation of peroxidase/catalase-
deficient mutants through the crossing of competent cells. It would be informative if 
survival assays could be carried out to determine if polyamines elicit protective effects for 
N. meningitidis (mutants) against human macrophages in culture as an assessment of 
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pathogenicity. Particular care must be paid, however, when selecting the appropriate cell 
lines in order to uphold relevance of any potential findings to in vivo settings. 
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Chapter 4 – Investigating a pathogen-specific genomic island in 
Neisseria meningitidis 
4.1 Introduction and Bioinformatics 
A previously discussed in Chapter 1, 9 genomic islands are found highly conserved in 
Neisseria meningitidis strains, but absent from its closely related commensal cousin 
Neisseria lactamica. One such pathogen-specific island is comprised of two genes of 
unknown function, NMB0239 and NMB0240 in N. meningitidis serogroup B strain MC58. 
The island (meningococcal Genomic Island 3) is present in both Neisserial pathogens (i.e. 
N. meningitidis and N. gonorrhoeae) but is absent from all other Neisseria species with 
sequenced complete genomes. It is believed to have been acquired via horizontal gene 
transfer followed by chromosomal rearrangements where flanking genes are of low 
synteny in N. lactamica. As previously shown in Figure 1.4-3, the adjacent divergently 
transcribed gene in N. lactamica could be found elsewhere in the meningococcal and 
gonococcal genome (i.e. in a circular N. meningitidis genome: NMB2127 is approximately 
281 kbp from start of NMB0240; in N. gonorrhoeae: NGO1963 is approximately 226 kbp 
from end of NGO1752). Homologues of neighbouring NMB0238 – a hypothetical protein, 
were predicted to contain similarities to annotated putative IS1016-like transposases. In N. 
lactamica the sequence is part of gene NLA_1870, which is flanked by repeated DNA 
uptake sequences (DUS). 
 
Fig. 4.1-1 – Genomic Island 3 is present in both pathogenic Neisseria species but absent in the 
commensal N. lactamica. (a) The meningococcal genes NMB0239 and NMB0240 are homologous 
to (b) gonococcal genes NGO1753 and NGO1752. (c) the N. lactamica gene NLA20220 
corresponds to meningococcal NMB2127 and gonococcal NGO1963 located further downstream in 
their respective genomes. Although N. lactamica lacks a homologue of the meningococcal island-
flanking gene NMB0238, it appears to contain a homologue of the gene further upstream, 
NMB0237 (i.e. NLA2170). The same also applies to the gonococcal homologue NGO1967.  
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When subject to protein BLAST analysis, the sequence of NMB0239 returns non-specific 
hits belonging to a superfamily of proteins with only annotated functions for spermidine 
synthase (E. coli SpeE). When Neisseria is excluded, the database only returns 
hypothetical bacterial proteins with hits of less than 60% sequence identity (Table 4.1). On 
the other hand, the sequence of NMB0240 results in specific hits towards the C-terminal 
(approximately 230 amino acids) for S-Adenosyl-L-Methionine (SAM) binding sites 
typical of spermidine synthases (E. coli SpeE) belonging to the SAM-dependent 
methyltransferase superfamily class I, as well as non-specific hits towards the N-terminal 
(approximately 170 amino acids) for proteins belonging to the Major Facilitator 
Superfamily (MFS) of transporters. When Neisseria is excluded, the database only returns 
hits with less than 50% sequence identity, and does not appear to return well-characterised 
bacterial proteins (Table 4.2).  
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Alignment hit 
Query 
cover 
E 
value 
Identity 
Accession 
number 
hypothetical protein F908_00393  
(Acinetobacter sp. NIPH 284) 
99% 2e-69 54% ENW84791.1 
hypothetical protein  
(Aggregatibacter aphrophilus) 
100% 4e-66 52% WP_005702990.1 
hypothetical protein  
(Acinetobacter sp. CIP 56.2) 
97% 1e-65 54% WP_004803936.1 
hypothetical protein  
(Basilea psittacipulmonis) 
97% 2e-65 59% WP_077315864.1 
hypothetical protein  
(Aggregatibacter 
actinomycetemcomitans) 
99% 3e-64 52% WP_019518403.1 
hypothetical protein  
(Acinetobacter towneri) 
100% 5e-63 51% WP_070153804.1 
hypothetical protein 
HMPREF9065_02107 (Aggregatibacter 
sp. oral taxon 458 str. W10330) 
98% 4e-62 50% ERH26145.1 
hypothetical protein A2W44_03925  
(Acinetobacter sp. 
RIFCSPHIGHO2_12_41_5) 
92% 1e-61 56% OFW94067.1 
membrane protein  
(Haemophilus ducreyi) 
98% 1e-59 54% WP_010945191.1 
hypothetical protein  
(Simonsiella muelleri) 
96% 5e-54 56% WP_002642737.1 
Table 4.1 – Top 10 hits from protein BLAST results of Genomic Island 3 member NMB0239 
against species outwith Neisseria. Redundant hits belonging to the same species are omitted. 
Accessed 4th May 2017. 
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Alignment hit 
Query 
cover 
E 
value 
Identity 
Accession 
number 
Hypothetical protein F908_00394 
(Acinetobacter sp. NIPH 284) 
100% 7e-159 45% ENW84792.1 
Hypothetical protein IX83_05845 
(Basilea psittacipulmonis DSM 24701) 
99% 1e-157 47% AIL32904.1 
Hypothetical protein 
(Simonsiella muelleri) 
100% 4e-157 49% WP_002642738.1 
Hypothetical protein 
(Basilea psittacipulmonis) 
99% 3e-154 47% WP_077315864.1 
Hypothetical protein A2W44_03920 
(Acinetobacter sp. 
RIFCSPHIGHO2_12_41_5) 
100% 4e-150 45% OFW94062.1 
Hypothetical protein 
(Acinetobacter towneri) 
100% 1e-146 44% WP_070153493.1 
Spermidine synthase 
(Acinetobacter sp. CIP 56.2) 
100% 2e-142 44% WP_004803939.1 
Spermidine synthase 
(Aggregatibacter 
actinomycetemcomitans) 
99% 3e-139 44% WP_005568859.1 
Spermidine synthase 
(Haemophilus ducreyi) 
99% 3e-139 44% WP_064083169.1 
Spermidine synthase 
(Aggregatibacter 
actinomycetemcomitans) 
99% 4e-139 44% WP_005578206.1 
Table 4.2 – Top 10 hits from protein BLAST results of Genomic Island 3 member NMB0240 
against species outwith Neisseria. Redundant hits belonging to the same species are omitted. 
Accessed 4th May 2017. 
NMB0239 encodes a protein of 206 amino acids (with a predicted molecular mass of 
22298), while NMB0240 encodes a protein of 483 amino acids (with a predicted molecular 
mass of 53511). NMB0239 as well as the 205 N-terminal amino acids of NMB0240 are 
predominantly hydrophobic, and are predicted to each contain 6 transmembrane helices 
(using online TMHMM software packages by CBS, SOSUI and by SACS). A soluble 
periplasmic domain is predicted towards the C-terminal of NMB0240 from amino acids 
205-483. Initial analyses have annotated NMB0240 and some of its homologues as 
spermidine synthase due to the purported presence of SAM-binding domains. However, N. 
meningitidis does not appear to contain functional homologues of the enzyme SAM 
decarboxylase (E. coli SpeD) whose product (decarboxylated SAM) is vital to the function 
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of spermidine synthases (See Chapter 3). Upon finer inspection, the similarities are low 
compared to experimentally-validated spermidine synthases (only 21% sequence identity 
with the E. coli SpeE). The domain also lacks 5 key amino acid residues (D88, D158, 
D161, Y63 and Y226) which are completely conserved and vital for 
aminopropyltransferase activity, rendering it unfeasible for the encoding of spermidine 
synthase (Figure 4.1-2).  
(a) 
 
(b) 
 
Fig. 4.1-2 – The E. coli spermidine synthase SpeE: (a) structural representation of SpeE and (b) 
key amino acid residues important for catalysis but not conserved in NMB0240) (from Zhou et al., 
2010). 
In order to analyse the overall properties of this putative structural element, the sequences 
of NMB0239 and the 205 N-terminal amino acids of NMB0240 were also fused in silico. 
When searched with aforementioned TMHMM software packages, the results yielded a 
putative protein with similarities to Major Facilitator Superfamily (MFS) transporters 
consisting of about 12 predicted transmembrane spans and a periplasmic C-terminus 
(Figure 4.1-3). Such a structural profile is typical of proteins involved in transport of 
metabolites (Henderson, 1993). Despite not having been previously characterised, the 
arrangement resembles a transporter consisting of a split membrane-spanning MFS-like 
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domain fused to a soluble periplasmic domain as a possible expression product, and is 
suggestive of a transporter for the capture and uptake of small molecule substrates into the 
meningococcus. 
 
Fig. 4.1-3 – TMHMM predicts the presence of 12 transmembrane spans split across 
NMB0239 and NMB0240. (a) The 12-helix arrangement is suggestive of (green) transporter 
functions, while; (b) the soluble region is annotated to have a role in (blue) metabolism. 
It is therefore hypothesised that Genomic Island 3 encodes for a transport system for the 
uptake of material(s) crucial to the maintenance and survival of N. meningitidis during 
aerobic growth. The supplementation of such material(s) should elicit a marked response in 
wild-type growth, which possesses intact copies of the island, while the mutant is not 
expected to respond to the same change due to the gene lesion.  
In this chapter, a knockout mutant unable to express intact NMB0240 was constructed by 
Catenazzi (2013) for the experimental characterisation of its metabolic properties with an 
aim of identifying the function(s) of Genomic Island 3. 
4.2 Construction of a Genomic Island 3 knockout mutant via the putative NMB0240 
gene of N. meningitidis 
A mutant strain of N. meningitidis serogroup B strain MC58 unable to synthesise intact 
copies of the gene NMB0240 was constructed by Catenazzi (2013). All N. meningitidis 
strains used were cultured according to methodologies as previously described (See 
Chapter 2), while protocols for the molecular work involved are reiterated as follows. 
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No. Primer Name Primer Sequence (5’ to 3’) Nucleotide Position 
(a) NMB0240-for 5’-CAGAAAGGATGGATATAGTGAAC-3’ 244652 – 244674 
(b) NMB0240-rev 5’-ACCCTTTCAGACGGCTAAATCCC-3’ 246167 – 246145 
(c) NMB0240bis-for 5'-CTGTTTGATTTCTGCTG-3' 245187 – 245206 
(d) NMB0240bis-rev 5'-CAGATAGGCACGTTCGATG-3' 245481 – 245463 
Table 4.3 – List of primers used for the construction of a NMB0240-deficient mutant strain of N. 
meningitidis MC58: (a) forward and (b) reverse cloning primers; (c) forward and (d) reverse 
transformation-confirming primers. Underlined bases are intended mismatches of the genomic 
sequence in order to increase frequencies of transformation through the introduction of DNA 
uptake sequences (Goodman and Scocca, 1988). 
 
Fig. 4.2-1 – The NMB0240 gene (in blue text) including its flanking regions (in black text), start 
(green outlined bold text) and stop (red outlined text) codons. Sequences of adjacent genes are 
denoted in grey text. The SspI restriction site (AATATT: cyan outlined bold text) shows the two 
bases (orange outlined bold text) where the enzyme cuts. Complementation sites of cloning primers 
NMB0240-for and NMB0240-rev (white text in blue arrow box) as well as insert-confirming 
primers NMB0240bis-for and NMB0240bis-rev (white text in pink arrow box) were also shown. 
Mismatched bases (“A” and “T”: orange text) in the reverse insert-confirming primer NMB0240-
rev were considered “G”. 
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The NMB0240 gene was amplified from wild-type N. meningitidis strain MC58 using the 
primers shown in Table 4.3 (a, b). Their respective sites of complementation are shown in 
Figure 4.2-1. The resulting 1516-base product was then cloned into an intermediate vector 
pCR-BluntII-TOPO (InvitrogenTM). The product was digested out with restriction enzyme 
SspI (only cuts at a single restriction site within the NMB0240 gene, and not in the rest of 
the vector) (Promega). The sticky ends were rendered blunt by treating with the DNA 
polymerase Klenow fragment (New England BioLabs®) in the presence of dNTPs. A 
spectinomycin resistance gene was digested from its native vector pHP45Ω (Prentki and 
Krisch, 1984) with the restriction enzyme SmaI (Promega), which was subsequently 
ligated with the linearised NMB0240 clone using T4 DNA ligase (Promega). This yields a 
construct containing a cloned copy of NMB0240 disrupted by the insertion of a 
spectinomycin resistance cassette (Figure 4.2-2), which was confirmed by Sanger 
sequencing.  
 
Fig. 4.2-2 – Layout of a Neisseria meningitidis serogroup B strain MC58 Genomic Island 3 
mutant. A spectinomycin resistance cassette containing transcription-terminators is inserted into 
NMB0240, resulting in a mutant deficient in intact copies of the gene as well as the rest of the 
genomic island. The cassette is located at the very start of the putative soluble periplasmic domain 
in NMB0240 (Prentki and Krisch, 1984). 
The above NMB0240-knockout construct was then transformed by Catenazzi (2013) into 
N. meningitidis following protocols as previously described by Heurlier et al., 2008, 
selecting for the mutant strain with 50 µg/ml spectinomycin.  The formation of a disrupted 
NMB0240 gene was confirmed by PCR (Figure 4.2-3) using primers (Table 4.2 (c,d)) that 
flank the spectinomycin cassette insertion site within NMB0240 (Figure 4.2-1).  
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Fig. 4.2-3 – PCR confirmation of spectinomycin resistance cassette insertion by primers 
NMB0240bis-for and NMB0240bis-rev which flank the site of disruption. The “bis” primers read 
the wild-type NMB0240 gene as a 295 bp product and the mutant (0.295 + 1.98 kbp cassette insert) 
as an approximately 2.275 kbp product. When referring to band weights, 1 kb DNA ladder (New 
England BioLabs®) was used. 
4.3 Effects of rich and minimal media on growth of N. meningitidis 
Müller-Hinton Broth (MHB) (Oxoid) is a rich, undefined liquid media commonly used in 
microbiology. It contains dehydrated beef infusion, casein hydrolysates, starch and is 
maintained at pH 7.3 at room temperature. In contrast, the chemically-defined minimal 
media (CDM) used in this study was derived from a modified version of the original Catlin 
formula (Catlin and Schloer, 1962; Catenazzi, 2013) and has a lower total nutrient 
availability than MHB. Details on how to obtain liquid cultures of N. meningitidis as well 
as the complete CDM formula used are described in Chapter 2 (Table 2.3).  
When culturing N. meningitidis, aerobic growth of the NMB0240- mutant in MHB showed 
only marginal differences in yield and rate compared to the wild-type despite the presence 
of the genetic lesion (Figure 4.3-1 (a)). In light of bioinformatics predictions discussed in 
Section 4.1, mutant growth was therefore assessed under the more tightly controlled 
conditions provided by the CDM. Although both the wild-type and NMB0240- mutant 
performed noticeably poorer in CDM, significant differences in both yield and rate 
manifested (Figure 4.3-1 (b)).  
  91 
(a)  
 
(b)  
 
Fig. 4.3-1 – Differences in growth phenotypes of NMB0240- mutant compared to wild-type in (a) 
rich (MHB) and (b) minimal media (CDM). The growth curves shown here are representative 
figures of experiments carried out in technical and biological replicates. 
While the relative paucity of nutrients in CDM may be responsible for a general low wild-
type growth rate and yield, the NMB0240- knockout mutant took a much steeper downturn 
in that respect. Owing to the differences in nutritional composition between MHB and 
CDM, it is believed therein lies possible explanations for the growth differences observed 
between the two strains and possibly the role played by Genomic Island 3.  
Hydrolysed casein is found in MHB, but is also marketed as a separate product sometimes 
referred to as casamino acids containing all essential amino acids, compared to a default 
supplementation of only 5 “core” amino acids at known concentrations in CDM. To 
investigate whether the shortfall in variety and availability of amino acids and peptides 
would rescue growth of the NMB0240- mutant, 0.1% casamino acids (Fisher Scientific) 
were supplemented to both strains and their growth was monitored (Figure 4.3-2 (a)). 
Apart from the 5 “core” amino acids, the other 15 amino acids not present by default in the 
complete Catlin CDM were also supplemented collectively to both strains for growth 
monitoring (Figure 4.3-2 (b)). In both cases, the addition of amino acids significantly 
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reduced the growth impairment of the NMB0240- mutant, increasing yields but not rates 
completely comparable to that of the supplemented wild-type.  
(a)  
 
(b)  
 
Fig. 4.3-2 – Differences in growth phenotypes of NMB0240- mutant compared to wild-type in 
CDM (a) supplemented with 0.1% casamino acids and (b) 15 amino acids at 0.1 mM. These amino 
acids were namely: L-alanine, L-leucine, L-isoleucine, L-valine, L-methionine, L-lysine, L-proline, 
L-histidine, L-threonine, L-asparagine, L-tyrosine, L-tryptophan, L-phenylalanine, L-aspartate and 
L-glutamate. Stocks were prepared by dissolving casamino acids or amino acids in water and filter 
sterilisation, which were then kept at 4 ˚C for up to one month. When supplemented in CDM, 
volume of sterile dH2O was adjusted accordingly to make room from the final volume of freshly-
mixed CDM stocks. Final pH of CDM should be maintained between 7 and 7.5. 
It is therefore proposed that the trends above show that supplementation of amino acids 
appeared to be able to largely account for the two strains’ original differences in growth 
under plain CDM. Although the initial hypothesis as stated in Section 4.1 no longer 
appeared relevant to the supplementation approach, as both strains responded with 
significant growth improvements, this nonetheless prompted further investigation.  
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4.4 Effects of amino acids on the NMB0240- knockout mutant lesion in N. meningitidis 
4.4.1 Aliphatic amino acids enable faster growth of both MC58 wild-type and 
NMB0240- mutant N. meningitidis 
Based on the observations from above, we set out to determine whether the effects are 
elicited by a particular set of amino acids. The 15 amino acids that were not originally 
included in CDM were divided into the following clusters: (a) aliphatic: L-alanine (Sigma-
Aldrich®), L-leucine (Sigma-Aldrich®), L-isoleucine (Sigma-Aldrich®), L-valine (Sigma-
Aldrich®), L-methionine (Sigma-Aldrich®); (b) hydrophilic: L-lysine (Sigma-Aldrich®), 
L-proline (Sigma-Aldrich®), L-histidine (Sigma-Aldrich®), L-threonine (Sigma-
Aldrich®), L-asparagine (Sigma-Aldrich®); (c) aromatic: L-tyrosine (Sigma-Aldrich®), 
L-tryptophan (Fisons), L-phenylalanine (Sigma-Aldrich®); (d) acidic: L-aspartate (Sigma-
Aldrich®) and L-glutamate (Sigma-Aldrich®). The clusters were then supplemented to 
complete, plain CDM, where each of the 15 amino acids were at final concentrations of 0.1 
mM. 
The results show that the aliphatic group of amino acids appears to be able to rescue 
growth of both wild-type and mutant N. meningitidis strains to an extent comparable to that 
elicited by supplementation of all 15 amino acids or casamino acids (Figure 4.4-1). 
Differences in growth rates between the two strains are noticeably reduced compared to 
growth in plain CDM. The yield of the mutant strain also reaches levels increasingly 
comparable to that of the wild-type. Other clusters of amino acids either resulted in 
negligible or deleterious effects on meningococcal growth.  
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
Fig. 4.4-1 – Effects of 15 amino acids supplemented in clusters on N. meningitidis growth in 
CDM, categorised into (a) aliphatic; (b) hydrophilic; (c) aromatic, and; (d) acidic. 
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The results strongly suggest that one or more members of the aliphatic group may be 
responsible for eliciting the growth trends and effects observed above, prompting 
specificity questions regarding the amino acids involved. The supplementation of the 
above materials continued to affect the growth of both strains significantly, which is not in 
concordance with the initial hypothesis set out in Section 4.1 where solely the wild-type 
was expected to respond to such changes in CDM composition. The objectives, however, 
were updated to continue identification as to which specific amino acid(s) could elicit a 
response in both strains.  
4.4.2 Branched-chain amino acids elicit positive effects on growth of N. meningitidis  
The phenotypes observed above (Section 4.4.1) warranted further investigation into 
whether the 5 aliphatic amino acids are general or specific in action. To assess their 
individual effects on meningococcal growth, each aliphatic amino acid – L-alanine, L-
leucine, L-isoleucine, L-valine and L-methionine – were supplemented at 0.1 mM to 
complete, plain CDM for both the wild-type and mutant strains. The results show that 
mutant growth supplemented by both L-leucine and L-isoleucine, two branched-chain 
amino acids (BCAAs), significantly mirrored trends found in supplementation by all 5 
aliphatic, all 15 amino acids and casamino acids in CDM (Figure 4.4-2a (b)). The 
remaining BCAA member L-valine, as well as L-methionine, showed negligible effects on 
meningococcal growth. On the other hand, L-alanine appears to inhibit growth of both 
strains, of which the delayed entry to log phase could be more easily observed in wild-type 
MC58 (Figure 4.4-2a (a)). 
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(a) 
 
(b) 
 
Fig 4.4-2a – Effects of supplementation by 5 aliphatic amino acids in CDM on N. meningitidis 
(a) wild-type MC58 and; (b) NMB0240- mutant growth. The growth curves shown here are 
representative figures of experiments carried out in technical and biological triplicates. 
The supplementation approach in conclusion does not support the initial hypothesis set out 
in Section 4.1, where the wild-type N. meningitidis was expected to respond to 
supplementation of materials due to its intact putative transporter function predicted for 
Genomic Island 3 while the knockout mutant was not expected to. In fact, the addition of 
extra exogenous amino acids in CDM affects both strains, be that positively or negatively. 
On the other hand, it is worth noting that L-isoleucine supplementation alone appears to 
distinguish itself as the strongest enhancer of NMB0240- mutant growth in CDM thus far. 
It should however be pointed out that L-isoleucine and L-leucine appear to improve growth 
of both wild-type and mutant strains. It is also suggested that L-isoleucine supplementation 
does not account for the NMB0240- mutant growth phenotype, as a shortfall in growth rate 
is still present compared to wild-type growth under the same conditions (Figures 4.4-2b).  
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Fig. 4.4-2b – Specific growth rates extrapolated for N. meningitidis wild-type MC58 and 
NMB0240- mutant in (gold) plain, complete CDM and (orange) CDM supplemented with minimal 
isoleucine. For statistical analyses, Student’s t-tests were carried out to compare growth differences 
(P £ 0.05). Asterisks are denoted as per formatting of GraphPad PRISM 7, where P-values of: ³ 
0.05 = not significant (ns); 0.01 to 0.05 = significant (*); 0.001 to 0.01 = very significant (**); 
0.0001 to 0.001 = extremely significant (***) and; < 0.0001 = extremely significant (****) 
(GraphPad Software Inc., 2017). 
The figure above shows the differences in growth rate of both N. meningitidis strains in 
CDM with and without isoleucine supplementation, where each bar is a relatively objective 
assessment of growth. These were derived by plotting natural log graphs of each hourly 
mean OD600 reading, from which a slope of best fit (outliers rejected to obtain R2 values of 
>0.90, with a minimum of three data points) was extrapolated to obtain the growth rate 
during exponential phase. The result is known as the specific growth rate (µ) of each 
growth curve (in h-1). The mean of each experimental condition, grouped by 
meningococcal strain used and growth media composition, were taken and plotted into bar 
charts. The analysis method is used extensively and further demonstrated in Section 4.4.4. 
The implications of the effects of isoleucine on meningococcal growth are discussed 
further in Chapter 5. 
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4.4.3 Removal of amino acids from CDM reveals intriguing growth trends from both 
MC58 wild-type and NMB0240- mutant N. meningitidis 
The above work showed that although the introduction of some exogenous amino acids 
appears to improve meningococcal growth, a definitive phenotype that may explicitly help 
identify the function of Genomic Island 3 remains elusive. It was therefore reasoned that 
the lesion may instead be due to an inability to make use of intrinsic components of the 
CDM where other nutrients are not present in excess (i.e. MHB). To update the initial 
hypothesis, the removal – rather than addition – of material(s) from the existing CDM 
recipe is now expected to affect the growth of the wild-type N. meningitidis strain due to 
its intact copy of Genomic Island 3, being a putative transporter of said material(s), while 
the mutant would not respond to such changes due to its gene lesion.  
As previously mentioned, the standard complete CDM used in our investigations is based 
on a modified version of the original Catlin recipe, and contains 5 amino acids: L-arginine, 
L-glycine, L-glutamine, L-serine and L-cysteine. Each of these amino acids were thus 
removed from CDM individually or in groups, which were then used to culture the two N. 
meningitidis strains. If NMB0239-0240 is a transporter complex for one or more of these 
amino acids, it may be hypothesised that their respective absence from CDM would result 
in marked growth deficit for the wild-type MC58 but not the NMB0240- knockout mutant. 
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(a) 
 
(b) 
 
(c) 
 
(d) 
   
Fig. 4.4-3 (a-d) – Effects of removal of the amino acids L-serine and L-glycine from CDM on 
N. meningitidis wild-type MC58 and NMB0240- mutant growth. The presence of a glyA (serine 
hydroxymethyl transferase) homologue at work serves as a plausible explanation for the trends 
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observed here where (a) only L-serine; (b) only L-glycine and; (c) both L-serine and L-glycine are 
withheld from CDM, compared to growth in (d) complete CDM. The growth curves shown here 
are representative figures of experiments carried out in technical and biological replicates. 
As shown in Figure 4.4-3 (a), the absence of L-serine alone did not appear to significantly 
impact either wild-type or mutant meningococcal growth. The absence of L-glycine alone, 
however, appeared to noticeably improve growth rate and yield of both strains (Figure 4.4-
3 (b)) when compared to growth in complete CDM (Figure 4.4-3 (d)). Notably the results 
showed that N. meningitidis growth required at least either L-serine or L-glycine, and 
cannot grow when both were absent (Figure 4.4-3 (c)). It is believed that this is due to the 
presence of an annotated meningococcal glyA homologue (serine hydroxymethyl 
transferase), NMB1055, which catalyses the reversible conversion between L-serine and L-
glycine (Blakley, 1960; Schirch et al., 1985). On the other hand, it should be remarked that 
wild-type N. meningitidis did appear to undergo net growth after the first 12 hours of 
aerobic culturing. It is possible that during that period the meningococci may be attempting 
to adapt to a nutritional diet different than complete CDM to compensate for the lack of 
exogenous L-serine and L-glycine.  
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(e) 
 
(f) 
 
Fig. 4.4-3 (e, f) – Effects of removal of the amino acid L-arginine from CDM on N. meningitidis 
wild-type MC58 and NMB0240- mutant growth, shown by the comparison of growth in (e) CDM 
without L-arginine and; (f) plain, complete CDM as control. The growth curves shown here are 
representative figures of experiments carried out in technical and biological triplicates. 
 
Compared to growth in complete CDM, the absence of L-arginine has no discernible effect 
on the growth of the NMB0240- mutant, whereas wild-type N. meningitidis suffers a 
decrease in both growth rate and yield (Figure 4.4-3 (e, f)). Although the subsequent 
compilation of specific growth rates appears to support that there is no statistically 
significant growth difference between arginine-free wild-type and mutant growth (See 
Section 4.4.4), cross-comparison with the above growth curves suggests a more complex 
picture. Since N. meningitidis has been annotated to possess alternative pathways for 
arginine-synthesis (See Section 4.6), it is possible that endogenous arginine may well have 
accounted for the persistence of the wild-type, which is only experiencing stunted growth. 
As this stage, the above results do not fit into the updated hypothesis, as both strains – 
instead of only the wild-type – responded (whether positively, negatively or neutrally) to 
the removal of 3 out of the 5 amino acids (individually or in tandem) originally present in 
the CDM recipe from the media. 
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(g) 
 
(h) 
 
(i) 
 
Fig. 4.4-3 (g-i) – Effects of removal of the amino acids L-cysteine and L-glutamine from CDM 
on N. meningitidis wild-type MC58 and NMB0240- mutant growth, shown by the comparison of 
growth in (g) CDM without L-cysteine; (h) without L-glutamine and; (i) plain, complete CDM as 
control. The growth curves shown here are representative figures of experiments carried out in 
technical and biological triplicates. 
The absence of L-cysteine (Figure 4.4-3 (g)) and L-glutamine (Figure 4.4-3 (h)), on the 
other hand, appear so debilitating to both strains that there is negligible net growth when 
compared to the complete CDM control (Figure 4.4 (j)). The relatively poor growth 
exhibited may be attributable to the fact that glutamine is a crucial substrate in a plethora 
of biochemical processes. In particular, glutamine serves as a universal nitrogen or amino 
group donor for biosynthetic processes involving other key amino acids, such as the 
conversion of pyruvate to serine. Likewise, poor growth tantamount to general cell death 
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exhibited by both strains in cysteine-free CDM may also be attributable to the fact that 
cysteine plays a crucial role in the control of oxidative stress due to its ability to undergo 
redox reactions. Moreover, cells maintain a reduced environment in the cytoplasm by 
finely balancing the intracellular concentrations of reducing agents such as cysteine 
(Gaupp et al., 2012). 
The above results still do not fit into the updated hypothesis where the wild-type was 
expected to respond exclusively to the removal of these amino acids. Both strains 
responded negatively to the removal of the remaining 2 amino acids out of the 5 originally 
present in media as part of the CDM recipe. 
4.4.4 Comparison of specific growth rates of N. meningitidis in CDM with various 
amino acid profiles reveals involvement of Genomic Island 3 in L-arginine and L-
glutamine metabolism 
Given the limitations in graphical representation, the ability to clearly distinguish 
differences between the phenotypes of the various experimental conditions involved 
through direct visual comparison of growth curves decreases over time as data 
accumulates. It is therefore crucial to adopt a method which allows for the objective 
assessment of growth trends. 
As briefly introduced at the end of Section 4.4.2, natural log graphs of each hourly mean 
OD600 reading were plotted, from which a slope of best fit (outliers rejected to obtain R2 
values of >0.90, with a minimum of three data points) was extrapolated to obtain the 
growth rate during exponential phase. The result is known as the specific growth rate (µ) 
of each growth curve (in h-1). The mean of each experimental condition, grouped by N. 
meningitidis strain used and growth media composition, were taken and plotted into bar 
charts. For statistical analyses, Student’s t-tests were conducted to compare growth 
differences (P £ 0.05). With regards to statistical significance, asterisks are denoted as per 
the plotting software’s instructions, where P-values of: ³ 0.05 = not significant (ns); 0.01 
to 0.05 = significant (*); 0.001 to 0.01 = very significant (**); 0.0001 to 0.001 = extremely 
significant (***) and; < 0.0001 = extremely significant (****) (GraphPad Software Inc., 
2017). Error bars are devised from the Standard Error of the Mean (SEM) of each amino 
acid profile that contains three or more data points. The results are as follows (Figures 4.5-
1 & 2): 
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(a) (b) 
  
(c) (d) 
  
(e) (f) 
  
Fig. 4.5-1 – Specific growth rates of N. meningitidis wild-type MC58 and NMB0240- mutant in 
(blue) plain, complete CDM and (red) CDM with one or more core amino acids removed: (a) 
arginine; (b) serine; (c) glycine; (d) cysteine; (e) glutamine and; (f) both serine and glycine. Bars 
are absent for conditions which did not result in observable net growth and therefore no growth rate 
extrapolation. For statistical analyses, Student’s t-tests were carried out to compare growth 
differences (P £ 0.05). Asterisks are denoted as per formatting of GraphPad PRISM 7, where P-
values of: ³ 0.05 = not significant (ns); 0.01 to 0.05 = significant (*); 0.001 to 0.01 = very 
significant (**); 0.0001 to 0.001 = extremely significant (***) and; < 0.0001 = extremely 
significant (****) (GraphPad Software Inc., 2017). 
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The analysis provides some statistical support for the previously discussed growth curve-
based observations. The absence of L-arginine significantly decreases wild-type specific 
growth rate to an extent where it is no longer statistically different from that of the mutant  
(Figure. 4.5-1 (a)). The absence of L-serine, cross-compared with results from growth 
curve experiments, shows small but statistically unapparent loss of growth (Figure 4.5-
1(b)). The others reinforce the importance of L-cysteine, L-glutamine and the glyA 
complex (Figures 4.5-1 (d-f)). The analysis also supports the notion that L-glycine may be 
preventing N. meningitidis from reaching higher levels of growth in CDM (Figure 4.5-1 
(c)), of which the implications are discussed in Chapter 5.  
(a) (b) 
  
(c)  
 
 
Fig. 4.5-2 – Specific growth rates of N. meningitidis wild-type MC58 and NMB0240- mutant in 
(blue) plain, complete CDM and (red) CDM with altered concentrations of core amino acids: (a) 
without arginine and 10-fold lower concentration of glutamine (i.e. from 4 mM to 0.4 mM); (b) 10-
fold lower concentration of glutamine (i.e from 4 mM to 0.4 mM); (c) 10-fold lower concentration 
of cysteine (i.e. from 0.4 mM to 0.04 mM). For effects of glutamine-free CDM on specific 
growth rate of both strains, refer to Figure 4.5-1 (e) for comparison. For statistical analyses, 
Student’s t-tests were carried out to compare growth differences (P £ 0.05). Asterisks are denoted 
as per formatting of GraphPad PRISM 7, where P-values of: ³ 0.05 = not significant (ns); 0.01 to 
0.05 = significant (*); 0.001 to 0.01 = very significant (**); 0.0001 to 0.001 = extremely significant 
(***) and; < 0.0001 = extremely significant (****) (GraphPad Software Inc., 2017). 
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Following up on the results in Figure 4.5-1, L-glutamine and L-cysteine were re-introduced 
into the CDM at 10-fold lower concentrations compared to complete CDM. Lowering the 
concentration of L-glutamine in CDM from 4 mM to 0.4 mM results in significantly poorer 
wild-type growth, while the mutant appears unaffected (Figure 4.5-2 (b), 4.5-3 (b)). 
Interestingly, lowering the concentration of L-cysteine in CDM from 0.4 mM to 0.04 mM 
results in a slight increase in both wild-type and mutant growth, albeit not statistically 
significant (Figure 4.5-2 (c), 4.5-3 (c)). The implications of this is explored in Chapter 5. 
From the above, it is also shown that lowered concentrations of L-glutamine, in tandem 
with the absence of L-arginine, are capable of significantly reducing wild-type N. 
meningitidis growth to mutant levels, whilst having little effect on that of the actual 
NMB0240- mutant strain (Figure 4.5-2 (a)). However, the above analysis has also implied 
that lowered availability of L-glutamine alone is sufficient to elicit a similar effect on both 
N. meningitidis strains. It is worth noting that the wild-type appears to grow noticeably 
poorer compared to the mutant in terms of specific growth rate when cultured in lowered 
concentrations of L-glutamine, albeit the difference is not statistically significant (not 
shown).  
Referring to their respective growth curves (Figure 4.5-3), it can be observed that there 
appear to be differences in the way that the two amino acid profiles affect the growth of 
wild-type N. meningitidis. In terms of specific growth rates and statistics, however, both 
the lowered availability of L-glutamine in CDM with and without L-arginine satisfy the 
criteria for an amino acid profile under which the wild-type grows poorer but the mutant 
remains unaffected.  
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(b) 
 
(c) 
 
(d) 
 
Fig. 4.5-3 – Effects of removal of L-arginine and simultaneously lowered L-glutamine 
concentrations, lowered L-glutamine concentrations alone and lowered L-cysteine concentrations 
from CDM on N. meningitidis wild-type MC58 and NMB0240- mutant growth, shown by the 
comparison of growth in (a) CDM without arginine and 10-fold lowered availability of glutamine (i.e. 
from 4 mM to 0.4 mM); (b) CDM with 10-fold lowered availability of glutamine alone (i.e. from 4 mM 
to 0.4 mM); (c) CDM with 10-fold lowered availability of cysteine (i.e. from 0.4 mM to 0.04 mM), and; 
(d) plain, complete CDM as control. The growth curves shown here are representative figures of 
experiments carried out in technical and biological triplicates. 
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It is possible that wild-type N. meningitidis attempts unsuccessfully to adapt its nutritional 
requirements around the low availability of L-glutamine, displaying a brief exponential 
growth before falling victim to the exhaustion of an amino acid whose biochemical 
importance to bacterial cell metabolism has previously been stressed. When coupled with 
the loss of L-arginine, it is also possible that a metabolic demand has arisen in the 
meningococci to utilise the limited L-glutamine in an attempt to compensate cellular 
processes that depend on the availability of L-arginine through its biosynthesis from L-
glutamine (See Section 4.6). Consequently, for the wild-type, the results are early depletion 
of free L-glutamine in solution and growth that is not energetically sustained in a 
favourable manner – not unlike that experienced by the NMB0240- knockout mutant. 
In summary, the effects of removing L-arginine from CDM and lowering L-glutamine 
concentrations in CDM in tandem do appear to support the updated hypothesis of Genomic 
Island 3 as a putative transporter of amino acid(s) (i.e. L-arginine), as only the wild-type 
was impacted by the change while the mutant was largely unaffected. 
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4.5 Genomic Island 3 can transport arginine 
To confirm whether Genomic Island 3 is involved in the transport of exogenous L-
arginine, potential movement of the amino acid across either side of the bacterial 
membrane was monitored, and the results compared between wild-type and NMB0240- 
knockout mutant N. meningitidis strains. The null hypothesis is that Genomic Island 3 does 
not play any role in the meningococcal intake of L-arginine; if true, a mutant deficient in 
the expression of the intact Island products would not see any reduction in L-arginine 
incorporation in peptides. 
To test this, N. meningitidis was cultured in complete CDM with either the naturally-
occurring L-arginine isotope, or replaced with a labelled isotope containing two 15N atoms 
in the guanidineimino side chain (Sigma-Aldrich®) at equal concentrations. Cell pellets 
were harvested from each strain respectively at mid-log phase by centrifuging 1 ml 
aliquots of liquid culture in 1.5 ml Eppendorf tubes at 12000 rpm for 5 minutes. The 
supernatant was discarded and the pellets were resuspended in 200 µl sample buffer with 
loading dye and 10% SDS, after which the lysis reaction was allowed to take place for one 
hour. SDS-PAGE of the samples were performed as described in Chapter 2, after which the 
gel was stained for 30 minutes with InstantBlueTM (Expedeon) and destained overnight 
with dH2O. Definitive bands across the samples with the same molecular mass were 
excised and trypsin-digested. The resulting trypsin-derived peptides were analysed by 
MALDI-MS/MS using a Bruker ultraflex III MALDI TOF/TOF instrument (Bruker) 
according to the manufacturer’s protocol. 
The tandem mass spectra obtained were searched against the unrestricted UniProt database 
for matches with known N. meningitidis proteins. The next step was to use the search result 
to locate arginine-containing peptides within the samples, which is facilitated by the fact 
that trypsin cleaves peptides exclusively C-terminal to arginine or lysine (Olsen et al., 
2004).  
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(a) 
 
(b) 
 
(c) 
 
Table. 4.4 (a-c) – Results of MALDI-MS/MS analyses of trypsin-derived peptides from three sets 
of protein bands excised at three different molecular mass respectively, showing incorporation of 
heavy (H) 15N2-labelled L-arginine isotope compared with light (L) natural L-arginine in 
percentages and as ratios of their signal intensities (from respective relative peak areas) in both 
wild-type (WT) and NMB0240- knockout mutant (MT) N. meningitidis strains. All trypsin-derived 
peptides shown are cleaved C-terminal to arginine (R). The above data are biological triplicates. 
 
 
 
 
 
 
Peptide	Identified Peptide	Expect	Score Intensity	L Intensity	H Ratio	(H/L) Log2(Ratio	H/L) Percent	H	MT
VSVGYDFGGWR 5.9	x	10-6 20011 55498 2.77 1.47 73.50
IAADYASYR 4.40E-03 2429 8387 3.45 1.79 77.54
ISTVSDYFR 5.4	x	10-5 2532 8833 3.49 1.80 77.72
SPYYVQADLAYAAER 2.9	x	10-9 29995 82187 2.74 1.45 73.26
Mean 1.63 75.51
Geometric	Ratio	Mean 3.09
Peptide	Identified Peptide	Expect	Score Intensity	L Intensity	H Ratio	(H/L) Log2(Ratio	H/L) Percent	H	WT
VSVGYDFGGWR 5.9	x	10-6 11202 62650 5.59 2.48 84.83
IAADYASYR 4.40E-03 1575 12084 7.67 2.94 88.47
ISTVSDYFR 5.4	x	10-5 1964 13587 6.92 2.79 87.37
SPYYVQADLAYAAER 2.9	x	10-9 20680 116232 5.62 2.49 84.90
Mean 2.68 86.39
Geometric	Mean 6.39
WT
MT
Peptide	Identified Peptide	Expect	Score Intensity	L Intensity	H Ratio	(H/L) Log2(Ratio	H/L) Percent	H	MT
DVQFGNEVR 0.023 70 235 3.36 1.75 77.05
YVTAGMNPTDLKR 0.059 12 55 4.58 2.20 82.09
AAVEEGVVAGGGVALLR 1.8	x	10-6 389 1346 3.46 1.79 77.58
SLENELDVVEGMQFDR 2.7	x	10-1 90 527 5.86 2.55 85.41
ENTTIIDGFGDAAQIEAR 7.3	x	10-11 234 1068 4.56 2.19 82.03
Mean 2.09 80.83
Geometric	Ratio	Mean 4.27
Peptide	Identified Peptide	Expect	Score Intensity	L Intensity	H Ratio	(H/L) Log2(Ratio	H/L) Percent	H	WT
DVQFGNEVR 3.3	x	10-4 84 1038 12.36 3.63 92.51
YVTAGMNPTDLKR 0.032 30 290 9.67 3.27 90.63
AAVEEGVVAGGGVALLR 1.8	x	10-10 579 4722 8.16 3.03 89.08
SLENELDVVEGMQFDR 1.3	x	10-11 246 2950 11.99 3.58 92.30
ENTTIIDGFGDAAQIEAR 1.4	x	10-14 362 3823 10.56 3.40 91.35
Mean 3.38 91.17
Geometric	Mean 10.40
MT
WT
Peptide	Identified Peptide	Expect	Score Intensity	L Intensity	H Ratio	(H/L) Log2(Ratio	H/L) Percent	H	MT
APVALVNEEAAR 0.62 29 203 7.00 2.81 87.50
SVTVETLENLER 6.6	x	10-3 12 91 7.58 2.92 88.35
VTASVGDAEVDQTVEILR 3.6	x	10-6 13 213 16.38 4.03 94.25
Mean 3.25 90.03
Geometric	Ratio	Mean 9.55
Peptide	Identified Peptide	Expect	Score Intensity	L Intensity	H Ratio	(H/L) Log2(Ratio	H/L) Percent	H	WT
APVALVNEEAAR 0.14 15 206 13.73 3.78 93.21
SVTVETLENLER 1.1	x	10-3 8 105 13.13 3.71 92.92
VTASVGDAEVDQTVEILR 9.3	x	10-8 5 318 63.60 5.99 98.45
Mean 4.49 94.86
Geometric	Mean 22.55
WT
MT
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The results show that approximately 90% of incorporated L-arginine belongs to the heavy 
labelled isotope in wild-type N. meningitidis, while the NMB0240- knockout mutant sees 
approximately 81% heavy L-arginine incorporation (Table 4.4). This is equivalent to a 
two-fold increase in incorporation of light labelled L-arginine isotope in the mutant 
compared to the wild-type. Note that the difference between the two meningococci strains 
in Table 4.4 (c) is statistically significant when analysed as pairs. Differences in mean 
incorporation of heavy isotope between wild-type and mutant strains may vary from run to 
run, which may be attributable to more complex MS spectra resulting in more confounding 
signals. In addition, the supplied labelled isotope is 98% in purity. Together with activity 
from possible arginine biosynthesis pathways via other present CDM components and 
residual incorporation from rich agar incubation, this can result in samples grown with 
heavy L-arginine not being completely free from the lighter naturally-occurring L-arginine 
isotope. It must be noted that, however, a relatively minor reduction in percentage 
incorporation of imported L-arginine in bacterial peptides observed does not necessarily 
reflect the extent of which meningococcal biomass yield and growth rate are reduced. It is 
possible that pathways that attempt to compensate for the need for arginine incorporation 
in protein synthesis are more energetically demanding in the NMB0240- mutant, leading to 
stress, which in turn may lead to halved specific growth rate and yield compared to that of 
the wild-type meningococci. 
4.6 Discussion 
Neisseria meningitidis and N. gonorrhoeae strains possess 9 highly conserved genomic 
islands not found in their commensal relative N. lactamica. Characterisation of their 
functions may provide new insights into their biology through distinguishing pathogenic 
from non-pathogenic Neisseria species. N. meningitidis serogroup B strain MC58 Genomic 
Island 3 consists of the genes NMB0239/0240 which are absent from all other members of 
the order Neisseriales apart from disease-causing meningococci and gonococci. Through 
the use of a chemically-defined media (CDM), the effects of various growth media 
constituents on the phenotype of a knockout mutant deficient in NMB0240 were 
investigated in a bid to uncover the functions of this putative island. This powerful tool 
enabled the identification of the role of Genomic Island 3 in the uptake of arginine. This is 
not an exclusive way of transport for these amino acids, however, as the NMB0240- 
knockout mutant appears to still be able to acquire them from exogenous sources. 
Nonetheless, the gene lesion does appear to have a significant impact on meningococcal 
growth, especially under nutrient-limiting conditions. Given the growth of the MC58 wild-
type (but not the NMB0240- knockout mutant) benefits from the presence of arginine, the 
  112 
results from growth experiments at first suggested the possibility of Genomic Island 3 
being the sole route of arginine uptake. Subsequent work involving the use of isotope-
labelled arginine, however, indicated that that the mutant is still capable of taking up 
externally-supplemented arginine at reduced efficiency compared to that of the wild-type. 
Although complemented by existing endogenous pathways for arginine biosynthesis, it 
appears that meningococci deficient in Genomic Island 3 would come to rely on that more 
heavily, resulting in a lower general growth rate. In summary, the results suggest that 
Genomic Island 3 can transport L-arginine, but can be complemented by the availability of 
L-glutamine at defined concentrations through mechanisms beyond the scope of this 
investigation. 
Overall, experimental results from the inclusion and exclusion of amino acid supplements 
in growth media reveals a rather complex metabolic requirement in N. meningitidis. Under 
conditions described in previous sections, glutamine and cysteine are crucial to the survival 
of N. meningitidis. With the predicted presence of a glyA (serine 
hydroxymethyltransferase) homologue, at least one of serine or glycine is also required. 
Arginine confers advantages to growth, and at least one arginine biosynthesis pathway – 
from glutamate – has been predicted in N. meningitidis (KEGG; www.kegg.jp). Despite the 
absence of a dedicated glutamate synthase homologue, ammonium normally present in 
CDM can serve as a nitrogen source for the NADP-specific glutamate dehydrogenase 
GdhA, providing a likely and alternative pathway for the biosynthesis of glutamate 
(Schoen et al., 2014). The presence of an annotated meningococcal glutamine synthetase 
homologue NMB0359 (E. coli GlnA), although normally responsible for catalysing the 
biosynthesis of L-glutamine from L-glutamate using ammonium, implies that synthesis of 
L-glutamate is also a likely product as hydrolysis of L-glutamine can occur (Eisenberg et 
al., 2000). It appears, however, that although endogenous supply of arginine supports 
meningococcal survival, it was not sufficient for sustaining growth at optimal levels 
demonstrated only in the presence of exogenous arginine. Last but not least, arginine is 
also a starting material for meningococcal polyamine biosynthesis, of which putrescine can 
be synthesised from arginine via agmatine in the presence of the relevant enzyme 
homologues as described in Chapter 3. 
Glutamine transport in another meningitis-causing pathogen Group B streptococci is 
carried out by GlnQ with great implications in virulence (Tamura et al., 2002). The 
meningococcal homologue NMB0787 and gonococcal homologue NGO0372 are involved 
in glutamine uptake in pathogenic Neisseriae, where exogenous glutamine as a substrate 
can induce upregulation of the N. gonorrhoeae clusters of ABC transporter genes and 
  113 
mediate expression of other virulence-associated genes (Friedrich et al., 2007). In that 
work L-glutamine was added at 2 mM to a glutamine-free culture 3 hours into gonococcal 
growth to elicit positive transcriptional changes, which was similar to the original 
glutamine concentration of 4 mM in CDM in this study. By lowering glutamine levels to 
0.4 mM, it is not inconceivable for it to have a profound effect on wild-type growth. The 
NMB0240- mutant, however, appeared unaffected by this change. The highly comparable 
phenotypes between the two strains therefore make the case for Genomic Island 3 in also 
having a (non-exclusive) role in glutamine uptake.  
Supplementation with some amino acids appears to prevent N. meningitidis from achieving 
higher yields during exponential growth, such as alanine and glycine. A possible theory 
would be that exogenous alanine and glycine, the two smallest amino acids, compete for 
the use of transporters shared by other key meningococcal nutrients, and hence the absence 
of alanine and removal of glycine from CDM may have facilitated the effective utilisation 
of compounds that were previously difficult to access. Cysteine, which forms a core part of 
the original chemically-defined media recipe, appears to be more advantageous to 
meningococcal growth rate (but deleterious to yield) at lower concentrations. Cysteine 
toxicity can impair bacterial growth particularly in minimal media, and multiple 
mechanisms that tightly regulate its effects have been reported in various 
Enterobacteriaceae (Kari et al., 1971; Ohtsu et al., 2010; Oguri et al., 2012; Takumi and 
Nonaka, 2016). In N. meningitidis cysteine has been demonstrated as a growth-limiting 
media component, where depletion can lead to lowered tolerance to oxidative stress (van 
de Waterbeemd et al., 2013). The exact mechanisms in play here, however, is unclear. 
The above findings appear to have painted an interesting picture with regards to the highly 
specific nature of CDM. The fact that the N. meningitidis wild-type strain used here 
(serogroup B MC58) is highly sensitive to alterations in amino acid composition 
demonstrates the versatility of the CDM used. Although very well designed, there appears 
to be some redundancy among the CDM components. In fact, it is not uncommon that 
minimal media often require more bespoke, strain-specific adjustments in order to achieve 
optimal growth which facilitates the conduction of experiments. Together with the 
generally growth-promoting effects of isoleucine which is relatable to global 
transcriptional upregulation, the implications of these are explored in Chapter 5. 
In conclusion, it is fundamental for pathogens to access host nutrient in order to survive 
and successfully establish themselves in their respective niches prior to pathogenesis. 
Many pathogenic bacteria have evolved ways to scavenge nutrients such as amino acids 
from the microenvironment, whilst evading the mechanisms employed by the host 
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response to starve them through limiting their availability (Zhang and Rubin, 2013). Some 
have even coined the term “nutritional virulence” (Abu Kwaik and Bumann, 2013). N. 
meningitidis, compounded by its relatively small genome size of ~2.3 Mbp, does not 
appear to possess a typical repertoire of virulence genes, and yet has become increasingly 
evident that metabolic adaption is the key determinant of the meningococcal capability to 
invade (Schoen et al., 2014). It therefore remains important that the characterisation of 
genes possibly involved in the mundane transport of metabolic products and cellular 
building blocks conserved only in pathogenic strains be given the same degree of attention 
as those which codes for direct means of cellular invasion.  
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Chapter 5 – Role of isoleucine in N. meningitidis regulation and 
chemically-defined minimal media 
5.1 Introduction 
In Section 4.4.2, the exogenous supplementation of L-isoleucine to liquid cultures of 
Neisseria meningitidis in chemically-defined media (CDM) was shown to universally 
enhance growth of both wild-type strain MC58 as well as that of the NMB0240- (Genomic 
Island 3) knockout mutant. Similarly, the removal or lowering the concentrations of certain 
amino acids also resulted in marked growth improvements. Here the implications of the 
aforementioned trends are explored in order to optimise the CDM for growth of N. 
meningitidis. The genetic basis for the impact of isoleucine on N. meningitidis growth was 
also examined. 
5.2 Isoleucine and the meningococcal lrp regulon 
As mentioned in Chapter 1, N. meningitidis consists of a handful of transcriptional 
regulator systems which monitor the uptake of essential nutrients, metabolism and respond 
to changes in their availability, one of which is Lrp. Lrp (L-leucine-responsive protein) is a 
small (~15 kDa) transcriptional regulator with homologues widely distributed as multimers 
in bacteria as well as archaea (Brinkman et al., 2003; Unoarumhi et al., 2016; Peeters and 
Charlier, 2010). Many operons important for bacterial maintenance and survival are 
controlled by this member of the Lrp/AsnC family, and thus Lrp is known as a global 
regulator. It is so named because the presence or absence of L-leucine mediates the 
activation or inhibition of pathways and cellular processes that are regulated by Lrp. E. coli 
as a model organism was used extensively to characterise Lrp, where lesions in the gene 
result in both positive and negative effects on the expression of many proteins arguably 
involved in adaptation to major environmental changes (Ernsting et al., 1992). Lrp had 
been shown to significantly affect transcription of about 10% of all E. coli genes, 
indicating a large regulatory network involving more than 400 genes (Tani et al., 2002). 
Despite its namesake, intracellular leucine levels or presence do not always have an effect 
on potentiating or antagonising Lrp-mediated genes (Calvo and Matthews, 1994). 
Nonetheless it was broadly suggested that leucine abundance together with that of Lrp are 
responsible for oversight in bacterial transition between “feast and famine” (Landgraf et 
al., 1996).  
Lrp orthologs from many genera collectively respond to wide range of amino acids aside 
from leucine (Hart and Blumenthal, 2011). The set of genes controlled by the Lrp regulon 
had been analysed in silico in E. coli using leucine as the signalling molecule (Cho et al., 
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2008). Additionally, it was also shown in Corynebacterium glutamicum that all branched 
chain amino acids (BCAAs) – L-leucine, L-isoleucine, L-valine, as well as the closely-
related (nominally aliphatic) L-methionine – were able to stimulate significant global 
expression changes induced by direct Lrp binding when supplemented in minimal media 
(Lange et al., 2012). This showed that for Lrp to function leucine is not always the 
exclusive effector amino acid, and that this depends on the species containing the Lrp 
homologue.  
Neisseria meningitidis encodes NMB0573 and NMB1650, which are two paralogous gene 
products that were annotated as members of the Lrp/AsnC family of regulators. In some 
instances, NMB1650 was regarded as the lrp gene (Hey et al., 2013). Solving the crystal 
structure of the NMB0573 octamer, however, provided a stronger case for NMB0573, 
where the protein was duly characterised as the meningococcal Lrp homologue (gene 
incorrectly annotated as asnC) responding to both leucine and methionine as ligands (Ren 
et al., 2007). Microarray analyses from the same work also showed that NMB0240 (part of 
Genomic Island 3) was upregulated in a NMB0573- knockout model, which provided a 
putative link between possible Lrp activity and the phenotypes induced by isoleucine 
supplementation in CDM.  
5.3 Effects of isoleucine on growth of N. meningitidis under various amino acid 
profiles of CDM 
In Section 4.4.2, among the branched chain amino acids (BCAAs) the inclusion of 
isoleucine in CDM was shown to be sufficient to bring about statistically significant 
enhanced growth rate and yield to both wild-type and NMB0240- mutant strains of N. 
meningitidis (shown below again as Figure 5.1). 
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Fig. 5.1 – Specific growth rates extrapolated for N. meningitidis wild-type MC58 and NMB0240- 
mutant in (green ochre) plain, complete CDM and (orange) CDM supplemented with minimal 
isoleucine. For statistical analyses, Student’s t-tests were carried out to compare growth differences 
(P £ 0.05). Asterisks are denoted as per formatting of GraphPad PRISM 7, where P-values of: ³ 
0.05 = not significant (ns); 0.01 to 0.05 = significant (*); 0.001 to 0.01 = very significant (**); 
0.0001 to 0.001 = extremely significant (***) and; < 0.0001 = extremely significant (****) 
(GraphPad Software Inc., 2017). 
 
As pointed out, this improved growth did not account for NMB0240- mutant growth 
phenotype, since a difference in growth remained between that and the wild-type (See 
Chapter 4). Moreover, when isoleucine was supplemented to CDM under varying amino 
acid profiles, in most cases both wild-type (Figure 5.2) and the NMB0240- mutant (Figure 
5.3) meningococci similarly experienced substantial improvements in terms of specific 
growth rate. Although it did not address the specific hypotheses discussed in Chapter 4, it 
was subsequently speculated that enhancement of growth by isoleucine might be a 
consequence of transcriptional changes mediated by the global regulator Lrp through a 
response to the presence of exogenous BCAAs. 
To test this hypothesis, a knockout mutant unable to express intact meningococcal Lrp 
homologue was constructed in this study. 
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Fig. 5.2 – Specific growth rates of N. meningitidis wild-type MC58 in (light purple) plain, 
complete CDM and (dark purple) CDM with altered concentrations of core amino acids: (from left 
to right) control; without arginine; without serine; without glycine; without cysteine; without 
glutamine, and; without both serine and glycine. Bars are absent for conditions which did not result 
in observable net growth and therefore no growth rate extrapolation. For statistical analyses, 
Student’s t-tests were carried out to compare growth differences (P £ 0.05). Asterisks are denoted 
as per formatting of GraphPad PRISM 7, where P-values of: ³ 0.05 = not significant (ns); 0.01 to 
0.05 = significant (*); 0.001 to 0.01 = very significant (**); 0.0001 to 0.001 = extremely significant 
(***) and; < 0.0001 = extremely significant (****) (GraphPad Software Inc., 2017). 
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Fig. 5.3 – Specific growth rates of N. meningitidis NMB0240- mutant strain in (pink) plain, 
complete CDM and (rose) CDM with altered concentrations of core amino acids: (from left to 
right) control; without arginine; without serine; without glycine; without cysteine; without 
glutamine, and; without both serine and glycine. Bars are absent for conditions which did not result 
in observable net growth and therefore no growth rate extrapolation. For statistical analyses, 
Student’s t-tests were carried out to compare growth differences (P £ 0.05). Asterisks are denoted 
as per formatting of GraphPad PRISM 7, where P-values of: ³ 0.05 = not significant (ns); 0.01 to 
0.05 = significant (*); 0.001 to 0.01 = very significant (**); 0.0001 to 0.001 = extremely significant 
(***) and; < 0.0001 = extremely significant (****) (GraphPad Software Inc., 2017). 
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5.4 Construction of a knockout mutant for the NMB0573 gene of N. meningitidis 
Dr. Vlaimir Pelicic from Imperial College kindly provided a total genomic DNA (gDNA) 
extraction of a NMV_1850-deficient (i.e. homologous to NMB0573-deficient) mutant 
from a library of kanamycin-resistant N. meningitidis serogroup C strain 8013 (Rusniok et 
al., 2009). This was based on the Himar1 mariner-based transposon-mediated high-
throughput in vitro mutagenesis of and subsequent chromosomal transposition into 
naturally competent N. meningitidis (Pelicic et al., 2000), resulting in thousands of 
randomly-generated mutants (Geoffroy et al., 2003).  
In this study, the gDNA (Figure 5.4-2) was transformed into N. meningitidis serogroup B 
strain MC58 wild-type according to the TSB protocol as described in Chapter 2 and 
selected for using 80 µg/ml kanamycin, and subsequently confirmed with colony PCR 
(primers shown in Table 5; sites of complementation shown in Figure 5.4-1; bands shown 
in Figure 5.4-3). 
No. Primer Name Primer Sequence (5’ to 3’) Nucleotide Position 
(a) NMB0573_for 5’-CCGAAAACAAAATTTGTCCCGG-3’ 601049 – 601070 
(b) NMB0573_rev 5’-TTTGCAGATTGCACGTGCGGG-3’ 601671 – 601691 
Table 5 – List of primers used for the PCR confirmation of the NMB0573-deficient mutant strain 
of N. meningitidis MC58: (a) forward and (b) reverse screening primers.  
 
Fig. 5.4-1 – The NMB0573 gene (in blue text) including its flanking regions (in black text), start 
(green outlined bold text) and stop (red outlined text) codons. Sequences of adjacent genes are 
denoted in grey text. Complementation sites of cloning/confirmation primers NMB0573_for and 
NMB0573_rev (white text in blue arrow box) were also shown, binding to intergenic sequences 
and ensuring inclusion of all NMB0573 coding sequences. 
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Fig. 5.4-2 – Schematics of NMB0573- (lrp) mutagenesis by Himar1 transposon, based on a 
protocol first described by Akerley et al. (1998). The first and last 100 bp from the Himar1 mariner 
transposon (Lampe et al., 1996) were cloned (“Mini-Himar1”). Summarily, the 1.6 kbp 
“minitransposon” constructed by Pelicic et al. (2000) consisted of a 1.5 kbp Neisseria kanamycin 
resistance cassette (KanR) with a neisserial uptake sequence (GCCGTCTGAA) flanked by the 
Mini-Himar1 and inverted repeats. The insert remains stable at site after transposition into 
meningococcal chromosome and random mutagenesis. A NMV_1850- mutant 8013 strain was 
generated from this, and the purified genomic DNA extract was used to create a NMB0573- mutant 
MC58 strain for this study following transformation and chromosomal rearrangement. 
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Fig. 5.4-3 – PCR products of the wild type NMB0573 gene (WT) and the disrupted mutant gene 
(0573-) using the NMB0573 screening primers in Table 5. Although NMB_1850 is 483 bp long, 
NMB0573 is slightly longer at 564 bp while perfectly aligned with NMV_1850 (See Appendices: 
Figure D). Therefore, the size of MC58 homologue NMB0573 (564 bp) plus the 1.6 kbp 
minitransposon described above (Pelicic et al., 2000) resulted in a 2.164 kbp product. This heavier 
product is present in N. meningitidis serogroup B strain MC58 successfully transformed with 
serogroup C strain 8013 mutant gDNA which is deficient in NMV_1850, which is now deficient in 
NMB0573. 
 
The resulting NMB0573- mutant strain (transformed MC58) displayed faster growth than 
the wild-type MC58 in CDM, while there were no observable differences between the two 
when cultured in MHB (Figure 5.4-4). This suggested that Lrp normally represses aerobic 
meningococcal growth under conditions present in nutrient-poor environments but not in 
the nutrient-rich MHB. 
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(a) 
 
(b) 
 
Fig. 5.4-4 – Differences in growth phenotypes of NMB0573- mutant compared to wild-type, 
showing (a) a significantly higher growth rate compared to that of wild-type MC58 when cultured 
in CDM, and; (b) highly comparable levels of exponential growth when cultured in MHB. The 
growth curves shown here are representative figures of experiments carried out in technical and 
biological triplicates. 
It can be argued that Lrp may have been preventing rapid depletion of nutrients when 
exposed to nutrient-limited environments by providing close regulation for balanced 
meningococcal proliferation (i.e. “feast and famine”). This can be supported by the fact 
that despite a faster growth rate during log phase, the NMB0573- mutant reached a similar 
maximum yield as the wild-type MC58 when cultured in CDM before levelling off.  
Likewise, as the role played by Lrp on N. meningitidis is global in effect, so are the 
respective changes exhibited when it is knocked out. A plethora of meningococcal genes 
were either upregulated or downregulated by the lrp lesion (Ren et al., 2007), and it would 
require additional efforts to ascertain which global changes in particular led to such growth 
phenotypes. A possible explanation for the almost identical growth phenotypes in MHB is 
that the rich media likely contains an excess of isoleucine. Overall the trends suggest that 
Lrp is not essential for N. meningitidis growth in a nutrient-rich environment. 
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5.5 Lrp knockout ablates effect of isoleucine on N. meningitidis growth 
To test the effects of exogenous isoleucine supplementation on meningococcal growth in 
CDM, wild-type MC58 and NMB0573- knockout mutant strains were cultured accordingly 
and cross-compared (Figure 5.5-1).  
(a) 
 
(b) 
 
Fig. 5.5-1 – Effects of L-isoleucine supplementation in CDM on N. meningitidis: (a) wild-type 
MC58 and NMB0573- knockout mutant growth in CDM with isoleucine, compared to; (b) wild-
type MC58 and NMB0573- knockout mutant growth in plain, complete CDM as control. The 
growth curves shown here are representative figures of experiments carried out in technical and 
biological replicates. 
If isoleucine indeed plays the role of an effector in meningococcal global regulation (See 
Section 5.3), at first glance it was questionable as to why the Lrp mutant strain would 
seemingly respond to the presence of isoleucine in CDM (Figure 5.5-1 (a)). Despite 
appearances, however, the addition of isoleucine did not confer statistically significant 
growth benefits to the NMB0573- mutant in CDM (Figure 5.5-2). The specific growth rates 
of the NMB0573- mutant were also highly similar to those of isoleucine-supplemented 
wild-type (i.e. all between 0.4 to 0.5 h-1). Taking into account of the predicted upregulation 
of NMB0240 expression (intact here) that accompanies an Lrp mutation, this did not appear 
to result in growth changes that may distinguish the NMB0573- mutant phenotype from 
that of the isoleucine-supplemented wild-type.  
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Fig. 5.5-2 – Specific growth rates of N. meningitidis (blue and purple) wild-type MC58 and (sand 
and orange) NMB0573- mutant in (horizontal stripes) plain, complete CDM and (vertical stripes) 
CDM supplemented with exogenous L-isoleucine. For statistical analyses, Student’s t-tests were 
carried to compare growth differences (P £ 0.05). Asterisks are denoted as per formatting of 
GraphPad PRISM 7, where P-values of: ³ 0.05 = not significant (ns); 0.01 to 0.05 = significant (*); 
0.001 to 0.01 = very significant (**); 0.0001 to 0.001 = extremely significant (***) and; < 0.0001 = 
extremely significant (****) (GraphPad Software Inc., 2017). 
The results suggested that regulation by Lrp can explain the effects of isoleucine on N. 
meningitidis in CDM. A wide range of pathways were both up-regulated and down-
regulated following knock out of NMB0573, resulting in significantly improved 
meningococcal growth. Supplementing CDM with exogenous isoleucine similarly resulted 
in marked growth improvements. Although not all changes in the meningococcal lrp- 
mutant can be unitarily replicable in the wild-type by isoleucine, this parallelism 
summarily implied that the effects of isoleucine on growth in CDM were ablated when the 
NMB0573 was knocked out. 
5.6 An improved CDM optimised for N. meningitidis MC58 
From the above, it was found that the effects of isoleucine on N. meningitidis growth can 
be explained as being due to its interaction with the global regulator Lrp. In practical 
terms, however, L-isoleucine would serve to greatly improve the potency of the CDM by 
making it easier to observe growth trends in future investigations into N. meningitidis 
response to nutritional changes. 
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From Figure 4.5-2 (d), 4.5-3 (c), it was observed that lowering the concentration of L-
cysteine in CDM elicited a slight but statistically insignificant increase in growth on both 
N. meningitidis wild-type MC58 and NMB0240- mutant. Taking into account the 
ameliorative effects shown by the removal of L-glycine from CDM and the fact that L-
isoleucine appeared to act as a general growth factor in culture, it was hypothesised that the 
combination of all three conditions may be able to generate the highest-performing 
meningococcal growth seen in CDM. The result, however, suggested otherwise (Figure 
5.6-1). 
 
 
(a) 
 
(b) 
 
(c) 
 
  127 
(d) 
 
(e) 
 
Fig. 5.6-1 – Effects of removal of L-glycine, lowered L-cysteine concentrations and L-
isoleucine supplementation in CDM on N. meningitidis wild-type MC58 and NMB0240- mutant 
growth, shown by comparison of growth in (a) CDM without L-glycine, 10-fold lowered 
availability of L-cysteine (i.e. from 0.4 mM to 0.04 mM) and addition of L-isoleucine; (b) CDM 
without L-glycine and addition of L-isoleucine; (c) CDM without L-glycine; (d) CDM with L-
isoleucine, and; (e) plain, complete CDM. The growth curves shown here are representative figures 
of experiments carried out in technical and biological triplicates. 
 
 
 
 
  128 
 
Fig. 5.6-2 – Specific growth rates of N. meningitidis wild-type MC58 and NMB0240- mutant in 
(blue) CDM with isoleucine; (red) CDM without glycine, 10-fold lower concentrations of cysteine 
(i.e. from 0.4 mM to 0.04 mM) and addition of isoleucine; (green) CDM without glycine and 
addition of isoleucine; (purple) CDM without glycine, and; (orange) plain, complete CDM. For 
statistical analyses, Student’s t-tests were carried out where there are comparisons of growth 
differences (P £ 0.05). Asterisks are denoted as per formatting of GraphPad PRISM 7, where P-
values of: ³ 0.05 = not significant (ns); 0.01 to 0.05 = significant (*); 0.001 to 0.01 = very 
significant (**); 0.0001 to 0.001 = extremely significant (***) and; < 0.0001 = extremely 
significant (****) (GraphPad Software Inc., 2017). 
 
The specific growth rates (Figure 5.6-2) reinforced the message conveyed by the growth 
curves above. Lowering the availability of cysteine resulted in poorer growth than the 
replacement of glycine with isoleucine alone, while excluding glycine from isoleucine-
supplemented CDM resulted in slightly poorer growth compared to isoleucine 
supplementation alone. The importance of cysteine and glycine had been discussed in 
Chapter 4. Overall apart from that between complete CDM without or without isoleucine, 
the above variations in CDM compositions amounted to no statistically significant 
differences with each other.  
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5.7 Conclusions 
Chemically-defined medium for nutritional investigations of N. meningitidis was first 
proposed more than three-quarters of a century ago (Frantz, 1942). It had subsequently 
seen numerous modifications. The original formulae upon which this study adapted its 
CDM from had been devised more than half a century ago in both agar and fluid forms for 
“quantitative genetic studies”, where the authors explicitly admitted that L-glycine was not 
essential and was only included because it had a slight stimulatory effect on colony counts 
of N. meningitidis strain 15 (Catlin and Schloer, 1962). In fact, chemically-defined media 
were often altered slightly in their composition for different strains or study aims. For 
example, some investigators would use L-cystine instead of L-cysteine (Catenazzi, 2013). 
In addition, a “maximal” media was also reported where L-isoleucine can be present in 
meningococcal or gonococcal cultures at a final concentration of 0.23 mM (Catlin, 1973). 
Together with the experimental results above, there is a case for an improved CDM 
tailored specifically for N. meningitidis serogroup B strain MC58 by introducing L-
isoleucine. In scenarios where the presence of L-isoleucine is not desirable, the exclusion 
of L-glycine from CDM would also be beneficial to meningococcal growth. As faster 
growth rates and higher yields often facilitate observation of growth phenotypes, this 
would be especially useful for mutant strains with growth-impairing lesions.  
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Chapter 6 – General Discussion and Future Directions 
6.1 General Discussion 
Determinants of virulence and pathogenicity are often intertwined with that of bacterial 
metabolism and fitness whilst residing in a host (Snyder and Saunders, 2006). To establish 
a steady presence in humans, bacteria need to evade host immune responses by showing 
variability or mimicry. The driving forces embodied by the various environmental 
challenges are met with a genomic readiness to embrace changes. Naturally competent 
bacteria can achieve this through their capacity to accommodate foreign genetic materials 
both inter- and intra-species of origin. Systems such as the Lrp/AsnC family or small 
regulatory RNAs also allow for switching between “feast or famine” metabolic phenotypes 
(Yokoyama et al., 2006; Pannekoek et al., 2017). 
Carriage of obligate commensals such as Neisseria meningitidis can normally be rendered 
harmless, as long as competition from other niche occupants keeps them at bay while 
immunosurveillance keeps them in check. When risk factors compromise such defences, 
this arguably provides a window for any capable bacteria to seize the opportunity and 
pursue more myopic but high-return lifestyles. Nonetheless, it can be suggested that the 
proportionally small sizes of the pathogen-specific genomic islands reflect a preference for 
more conservative, localised genomic changes while fundamentally preserving speciation. 
The purported functions involved range from various amino acids, biotin to the more 
recently characterised propionic acid metabolism – arguably traits which one might not 
instinctively associate with pathogenicity.  
This trend was reflected by the findings of this work. In general, the pathways investigated 
oversaw the transport, utilisation and biosynthesis of amino acids and their derivatives. The 
three-gene Genomic Island 5 synthesises the polyamine putrescine by expressing arginine 
decarboxylase (NMB0468) and agmatinase (NMB0469), as well as containing a putative 
transporter (NMB0470) of unknown function. Although the most straightforward finding 
of this work was confirming the function of NMB0468 and NMB0469, it was not possible 
to quantify the amount of putrescine present in culture. Considering the bacteria was very 
sensitive towards even minimal amounts of putrescine in terms of toxicity, perhaps the 
physiological levels of putrescine required to complement N. meningitidis was either very 
low, or that they fulfil their role in meningococci lifestyle and disease through less 
traditional, unclear means. The role of the transmembrane protein NMB0470 also remains 
open for future investigations, as its initial predicted function had no strong homology to 
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known C4-dicarboxylate transporters, and showed neither essentiality nor immediate 
connection to putrescine biosynthesis. 
Genomic Island 3 contains two genes (NMB0239 and NMB0240) which have a role in 
meningococcal arginine and possibly glutamine metabolism under nutrient-limiting 
conditions. Misleading initial predictions suggested its involvement in synthesising 
spermine or spermidine due to query hits with low homology, which was contradicted with 
the absence of crucial precursor substrates and upstream pathways. With that route 
rejected, we endeavoured to the best of our efforts to identify nutritional conditions which 
may explain growth trends displayed by the mutant strain. When arginine and (to a large 
extent) glutamine were withheld from the defined media, wild-type growth was impaired 
to levels highly-comparable to the mutant strain deficient in these genes. Subsequent 
labelled-isotope assays reinforced the notion that Genomic Island 3 is required for optimal 
uptake and utilisation of arginine and glutamine in N. meningitidis.  
A common theme was the role and fate of arginine in meningococcal maintenance. 
Preferably acquired from exogenous sources, intrinsic synthesis of arginine appeared to 
invoke substantial energetic stress as the meningococci attempt to compensate using 
alternative materials and mechanisms. Arginine is a key component in many metabolic 
processes and also the starting material for the meningococcal putrescine synthesis 
pathway. The clinical importance of such a system had also been previously explored in 
pathogenic N. gonorrhoeae (Gong et al., 2016). However, it is uncertain whether the 
mechanisms encoded by both Genomic Islands 3 and 5 are critical for virulence. Aside 
from further characterisation work, ex vivo techniques using suitable models may also help 
address their real-world relevance and determine whether mutant behaviours can be aptly 
reflected in vivo. 
Interestingly, the absence of Genomic Island 3 was not entirely detrimental to 
meningococcal replication under nutrient-rich media, while the same could be said for both 
islands when cultured under microaerobic conditions. We propose that the essentiality and 
activity of these genomic islands are environment-dependent. Overall this work continues 
to broadly reflect a highly elastic genetic structure which empowers N. meningitidis to 
adapt to different environmental conditions likely to be encountered in vivo, whether it is 
the nasopharyngeal mucosa, the bloodstream or the CSF. It should be noted that, whilst 
tempting to attribute so, “nutritional virulence” describes specialised means through which 
pathogens scavenge nutrients or compromise host denial mechanisms in order to enrich 
their own supply (Abu Kwaik and Bumann, 2013). Although this aspect is increasingly 
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relevant in meningococcal research (Schoen et al., 2014), such paradigm has not yet been 
observed amongst the genomic islands in question. 
A widely accepted notion is that virulent N. meningitidis strains are “accidental” 
pathogens, given that host death terminates further bacterial propagation through the more 
harmonious state of commensal co-existence (Moxon and Jansen, 2005). On the other 
hand, N. gonorrhoeae is capable of recurrent infections which establishes a comparatively 
more long-term presence within its host. The high degree of genetic similarities between 
all strains of the genus Neisseria was contrasted by their diverse phenotypes, especially 
among the very definitive pathogenic species (Maiden, 2008). Extensive polymorphisms 
such as phase and antigenic variations were often displayed by pathogenic Neisseriae and 
allowed for very different behaviours and specialisations (Marri et al., 2010). Many of 
these genes are key to both meningococcal pathogenicity and commensalism, such as 
capsular antigens, outer membrane proteins and adhesins (Caugant, 2008). Evolutionary 
gain or loss of function in genes of individual Neisseria strains is also possible as the 
bacteria adapts accordingly to its typical microenvironment (Moir, 2011). Summarily, the 
core to both meningococcal success in outgrowth and downfall by host fatality lies in its 
enhanced flexibility in face of change (Schoen et al., 2007). 
6.2 Future Directions 
In general, follow-up work should involve further exploration of the relationship between 
polyamines and the expression of oxidative stress response genes in N. meningitidis, as this 
project contains preliminary data that may serve as a foundation. This would complement 
the current knowledge on Genomic Island 5, where ideally the function of the third gene 
product NMB0470 may also be ascertained. Putting Neisseria research into clinical 
context, future prospects must include the alleviation of the antibiotic crisis with effective 
universal vaccines (Lipsitch and Siber, 2016). This is of utmost relevance to the genus 
given the notoriety of N. gonorrhoeae (Baarda et al., 2017).  
Specifically, future works may include the creation of a NMB0470-deficient mutant strain 
to ascertain the precise effects of the knocking out of this gene on meningococcal growth. 
The creation of a NMB0240- and NMB0573- double mutant strain can also be used to verify 
the predicted relationship between Lrp and Genomic Island 3, for example by comparing 
growth with the single mutant strains. Despite its crystal structure has not yet been solved, 
investigating the nature of the alternative Lrp/AsnC regulator NMB1650 is also 
encouraged, as its characterisation may serve as important groundwork for studies on 
meningococcal regulation. The apparent diauxic growth displayed in many putrescine-
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related growth curves in Chapter 3 is also worthy of closer investigation, as it would be 
useful to understand what changes were taking place and what triggered these phenomena. 
Taking a broader perspective, the comparison of results form a similar analysis in alternate 
Neisseria spp. such as N. lactamica would reveal the importance of the possession of these 
genomic islands and how commensal species cope with their absence. The relevance of the 
findings in this study to host-pathogen interactions is of particular interest. It would be of 
great significance if an infection model could be devised to investigate the role played by 
the genomic islands in pathogenesis, possibly by co-culturing human cell lines (e.g. 
macrophages) with mutant strains and comparing observations to that cultured with wild-
type N. meningitidis. General ecological and evolutionary questions associated with N. 
meningitidis that arose from these results may also be explored in future works. A closing 
remark would be the re-emphasis of the usefulness of a dedicated plate reader/incubator for 
growth curve-based experiments with pathogenic Neisseria, as this could greatly alleviate 
logistical constraints and free-up invaluable resources for other investigations. 
6.3 Final Conclusion 
In conclusion, N. meningitidis is a small, versatile bacterium with a relatively humble arms 
profile, but is willing to adapt, and, using limited resources, punches above its weight. 
Aside from clinical implications, this brings food for thought regarding the relationship 
between mankind and its microbiota. 
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Appendix A – Sequence alignment: speA and NMB0468 
 
 
(Figure continued in next page) 
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Fig. A – Structure-based alignment of (top to bottom) E. coli strain BL21 speA (NCBI 
GenBankTM accession no.: NP418541) (from Andréll et al., 2009) and N. meningitidis NMB0468 
(NCBI GenBankTM accession no.: NP273515). Conserved key amino acid residues: D202; Not 
conserved: H255, K386, E739. Sequences were aligned using T-Coffee (http://tcoffee.vital-it.ch; 
Di Tommaso et al., 2011) and displayed with secondary structures using ESPript 3 
(http://espript.ibcp.fr; Robert and Gouet, 2014). 
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Appendix B – Sequence alignment: speB and NMB0469 
 
Fig. B – Structure-based alignment of (top to bottom) Deinococcus radiodurans manganese-
activated speB (NCBI GenBankTM accession no.: NP285473) (from Ahn et al., 2004) and N. 
meningitidis NMB0469 (NCBI GenBankTM accession no.: NP273516). Conserved key amino acid 
residues: H121, D143, H145, D147, D229, D231, E274; Not conserved: L146, T149, N159, D187, 
S243. Sequences were aligned using T-Coffee (http://tcoffee.vital-it.ch; Di Tommaso et al., 2011) 
and displayed with secondary structures using ESPript 3 (http://espript.ibcp.fr; Robert and Gouet, 
2014). 
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Appendix C – Sequence alignment: VcINDY and NMB0470 
 
Fig. C – Structure-based alignment of (top to bottom) Vibrio cholerae sodium-dependent 
dicarboxylate transporter INDY (VcINDY) (NCBI GenBankTM accession no.: NP232426) (from 
Mancusso et al., 2012) and N. meningitidis NMB0470 (NCBI GenBankTM accession no.: 
NP273517). Conserved key amino acid residues: S150, N151, T152, P202, S377, T379, T421; Not 
conserved: S200, P201, N378, P422, P423. Sequences were aligned using T-Coffee 
(http://tcoffee.vital-it.ch; Di Tommaso et al., 2011) and displayed with secondary structures using 
ESPript 3 (http://espript.ibcp.fr; Robert and Gouet, 2014). 
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Appendix D – Sequence alignment: lrp, NMB0573 and NMV_1850 
 
Fig. D – Alignment of (top to bottom) E. coli strain K12 lrp (NCBI GenBankTM accession number 
NP415409), N. meningitidis serogroup B strain MC58 NMB0573 (NCBI GenBankTM accession 
number NP273617) and serogroup C strain 8013 NMV_1850 (NCBI GenBankTM accession number 
CAX50652). Sequences were aligned using T-Coffee (http://tcoffee.vital-it.ch; Di Tommaso et al., 
2011) and displayed with secondary structures using ESPript 3 (http://espript.ibcp.fr; Robert and 
Gouet, 2014).
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